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1. MULTICOMPONENT REACTIONS 
 
Figure 1. Principles of green chemistry (fig. from ref 4, pg. 2659). 
Multicomponent approaches to the synthesis of small bioactive molecules 
6 
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Figure 2. The "ideal synthesis" principles (fig. from ref 12, pg 666). 
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Scheme 1. Linear vs. multicomponent synthesis of Praziquantel.13 
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Scheme 2. Ruijter’s multicomponent approach to the synthesis of Telaprevir.14 
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Scheme 3. Recent example of successful design of multicomponent reactions  
for the synthesis of small bioactive molecules.25 
1. Multicomponent reactions 
11 
 
  
Figure 3. Build/couple/pairing multicomponent strategy for the synthesis of libraries  
of small bioactive molecules (fig. from ref 26, pg. 51). 
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1.1 Ugi four-component reaction (U-4CR) 
Scheme 4. Possible U-4CR mechanisms.28 
˗
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Scheme 5.  U-4CR mechanism proposed through computational studies.30 
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Scheme 6. Imidazolium-tagged reagents. 
 
Figure 4. ESI(+)-MS/MS of the ion of m/z 343 (fig. from ref. 31, pg. 339). 
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Figure 5. ESI(+)-MS/MS of the ion of m/z 221 (fig. from ref. 31, pg. 340). 
˗
 
Figure 6. DFT calculation of the Mumm rearrangement with a molecule of methanol (fig. from ref. 31, pg. 342). 
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Scheme 7. Example of diastereoselective U-4CR using S-α-methylbenzyl amine as chiral auxiliary.33 
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Scheme 8. Hypothetical mechanisms for isocyanoacetates epimerization.38 
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Scheme 9. Examples of build/couple/pair strategy applied to U-4CR.40 
 
1. Multicomponent reactions 
21 
 
1.2 N-split Ugi reaction (N-split U-4CR) 
 
Scheme 10. McFarland’s experiments that demonstrated the trapping  
of the imino-anhydride by the excess of secondary amine.44  
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Scheme 11. N-split Ugi reaction proposed mechanism.45 
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Scheme 12. N-split Ugi applications in medicinal chemistry.49 
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1.3 van Leusen three-component reaction (vL-3CR) 
 
Scheme 13. Improved synthesis of tosylmethyl isocyanide (TosMIC).52 
 
 
Scheme 14. Examples of transformations involving TosMIC as reagent. 51,52 
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Scheme 15. Proposed mechanisms for the vL-3CR.54 
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Scheme 16. Application of the vL-3CR for the rapid synthesis  
of 1,4,5-imidazoles as aspartyl protease inhibitors.55  
β
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1.4 Biginelli three-component reaction (Bg-3CR) 
 
Scheme 17. Plausible Biginelli three-component reaction mechanisms. 
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Figure 7. Ions detected by ESI(+)-MS for different mixtures of Biginelli reactants.60 
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β
 
Figure 8. Examples of marketed drugs or lead compounds bearing a DHMP core.62 
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Figure 9. Recently reported organocatalytic systems for enantioselective Biginelli reactions.72 
Primary amines Secondary amines Phosphoric acids
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2. CONFORMATIONALLY CONSTRAINED 
PEPTIDOMIMETICS AS INHIBITORS OF PPIs 
 
Figure 10. Examples of the role of PPIs in human physiology.5 
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2. Conformationally constrained peptidomimetics as inhibitors of PPIs 
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2.1 Ketopiperazine-based minimalist peptidomimetics 
β
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Figure 11. Early examples of minimalist peptidomimetics.14,15 
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Figure 12. Comparison between Cβ-Cβ separation between a β-turn and a minimalist peptidomimetic  
(fig. from ref 12a, pg. 4414). 
 
α
α
 
Scheme 18. Build/couple/pair strategy applied to the synthesis of a library  
of ketopiperazine-based minimalist peptidomimetics. 
α
α
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under Danishefsky’s conditions19
 
Scheme 19. Synthesis of optically pure N-methyl-N-protected α-amino aldehydes 1-4  
and methyl α-isocyanoacetates 5-6. 
α
α
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Scheme 20. Synthesis of 2,5-diketopiperazine-based peptidomimetics 11-14. 
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Scheme 21. Synthesis of 2,6-diketopiperazine-based peptidomimetics 19-22. 
 
α
 
Scheme 22. Synthesis of 3,4-dihydropyrazin-2(1H)-one-based peptidomimetics 23-26. 
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  Legend: s, strong; m, medium; w, weak; –, no NOE. 
 
Figure 13. a) Predicted and experimentally observed diagnostic NOE’s.  
b) Felkin-Ahn attack mode proposed for the observed stereochemistry. 
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Figure 14.  Above: 2D structures of models a, b and c with their low energy conformers 3D images.  
Blue dotted line on model c represents the internal hydrogen-bond.  
Below: tables reporting the Boltzmann distributions and the Cβ-Cβ distances. 
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Table 1. Correspondence of Cβ- Cβ distances for model a, b and c with those reported for the most common 
peptide secondary structures. Numbers highlighted by color represent the conformer percentage showing that 
specific Cβ- Cβ distance/secondary structure. They were retrieved from the Boltzmann distribution showed on Figure 
14. 
Structure Sequence 
Cβ-Cβ 
distances (Å) 
a b C 
α-Helix 
i-i+3 5,6 
 
6 
 
i-i+4 6,5 72 64 96 
β-Sheet (parallel) 
i-i+1 5,8 
 
36 
 
i-i' 5,5 
 
36 
 
β-Sheet (anti-parallel) 
i-i+1 5,8 
 
36 
 
i-i+2 6,5 72 64 96 
i-i' 4,5 1 2 
 
γ-Turn (type-1) 
i-i+1 5,7 
 
36 
 
i+2-i+3 5,6 
 
36 
 
γ-Turn (classic) i-i+1 4,7 1 2 2 
γ-Turn (inverse) 
i-i+1 5,7 
 
36 
 
i+1-i+2 6,2 27 64 13 
 
α α
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GENERAL INFORMATION 
All commercial materials (Aldrich, Fluka) were used without further purification. All solvents were of reagent grade or 
HPLC grade. All reactions were carried out under a nitrogen atmosphere unless otherwise noted. All reactions were 
monitored by thin layer chromatography (TLC) on precoated silica gel 60 F254; spots were visualized with UV light or 
by treatment with a 1% aqueous KMnO4 solution. Products were purified by flash chromatography on silica gel 60 
(230–400 mesh). 1H NMR spectra and 13C NMR spectra were recorded on 300 and 400 MHz spectrometers. 
Chemical shifts are reported in parts per million relative to the residual solvent. 13C NMR spectra have been recorded 
using the APT pulse sequence (for further details see Appendix A.1). Multiplicities in 1H NMR are reported as follows: 
s = singlet, d = doublet, t = triplet, m = multiplet, br s = broad singlet. High-resolution MS spectra were recorded 
with an FT-ICR (Fourier Transform Ion Cyclotron Resonance) instrument, equipped with an ESI source. CD spectra 
were obtained with JASCO J-715 spectropolarimeter. 
GENERAL PROCEDURE FOR THE SYNTHESIS OF COMPOUNDS 7-10  
Aldehyde (1 or 2) (1.0 mmol, 1 eq) was dissolved in 1 mL of dry methanol under nitrogen, 4-methoxy aniline (1.0 
mmol, 123 mg, 1 eq) was added and the resulting mixture was kept under stirring for 2h at room temperature. 2-
Chloroacetic acid (1.0 mmol, 94.5 mg, 1 eq) and isocyanide (5 or 6) (1.2 mmol, 1.2 eq) were sequentially added and 
the reaction was stirred for additional 60h at room temperature. The resulting mixture was then concentrated under 
reduced pressure, to give a residue which was purified by flash chromatography (FC) as indicated below. 
(S)-methyl-2-((2R,3S)-3-((tert-butoxycarbonyl)(methyl)amino)-2-(2-chloro-N-(4-ethoxyphenyl)acetamido)butanamido)propanoate, 
5a and (S)-methyl-2-((2S,3S)-3-((tert-butoxycarbonyl)(methyl)amino)-2-(2-chloro-N-(4-
methoxyphenyl)acetamido)butanamido)propanoate (7b) 
Prepared according to the above general procedure from aldehyde 1 and isocyanide 5; FC: ethyl acetate:n-hexane, 
1:1.5; yield: 7a (97 mg, 19%), 7b (356 mg, 71%). 7a: colorless oil; Rf  0.21 (1.5:1 n-hexane/EtOAc); [α]30D  - 16.3 (c 0.5, 
CHCl3); 
1H NMR (300 MHz, CD3CN, 1:1 mixture of rotamers) δ 7.38-7.08 (m, 3H), 6.95 (d, J = 8.8 Hz, 2H), 4.45-4.09 
(br, s, 1H), 3.85 (br, s , 2H), 3.81 (s, 3H),  3.82-3.75 (m, 1H), 3.69 (s, 1.5H), 3.71-3.63 (m, 1H), 3.67 (br, s, 1.5H), 2.65 
(s, 3H), 1.46˗1.31 (m,12H), 1.27 (br, d, J = 6.8 Hz, 3H); 13C NMR (75 MHz, CD3CN) δ 178.1, 173.0 (2C), 165.4, 160.2, 
136.5, 136.2, 135.5, 120.0, 119.8, 84.8 and 84.6 (1C), 60.6, 60.5, 57.2, 53.5, 53.4, 48.5, 48.3, 34.3, 33.0 (3C), 22.2 and 
21.9 (1C), 19.7 and 19.6 (1C); HRMS (ESI) calcd for C23H34ClN3NaO7
+  [MNa]+ 522.1977, found 522.1983. 7b: 
colorless oil; Rf  0.18 (1.5:1 n-hexane/EtOAc); [α]30D  + 8.5 (c 0.5, CHCl3); 1H NMR (300 MHz, CD3CN, 1:1 mixture of 
rotamers) δ 7.40-7.08 (br, m, 1H), 7.20 (m,  2H), 6.95 (d, J = 9.1 Hz, 2H), 4.41-4.12 (br, m, 1H), 3.86 (br, s, 2H), 3.81 
(s, 3H), 3.79 (m, 1H), 3.67 (br, s, 1.5H), 3.65 (m, 1H), 3.64 (s, 1.5H), 2.67 (s, 3H), 1.38 (s, 9H), 1.32 (m, 3H), 1.27 (br, 
d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 173.5 and 173.4 (1C), 169.4-168.7 (2C), 160.6, 157.0 and 156.8 (1C), 
131.4, 130.8, 130.2, 115.7, 115.5, 81.0 and 80.6 (1C), 56.1 (2C), 53.0, 52.9, 48.9 (2C), 43.1 and 43.0 (1C), 29.1 (4C), 
18.2, 16.1; HRMS (ESI) calcd for C23H34ClN3NaO7
+  [MNa]+  522.1977, found 522.1961. 
(2S)-methyl 2-((3S)-3-((tert-butoxycarbonyl)(methyl)amino)-2-(2-chloro-N-(4-methoxyphenyl)acetamido)butanamido)-3-
phenylpropanoate (8) 
Prepared according to the above general procedure from aldehyde 1 and isocyanide 6; FC: ethyl acetate:n-hexane, 
1:1.5; yield 524 mg, (91%) as an inseparable mixture of diastereoisomers (d.e. 50%, NMR analysis): pale yellow oil; Rf 
0.24 (1.5:1 n-hexane/EtOAc); 1H NMR (300 MHz, CD3CN, rotameric mixture of a mixture of diastereoisomers) δ 
7.47-6.99 (m, 8H), 6.89 (br, d, J = 8.8 Hz, 2H), 4.80-4.40 (br, m, 1H), 3.81 (br, s , 2H), 3.80-3.74 (m, 4H), 3.69 (s, 
0.5H), 3.69-3.63 (m, 3.5H), 3.24-3.05 (br, m, 1H), 3.03-2.80 (br, m, 1H), 2.62 (s, 2.75H), 2.58 (s, 0.25H),  1.36 (s,9H), 
1.28-1.21 (m, 3H); HRMS (ESI) calcd for C29H38ClN3NaO7
+  [MNa]+  598.2290, found 598.2305. 
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(2S)-methyl 2-((3S)-3-((tert-butoxycarbonyl)(methyl)amino)-2-(2-chloro-N-(4-methoxyphenyl)acetamido)-4-
phenylbutanamido)propanoate (9) 
Prepared according to the above general procedure from aldehyde 2 and isocyanide 5; FC: ethyl acetate:n-hexane, 
1:1.5; yield 501 mg, (87%) as an inseparable mixture of diastereoisomers (d.e. 56%, NMR analysis): pale yellow oil; Rf 
0.22 (1.5:1 n-hexane/EtOAc); 1H NMR (300 MHz, CD3CN, rotameric mixture of a mixture of diastereoisomers) δ 
7.40-7.04 (m, 8.4H), 6.96 (br, d, J = 8.4 Hz, 1.6H), 4.59-4.40 (br, m, 1H), 3.93-3.64 (m , 10H), 3.33-2.87 (m, 1H), 2.80 
(s, 0.66H), 2.76 (s, 2.34H), 2.64 (m, 1H), 1.52-1.26 (m, 12H); HRMS (ESI) calcd for C29H38ClN3NaO7
+  [MNa]+  
598.2290, found 598.2305. 
(2S)-methyl 2-((3S)-3-((tert-butoxycarbonyl)(methyl)amino)-2-(2-chloro-N-(4-methoxyphenyl)acetamido)-4-phenylbutanamido)-3-
phenylpropanoate (10) 
Prepared according to the above general procedure from aldehyde 2 and isocyanide 6; FC: ethyl acetate:n-hexane, 
1:1.5; yield 573 mg, (88%) as an inseparable mixture of diastereoisomers (d.e. 51%, NMR analysis): oil; Rf 0.44 (1.5:1 n-
hexane/EtOAc); 1H NMR (400 MHz, CDCl3, rotameric mixture of a mixture of diastereoisomers) δ 7.38-7.06 (m, 
11.4H), 7.02-6.80 (br, m, 3.6H), 5.05-4.67 (br, m, 1H), 3.93-3.58 (m , 10H), 3.32-3.18 (m, 1H), 3.05-2.86 (m, 2H), 2.78 
(s, 0.75H), 2.75 (s, 2.25H), 2.65 (m, 1H), 1.40 (m, 9H); HRMS (ESI) calcd for C35H42ClN3NaO7
+  [MNa]+  674.2603, 
found 674.2622. 
GENERAL PROCEDURE FOR THE SYNTHESIS OF COMPOUNDS 11-14  
To a solution of the Ugi product (7a, 7b, 8, 9 or 10)  (0.5 mmol, 1 eq) in dry acetonitrile (4.5 mL) under nitrogen, 
cesium carbonate (1 mmol, 326 mg, 4 eq) and LiI (0.05 mmol, 7 mg, 0.1 eq) were added, and the mixture was stirred 
for 20h, at room temperature (or at 60 oC, for 7a). The mixture was quenched with satd aq NH4Cl (20 mL) and 
extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine, dried by Na2SO4 and 
concentrated under reduced pressure, to give a residue, which was purified by flash chromatography (FC) as indicated 
below. 
(S)-methyl 2-((R)-3-((S)-1-((tert-butoxycarbonyl)(methyl)amino)ethyl)-4-(4-methoxyphenyl)-2,5-dioxopiperazin-1-yl)propanoate 
(11a) 
Prepared according to the above general procedure from 7a; FC: ethyl acetate:n-hexane, 1:1.5; yield: 37 mg (16%); 
colorless oil; Rf  0.18 (1.5:1 n-hexane/EtOAc); [α]30D - 12.7 (c 0.5, CHCl3); 1H NMR (300 MHz, CD3CN) δ 7.43 (br, m, 
2H), 6.98 (d, J = 8.8 Hz, 2H), 5.03 (q, J = 7.0 Hz, 1H), 4.63 (br, m, 1H), 4.34 (br, m, 1H), 4.30 (br, d, J = 16.6 Hz, 1H), 
3.88 (d, J = 16.7 Hz, 1H), 3.83 (s, 3H), 3.73 (s, 3H), 2.67 (s, 3H), 1.45 (s, 9H), 1.44 (d, J = 7.0 Hz, 3H), 1.24 (br, d, J = 
7.5 Hz, 3H); 13C NMR (100 MHz, CD3CN) δ 172.2, 168.4, 165.0 (2C), 160.7, 133.9, 131.4 (2C), 130.0, 115.3 (2C), 
80.9, 68.5, 55.8, 52.5 (2C), 49.1 and 48.9 (1C), 48.0, 28.3 (3C), 17.4, 14.2; HRMS (ESI) calcd for C23H33N3NaO7
+  
[MNa]+  486.2211, found 486.2227. 
(S)-methyl 2-((S)-3-((S)-1-((tert-butoxycarbonyl)(methyl)amino)ethyl)-4-(4-methoxyphenyl)-2,5-dioxopiperazin-1-yl)propanoate 
(11b) 
Prepared according to the above general procedure from 7b; FC: ethyl acetate:n-hexane, 1:1.5; yield: 176 mg (76%); 
colorless oil; Rf  0.16 (1.5:1 n-hexane/EtOAc); [α]30D  + 24.2 (c 1.0, MeOH); 1H NMR (400 MHz, CD3CN) δ 7.36 (br, d, 
J = 8.9 Hz, 2H), 6.98 (d, J = 9.2 Hz, 2H), 5.12 (q, J = 7.3 Hz, 1H), 4.73 (br, m, 1H), 4.29 (d, J = 16.7 Hz, 1H), 4.27 (br, 
m, 1H), 3.88 (br, d, J = 16.7 Hz, 1H), 3.83 (s, 3H), 3.69 (s, 3H), 2.68 (s, 3H), 1.46 (d, J = 7.3 Hz, 3H), 1.45 (s, 9H), 1.16 
(br, d, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CD3CN) δ 172.2, 165.9, 164.9, 159.1, 133.9, 130.0, 129.2 (2C), 114.6 
(2C), 80.2, 68.4, 55.9, 52.7, 52.1, 51.5, 48.0, 29.5, 28.3 (3C), 16.5, 13.8; HRMS (ESI) calcd for C23H33N3NaO7
+  [MNa]+  
486.2211, found 486.2216. 
(S)-methyl-2-((S)3-((S)-1-((tert-butoxycarbonyl)(methyl)amino)ethyl)-4-(4-ethoxyphenyl)- 2,5-dioxopiperazin-1-yl)-3-
phenylpropanoate (12) 
Prepared according to the above general procedure from 8; FC: ethyl acetate:n-hexane, 3:7; yield: 124 mg (46%); wax; 
Rf 0.15 (7:3 n-hexane/EtOAc); [α]22D - 55.2 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.34-7.23 (m, 3H), 7.21-7.16 
(m, 2H), 7.14-7.05 (m, 2H), 6.90 (d, J = 8.9 Hz, 2H), 5.68 (dd, J = 11.4, 5.1 Hz, 1H), 4.70 (br, m, 1H),  4.41 (d, J = 17.3 
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Hz, 1H), 4.03 (d, J = 17.3 Hz, 1H), 3.88 (br, m, 1H), 3.81 (s, 3H), 3.80 (s, 3H) 3.40 (dd, J = 14.4 and 5.1 Hz, 1H), 2.99 
(dd, J = 14.4, 11.4 Hz, 1H), 2.68 (s, 3H), 1.46 (s, 9H), 1.17 (d, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 170.7, 
166.8, 164.7, 159.3, 156.7, 136.1, 133.0, 129.8 (2C), 129.4 (2C), 129.2 (2C), 127.7,  115.0 (2C), 80.9, 69.0, 56.6, 56.1, 
53.0, 51.9, 47.6, 35.5, 29.9, 29.1 (3C), 17.1; HRMS (ESI) calcd for C29H37N3NaO7
+  [MNa]+  562.2524, found 562.2509. 
(S)-methyl-2-((S)3-((S)-1-((tert-butoxycarbonyl)(methyl)amino)-2-phenylethyl)-4-(4-methoxyphenyl)-2,5-dioxopiperazin-1-
yl)propanoate (13) 
Prepared according to the above general procedure from 9; FC: ethyl acetate:n-hexane, 1:1.5; yield: 178 mg (66%); 
pale yellow oil; Rf 0.15 (1.5:1 n-hexane/EtOAc); [α]30D + 2.2 (c 0.5, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.35-7.24 (m, 
2H), 7.24-7.12 (m, 3H), 7.12-7.05 (m, 2H), 6.92 (d, J = 8.6 Hz, 2H), 5.29 (q, J = 7.1 Hz, 1H), 4.97 (br, m, 1H),  4.43-
4.30 (m, 2H), 3.99 (d, J = 16.7 Hz, 1H), 3.83 (s, 3H), 3.74 (s, 3H) 3.08 (br, m, 1H), 2.77 (br, m, 2H), 2.67 (s, 3H), 1.47 
(d, J = 7.1 Hz, 3H), 1.44 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 171.8, 166.0, 164.7, 159.3, 157.1, 137.7, 132.9, 129.6 
(2C), 129.1 (2C), 128.8 (2C), 127.2,  115.1 (2C), 81.0, 67.3, 57.7, 56.1, 52.3, 51.7, 47.6, 36.9, 30.8, 28.9 (3C), 14.5; 
HRMS (ESI) calcd for C29H37N3NaO7
+ [MNa]+  562.2524, found 562.2536. 
(2S)-methyl˗2-((S)3-((S)-1-((tert-butoxycarbonyl)(methyl)amino)-2-phenylethyl)-4-(4-methoxyphenyl)-2,5-dioxopiperazin-1-yl)-3-
phenylpropanoate (14) 
Prepared according to the above general procedure from 10; FC: ethyl acetate:n-hexane, 3:7; yield: 151 mg (56%); 
yellow oil; Rf 0.21 (7:3 n-hexane/EtOAc); [α]31D = - 74.7 (c 1.0, MeOH); 1H NMR (400 MHz, CDCl3) δ 7.35˗7.23 (m, 
4H), 7.23-7.18 (m, 2H), 7.18-7.11 (m, 2H), 7.10-6.99 (m, 4H), 6.88 (d, J = 8.8 Hz, 2H), 5.73 (dd, J = 11.3 and 5.3 Hz, 
1H), 4.94 (br, m, 1H), 4.40 (d,  J = 17.2 Hz, 1H), 4.05 (d,  J = 17.2 Hz, 1H), 4.03 (br, m, 1H),  3.83 (s, 3H), 3.81 (s, 3H), 
3.44 (dd, J = 14.4 and 5.3 Hz, 1H), 3.03 (dd, J = 14.4 and 11.3 Hz, 1H), 3.05˗2.77 (m, 2H), 2.64 (s, 3H), 1.40 (s, 9H); 
13C NMR (100 MHz, CDCl3) δ 170.6, 166.8, 164.7, 159.5, 157.0, 137.5, 136.1, 132.2, 129.7 (2C), 129.4˗129.0 (8C), 
127.8, 127.1 (2C), 115.1, 80.9, 67.1, 56.7, 56.1 (2C), 53.1, 47.4, 36.7, 35.4, 30.3, 28.9 (3C); HRMS (ESI) calcd for  
C35H41N3NaO7
+  [MNa]+  638.2837, found 638.2847. 
GENERAL PROCEDURE FOR THE SYNTHESIS OF COMPOUNDS 15-18  
Aldehyde (1 or 2) (1.0 mmol, 1 eq) was dissolved in 1 mL of dry methanol under nitrogen, O-benzyl glycine (1.0 mmol, 
165 mg, 1 eq) was added and the resulting mixture was kept under stirring for 2h at room temperature. Acetic acid 
(1.0 mmol, 60 mg, 1 eq) and isocyanide (5 or 6) (1.2 mmol, 1.2 eq) were sequentially added and the reaction was 
stirred for additional 60h at room temperature. The resulting mixture was diluted with water (10 mL) and extracted 
with EtOAc (3 x 5 mL). The combined organic layers were dried over Na2SO4 and the solvent removed under 
reduced pressure to afford the crude Ugi product, which was purified by flash chromatography (FC) as indicated 
below. 
(S)-methyl 2-((2R,3S)-2-(N-(2-(benzyloxy)-2-oxoethyl)acetamido)-3-((tert-
butoxycarbonyl)(methyl)amino)butanamido)propanoate, 13a and (S)-methyl 2-((2S,3S)-2-(N-(2-(benzyloxy)-2-
oxoethyl)acetamido)-3-((tert-butoxycarbonyl)(methyl)amino)butanamido)propanoate (15b) 
Prepared according to the above general procedure from aldehyde 1 and isocyanide 5; FC: ethyl acetate:n-hexane, 
1:1.5; yield: 15a (35 mg, 7%), 15b (276 mg, 54%). 15a: amber oil; Rf  0.18 (1:1.5 n-hexane/EtOAc); [α]30D - 3.4 (c 0.5, 
CHCl3); 
1H NMR (300 MHz, CDCl3, 1:1 mixture of rotamers) δ 7.34 (br, m, 5H), 6.62-6.27 (br, m, 1H), 5.16˗5.08 (m, 
2H), 5.06 (br, m, 1H),  4.79˗4.61 (br, m, 1H), 4.47 (d, J = 19.5 Hz, 0.5H), 4.45 (d, J = 19.5 Hz, 0.5H), 4.23 (br, m, 1H), 
4.01 (br, d, J = 19.5 Hz, 1H), 3.72 (s, 1.5), 3.71 (s, 1.5),  2.62 (br, s, 3H), 1.98 (br, s, 1.5), 1.95 (s, 1.5), 1.42 (s, 9H), 1.36 
(d, J = 6.8 Hz 3H), 1.14 (br, m, 3H); 13C NMR (75 MHz, CDCl3, mixture of rotamers) δ 173.0 and 172.9 (1C), 172.6 
and 172.4 (1C), 168.2 and 168.1 (1C), 167.8, 155.8, 135.4, 128.6-128.2 (5C), 79.4, 66.9, 57.4-56.0 (br, 1C), 52.3, 48.4, 
48.1, 47.1 and 46.7 (br, 1C), 28.7, 28.4 (3C), 21.6, 18.0, 15.2 and 14.8 (1C); HRMS (ESI) calcd for C25H37N3Na O8
+ 
[MNa]+ 530.2473, found 530.2455. 15b: Rf  0.15 (1:1.5 n-hexane/EtOAc); [α]30D + 8.8 (c 0.5, CHCl3); 1H NMR (300 
MHz, CDCl3, 1:1 mixture of conformers) δ 7.35 (br, m, 5H), 6.65-6.28 (br, m, 1H), 5.17 (br, m, 3H), 4.51˗4.19 (br, m, 
4H), 3.70 (s, 1.5), 3.68 (s, 1.5), 2.81 (s, 3H), 2.03 (br, s, 3H), 1.42 (s, 9H), 1.32 (d, J = 6.8 Hz 3H), 1.15 (d, J = 6.8 Hz 
1.5H),  1.12 (d, J = 6.8 Hz 1.5H),  ; 13C NMR (75 MHz, CDCl3, mixture of rotamers) δ 172.4-172.0 (2C), 169.6, 168.9 
and 168.8 (1C), 155.4 and 155.2 (1C), 135.4 and 135.2 (1C), 129.1-128.0 (5C), 80.3, 67.4 and 67.2 (1C), 59.6, 52.6, 
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48.5, 48.1, 47.8, 29.7, 28.4 (3C), 21.6, 17.6, 15.7 and 15.3 (1C); HRMS (ESI) calcd for C25H37N3Na O8
+ [MNa]+ 
530.2473, found 530.2482. 
(2S)-methyl-2-((3S)-2-(N-(2-(benzyloxy)-2-oxoethyl)acetamido)-3-((tert-butoxycarbonyl)(methyl)amino)butanamido)-3-
phenylpropanoate, (16) 
Prepared according to the above general procedure from aldehyde 1 and isocyanide 6; FC: ethyl acetate:n-hexane, 1:1; 
yield: 344 mg (59%), as an inseparable mixture of diastereoisomers (d.e. 80%, NMR analysis): pale yellow oil; Rf  0.27 
(1:1 n-hexane/EtOAc); 1H NMR (300 MHz, CDCl3, rotameric mixture of two diastereoisomers) δ 7.41˗7.03 (m, 11H), 
5.28˗5.10 (m, 3H), 4.78 (br, m, 0.9H),  4.78˗3.93 (m, 3.1H), 3.68 (s, 0.3H), 3.65 (s, 2.7H), 3.09 (br, m, 1H), 3.01 (m, 
1H), 2.75 (br, s, 2.7H), 2.58 (s, 0.3H), 1.97 (br, m, 3H), 1.42 (s, 0.9H), 1.39 (s, 8.1H), 1.09 (br, d, J = 6.8 Hz 3H ); 
HRMS (ESI) calcd for  C31H41N3NaO8
+  [MNa]+  606.2786, found 606.2800. 
(2S)-methyl-2-((3S)-2-(N-(2-(benzyloxy)-2-oxoethyl)acetamido)-3-((tert- butoxycarbonyl)(methyl)amino)-4-
phenylbutanamido)propanoate (17) 
Prepared according to the above general procedure from aldehyde 2 and isocyanide 5; FC: ethyl acetate:n-hexane, 
1.5:1; yield: 256 mg (44%), as an inseparable mixture of diastereoisomers (d.e. 84%, NMR analysis): pale yellow oil; Rf  
0.20 (1:.5 n-hexane/EtOAc); 1H NMR (300 MHz, CDCl3, rotameric mixture of two diastereoisomers) δ 7.46˗7.04 (m, 
11H), 5.34˗5.10 (m, 3H), 4.88 (br, m, 0.9H),  4.62˗3.91 (m, 3.1H), 3.73 (s, 0.24H), 3.65 (s, 2.76H), 3.32 (br, m, 1H), 
3.07 (br, m, 1H), 2.81 (br, s, 2.76H), 2.65 (s, 0.24H), 2.00 (br, s, 2.76H), 1.97 (s, 0.24H), 1.43 (br, s, 9H), 1.36 (br, m, 
3H ); HRMS (ESI) calcd for  C31H41N3NaO8
+  [MNa]+  606.2786, found 606.2761. 
(2S)-methyl-2-((3S)-2-(N-(2-(benzyloxy)-2-oxoethyl)acetamido)-3-((tert-butoxycarbonyl)(methyl)amino)-4-phenylbutanamido)-3-
phenylpropanoate (18) 
Prepared according to the above general procedure from aldehyde 2 and isocyanide 6; FC: ethyl acetate:n-hexane, 
1:1.5; yield: 587 mg (89%), as an inseparable mixture of diastereoisomers (d.e. 72%, NMR analysis): colorless oil; Rf  
0.18 (1.5:1 n-hexane/EtOAc); 1H NMR (300 MHz, CDCl3, rotameric mixture of two diastereoisomers) δ 7.43-7.01 (m, 
16H), 5.29-5.09 (m, 3H), 4.88 (m, 0.86H), 4.74 (m, 0.14H), 4.64-4.43 (m, 1.86H), 4.29 (m, 0.14H), 4.01 (br, d, J = 16.6 
Hz, 1H), 3.74 (s, 0.24H), 3.67 (s, 1.26H), 3.65 (s, 1.5H), 3.54-2.84 (m, 4H), 2.70 (s, 2.52H), 2.63 (s, 0.48H), 2.07 (s, 
0.24H), 1.98 (s, 1.5H), 1.95 (s, 1.26H), 1.41 (s, 9H); HRMS (ESI) calcd for  C37H45N3NaO8
+  [MNa]+  682.3099, found 
682.3114. 
GENERAL PROCEDURE FOR THE SYNTHESIS OF COMPOUNDS 19-22  
Palladium (10 wt.% on carbon, 70 mg) was added to a solution of the Ugi product (15a, 15b, 16, 17 or 18) (0.30 
mmol, 1 eq) in methanol (3 mL). The reaction mixture was degassed in vacuo, placed under an atmosphere of H2 (g), 
and stirred in the dark at rt for 2h. The mixture was filtered through a pad of Celite eluting with methanol (10 mL), 
and the combined organic layers were concentrated in vacuo to give the crude carboxylic acid intermediate, which was 
directly used in the next step, as follows. 1,1'- Carbonyl diimidazole (0.30 mmol, 127 mg, 1 eq) was added to a 
solution of the crude carboxylic acid in dry tetrahydrofuran (3 mL), under nitrogen, and the resulting mixture was 
refluxed for 60 min and then stirred for additional 3h at room temperature. The solvent was removed under reduced 
pressure to give a residue which was partitioned between CHCl3 (10 mL) and 1M HCl, (10 mL). The aqueous phase 
was extracted with CHCl3 (3 x 10 mL) and the combined organic layers were washed with H2O, dried over Na2SO4 
and concentrated in vacuo to afford the crude product, which was purified by flash chromatography (FC), as indicated 
below. 
(S)-methyl 2-((R)-4-acetyl-3-((S)-1-((tert-butoxycarbonyl)(methyl)amino)ethyl)-2,6-dioxopiperazin-1-yl)propanoate (19a) 
Prepared according to the above general procedure from 15a; FC: ethyl acetate:n-hexane, 7:3; yield: 18 mg (15%); 
colorless oil; Rf  0.33 (3:7 n-hexane/EtOAc); [α]30D - 15.6 (c 0.5, CHCl3); 1H NMR (300 MHz, CDCl3) δ 4.63-3.90 (m, 
5H), 3.72 (br, s, 3H), 2.82 (br, s, 3H), 2.08 (br, s, 3H), 1.45 (s, 9H), 1.37 (br, d, J = 6.8 Hz, 3H), 1.12 (br, d, J = 6.8 Hz, 
3H); 13C NMR (100 MHz, CDCl3) δ 170.1, 169.1, 167.0, 166.5 and 166.4 (1C), 155.9, 80.5, 55.0, 52.5, 49.5, 48.8, 46.5, 
29.0, 28.3 (3C), 21.1, 15.5 and 15.4 (1C), 14.2 and 13.9 (1C); HRMS (ESI) calcd for C18H29N3NaO7
+  [MNa]+  422.1898, 
found 422.1924. 
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(S)-methyl 2-((S)-4-acetyl-3-((S)-1-((tert-butoxycarbonyl)(methyl)amino)ethyl)-2,6-dioxopiperazin-1-yl)propanoate (19b) 
Prepared according to the above general procedure from 15b; FC: ethyl acetate:n-hexane, 7:3; yield: 71 mg (59%); 
colorless oil; Rf  0.29 (3:7 n-hexane/EtOAc); [α]30D + 39.9 (c 0.5, CHCl3); 1H NMR (400 MHz, CDCl3, mixture of 
conformers 1.5:1) δ 5.36 (br, d, J = 9.9 Hz, 1H), 5.19 (m, 1H), 4.72 (m, 1H), 4.57 (d, J = 18.7 Hz, 0.6H), 4.52 (d, J = 
18.7 Hz, 0.4H), 4.29 (d, J = 18.7 Hz, 0.4H), 4.24 (d, J = 18.7 Hz, 0.6H),   3.68 (s, 1.8H), 3.67 (s, 1.2H), 2.82 (br, s, 
1.8H), 2.80 (s, 1.2H), 2.23-2.15 (m, 3H), 1.52 (d, J = 7.0 Hz, 1.8H), 1.45 (d, J = 7.0 Hz, 1.2H), 1.44-1.38 (m, 9H), 1.19 
(br, d, J = 6.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 169.9, 169.0, 167.0, 166.4, 156.1, 80.2, 54.7, 52.4, 49.4, 48.7, 
46.8, 28.9, 28.3 (3C), 21.4, 15.5, 14.1; HRMS (ESI) calcd for C18H29N3NaO7
+  [MNa]+  422.1898, found 422.1917. 
(2S)-methyl-2-(4-acetyl-3-((S)-1-((tert-butoxycarbonyl)(methyl)amino)ethyl)-2,6-dioxopiperazin-1-yl)-3-phenylpropanoate (20) 
Prepared according to the above general procedure from 16; FC: ethyl acetate:n-hexane, 1.5:1; yield: 105 mg (74%), as 
an inseparable mixture of diastereoisomers (d.e. 80%, NMR analysis); foam; Rf  0.36 (1:1.5 n-hexane/EtOAc); 
1H NMR 
(400 MHz, CD3CN, mixture of two diastereoisomers) δ 7.34-7.03 (m, 5H), 5.56-5.37 (br, m, 1.9H), 4.59 (br, m, 1H), 
4.57 (d, J = 18.7 Hz, 1H), 4.83-4.11 (m, 2H), 3.66 (br, s, 3H), 3.43 (m, 1H), 3.17-2.99 (m, 1H), 2.79 (s, 0.3H), 2.77 (s, 
2.7H), 2.23 (s, 2.7H), 2.14 (s, 0.3H), 1.42 (s, 9H), 1.14 (m, 3H); 13C NMR (101 MHz, CD3CN), δ 170.2-167.8 (4C), 
156.3 and 156.0 (1C), 138.2, 129.8 (2C), 129.0 (2C), 127.3 (1C), 80.4, 54.2-53.8 (2C), 52.8, 51.4 and 50.9 (1C), 47.1 
and 46.9 (1C), 34.7, 30.4, 28.4 (3C), 21.3, 15.2 and 14.8 (1C); HRMS (ESI) calcd for  C24H33N3NaO7
+  [MNa]+  
498.5239, found 498.5223. 
(2S)-methyl-2-(4-acetyl-3-((S)-1-((tert-butoxycarbonyl)(methyl)amino)-2-phenylethyl)-2,6-dioxopiperazin-1-yl)propanoate (21) 
Prepared according to the above general procedure from 17; FC: ethyl acetate:n-hexane, 1:1.5; yield: 110 mg (77%), as 
an inseparable mixture of diastereoisomers (d.e. 95%, NMR analysis); foam; Rf  0.13 (1.5:1 n-hexane/EtOAc); 
1H NMR 
(400 MHz, CD3CN,1:1 rotameric mixture) δ 7.37-7.19 (m, 5H), 5.50(m, 1H), 5.25 (m, 1H), 5.02-4.58 (m, 2H), 4.41 (d, 
J = 18.6 Hz, 1H), 3.66 (s, 1.5H), 3.65 (s, 1.5H), 3.04-2.77 (br, m, 2H), 2.79 (s, 3H), 2.18 (s, 3H), 1.45 (d, J = 6.9 Hz, 
1.5H), 1.44 (d, J = 6.9 Hz, 1.5H), 1.35 (br, m, 9H); 13C NMR (100 MHz, CD3CN), δ 170.7 and 170.1 (1C), 170.0-169.7 
(1C), 169.1, 167.5, 156.2 and 156.1 (1C), 137.8, 129.1, 128.9, 128.3 (2C), 126.5 and 126.4 (1C),  79.7 and 79.4 (1C), 
56.4, 54.9 and 54.5 (1C), 52.0, 48.3, 46.7, 34.4 and 34.3 (1C), 27.9, 27.5 (3C), 20.9, 13.6 and 13.4 (1C); HRMS (ESI) 
calcd for  C24H33N3NaO7
+  [MNa]+ 498.2211, found 498.2225. 
(2S)-methyl-2-(4-acetyl-3-((S)-1-((tert-butoxycarbonyl)(methyl)amino)-2-phenylethyl)-2,6-dioxopiperazin-1-yl)-3-phenylpropanoate, 
(22) 
Prepared according to general procedure above from 18; FC: ethyl acetate:n-hexane, 1:1.5; yield: 117 mg (71%), as an 
inseparable mixture of diastereoisomers (d.e. 80%, NMR analysis); thick oil; Rf  0.39 (1.5:1 n-hexane/EtOAc); 
1H NMR 
(400 MHz, CD3CN, rotameric mixture of  two distereoisomers) δ 7.36-7.07 (m, 10H), 5.56-5.40 (m, 1H), 5.14 (d, J = 
9.3 Hz, 0.9H), 5.03 (d, J = 10.5 Hz, 0.1H), 4.95-4.80 (m, 0.9H), 4.65 (d, J = 18.5 Hz, 0.1H), 4.62 (d, J = 18.6 Hz, 0.9H), 
4.42 (m, 0.1H),  4.33 (d, J = 18.5 Hz, 1H), 3.71 (s, 0.3H), 3.66 (s, 2.7H), 3.59-3.38 (m, 1H), 3.19-3.03 (m, 1H), 2.92-2.80 
(m, 1H), 2.80-2.67 (m, 1H), 2.67 (s, 2.7H), 2.58 (s, 0.3H), 2.10 (s, 2.7H), 2.08 (s, 0.3H), 1.45 (br, s, 9H); 13C NMR (101 
MHz, CD3CN), δ 169.7-168.5 (3C), 167.8 and 167.6 (1C), 154.7 and 154.6 (1C),  138.3-137.8 (1C), 137.2-137.0 (1C), 
129.1 (4C), 128.4 and 128.3 (4C), 126.7-126.4 (2C), 79.7-79.4 (1C), 56.2, 54.9-54.6 (1C), 53.8, 52.1 and 52.0 (1C), 
46.8 and 46.5 (1C), 34.4-34.2 (2C), 27.9, 27.7 (3C), 21.0 and 20.8 (1C); HRMS (ESI) calcd for  C30H37N3NaO7
+  [MNa]+  
574.2524, found 574.2506. 
GENERAL PROCEDURE FOR THE SYNTHESIS OF COMPOUNDS 23-26  
Aldehyde (3 or 4) (1.0 mmol, 1 eq) was dissolved in 1 mL of dry methanol under nitrogen, 2,2-diethoxyethanamine 
(1.0 mmol, 133 mg, 1 eq) was added and the resulting mixture was kept stirring for 2h at room temperature. Benzoic 
acid (1.0 mmol, 122 mg, 1 eq) and isocyanide (5 or 6) (1.2 mmol, 1.2 eq) were sequentially added and the reaction was 
stirred for additional 24h at room temperature. The solvent was removed under reduced pressure, to afford the 
unstable crude Ugi product, which was directly used in the next step. The crude was dissolved in 4.5 mL of 50% 
trifluoroacetic acid in dichloromethane, and the resulting solution was kept under stirring for 24h. The solvent was 
removed under reduced pressure to give a residue which was dissolved in EtOAc (10 mL) and washed with satd aq 
NaHCO3 (2 x 10 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo, to afford the crude 
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product, which was purified by flash chromatography (FC) as indicated below. 
(S)-methyl 2-((R)-4-benzoyl-3-((S)-1-(((benzyloxy)carbonyl)(methyl)amino)ethyl)-2-oxo-3,4-dihydropyrazin-1(2H)-yl)propanoate, 
23a and (S)-methyl 2-((S)-4-benzoyl-3-((S)-1-(((benzyloxy)carbonyl)(methyl)amino)ethyl)-2-oxo-3,4-dihydropyrazin-1(2H)-
yl)propanoate (23b) 
Prepared according to the above general procedure from aldehyde 3 and isocyanide 5; FC: ethyl acetate:n-hexane, 7:3; 
yield: 23a (24 mg, 5%), 23b (311 mg, 65%). 23a: thick oil; Rf  0.30 (7:3 n-hexane/ EtOAc); [α]30D - 22.4 (c 0.5, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.60-7.20 (m, 10H), 6.04 (br, d, J = 5.9 Hz, 1H), 5.68 (d, J = 5.9 Hz, 1H), 5.28 (br, d, J = 
9.2 Hz, 1H), 5.20-4.61 (m, 4H), 3.74 (s, 3H), 2.92 (s, 3H), 1.52 (d, J = 7.0 Hz, 3H), 1.24 (br, m, 3H); 13C NMR (75 MHz, 
CDCl3) δ 170.9, 168.1, 162.9, 155.0, 136.7, 132.3, 130.8, 128.5-127.7 (9C), 112.3, 110.6,  67.2, 56.8, 52.6, 52.0, 48.0, 
29.7, 15.2, 14.9; HRMS (ESI) calcd for C26H29N3NaO6
+  [MNa]+  502.1949, found 502.1953. 23b: foam; Rf  0.37 (7:3 n-
hexane/ EtOAc); [α]20D + 27.6 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3, 1:1 mixture of rotamers) δ 7.61-7.40 (m, 
5H), 7.39-7.27 (m, 5H), 5.96 (br, m, 0.5H), 5.88 (br, d, J = 5.4 Hz, 0.5H),  5.73 (m, 1H), 5.42-5.29 (m, 1H), 5.20-4.95 
(m, 3H), 4.93-4.74 (m, 1H), 3.77 (s, 1.5H), 3.74 (s, 1.5H), 3.00 (s, 1.5H), 2.94 (s, 1.5H), 1.50 (d, J = 7.1 Hz, 1.5H), 1.38 
(d, J = 7.3 Hz, 1.5H), 1.35-1.24 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 171.6 and 170.9 (1C), 168.7 and 168.6 (1C), 
163.1 and 162.9 (1C), 156.6, 137.0, 134.0 and 133.9 (1C), 131.1 and 131.0 (1C), 128.6-127.4 (9C),  111.9 and 111.0 
(1C), 111.4 and 110.3 (1C), 67.3 and 67.0 (1C), 57.9 and 57.1 (1C), 52.5, 52.0 and 50.3 (1C), 50.1 and 49.0 (1C), 29.1 
and 28.8 (1C), 15.9-14.4 (2C); HRMS (ESI) calcd for C26H29N3NaO6
+  [MNa]+  502.1949, found 502.1961. 
(S)-methyl 2-((R)-4-benzoyl-3-((S)-1-(((benzyloxy)carbonyl)(methyl)amino)ethyl)-2-oxo-3,4-dihydropyrazin-1(2H)-yl)-3-
phenylpropanoate, 24a and (S)-methyl 2-((S)-4-benzoyl-3-((S)-1-(((benzyloxy)carbonyl)(methyl)amino)ethyl)-2-oxo-3,4-
dihydropyrazin-1(2H)-yl)-3-phenylpropanoate (24b) 
Prepared according to the above general procedure from aldehyde 3 and isocyanide 6; FC: ethyl acetate:n-hexane, 3:7; 
yield: 24a (16 mg, 3%), 24b (223 mg, 40%). 24a: colorless oil; Rf 0.23 (7:3 n-hexane/ EtOAc); [α]20D - 13.6 (c 0.9, 
CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.61- 7.08 (m, 15H), 5.93 (br, d, J = 5.9 Hz, 0.7H), 5.75 (br, d, J = 5.9 Hz, 0.3H), 
5.66 (d, J = 5.9 Hz, 0.7H), 5.60 (d, J = 5.9 Hz, 0.3H), 5.36-4.97 (m, 4H), 4.72 (m, 0.3H), 4.33 (dq, J = 10.7 and 6.8 Hz, 
0.7H), 3.82 (s, 2.1H), 3.80 (s, 0.9H), 3.48 (dd, J = 14.7 and 4.9 Hz, 0.7H), 3.43 (dd, J = 14.7 and 4.9 Hz, 0.3H), 3.17 (dd, 
J = 14.7 and 12.7 Hz, 0.7H), 3.04 (dd, J = 13.8 and 11.7 Hz, 0.3H), 2.92 (s, 0.9H), 2.85 (s, 2.1H), 0.73 (d, J = 6.8 Hz, 
2.1H), 0.64 (d, J = 6.8 Hz, 0.9H); 13C NMR (75 MHz, CDCl3) δ 170.0, 168.7, 163.7 and 163.2 (1C), 155.9, 136.0, 135.7, 
133.8, 130.8, 129.1-127.2 (14C), 111.8 and 111.3 (1C), 111.0 and 110.0 (1C), 67.4 and 67.0 (1C), 57.7, 56.7, 55.0, 52.7, 
34.8, 28.5, 14.6 and 14.3 (1C); HRMS (ESI) calcd for C32H33N3NaO6
+  [MNa]+  578.2262, found 578.2250. 24b: oil; Rf  
0.27 (7:3 n-hexane/ EtOAc); [α]20D  + 34.5 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.56- 7.18 (m, 15H), 5.90 (d, J 
= 5.9 Hz, 0.7H), 5.78 (br, d, J = 5.7 Hz, 1H), 5.72 (dd, J = 11.3 and 5.4 Hz, 0.3H), 5.59 (m, 1H), 5.38 (br, d, J = 9.3 Hz, 
0.7H), 5.23-5.01 (m, 2.3H), 4.83 (br, m, 1H), 3.73 (s, 2.1H), 3.70 (s, 0.9H), 3.45 (dd, J = 14.4 and 5.4 Hz, 0.3H), 3.40 
(dd, J = 14.4 and 5.7 Hz, 0.7H), 3.02 (dd, J = 14.4 and 10.8 Hz, 1H), 2.90 (s, 2.1H), 2.86 (s, 0.9H), 1.25 (m, 3H); 13C 
NMR (100 MHz, CDCl3) δ 170.2, 168.6, 163.7 and 163.3 (1C), 156.6 and 156.0 (1C), 137.0 and 136.6 (1C), 135.7, 
133.9, 131.0, 129.3-126.9 (14C), 112.7 and 111.6 (1C), 111.4 and 110.4 (1C), 67.0 and 66.9 (1C), 57.8 and 57.4 (1C), 
54.6 and 54.4 (1C), 52.5, 49.9 and 49.7 (1C), 36.7, 28.9, 15.2 and 15.1 (1C); HRMS (ESI) calcd for C32H33N3NaO6
+  
[MNa]+  578.2262, found 578.2248. 
(S)-methyl 2-((R)-4-benzoyl-3-((S)-1-(((benzyloxy)carbonyl)(methyl)amino)-2-phenylethyl)-2-oxo-3,4dihydropyrazin-1(2H)-
yl)propanoate, 25a and (S)-methyl 2-((S)-4-benzoyl-3-((S)-1-(((benzyloxy)carbonyl)(methyl)amino)-2-phenylethyl)-2-oxo-3,4-
dihydropyrazin-1(2H)-yl)propanoate (25b) 
Prepared according to the above general procedure from aldehyde 4 and isocyanide 5; FC: ethyl acetate:n-hexane, 
1:1.5; yield: 25a (27 mg, 5%), 25b (372 mg, 67%). 25a: colorless oil; Rf  0.19 (1.5:1 n-hexane/ EtOAc); [α]20D - 5.9 (c 
0.5, CHCl3); 
1H NMR (300 MHz, CDCl3) δ 7.74-6.96 (m, 15 H), 6.47 (d, J = 6.8 Hz, 0.5H), 6.32 (d, J = 6.8 Hz, 0.5H), 
6.09-6.01 (m, 0.5H), 5.93-5.84 (m, 0.5H), 5.36-4.83 (m, 4.5H), 4.49 (m, 0.5H), 3.75 (s, 1.5H), 3.70 (s, 1.5H), 3.18-2.69 
(m, 5H), 1.32 (d, J = 7.8 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 173.0, 167.4, 162.8, 160.2 and 159.6 (1C), 137.2, 136.2, 
133.0, 131.8, 129.4-127.1 (14C), 112.1-112.3 (2C), 68.1 and 66.8 (1C), 53.4, 52.8, 52.5, 48.3, 37.9 and 37.6 (1C), 29.1, 
18.2; HRMS (ESI) calcd for C32H33N3NaO6
+  [MNa]+  578.2262, found 578.2270. 25b: pale yellow oil; Rf  0.35 (1.5:1 n-
hexane/ EtOAc); [α]20D  - 72.1 (c 0.5, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.61- 7.11 (m, 15H), 5.91 (br, d, J = 5.6 
Hz, 0.6H), 5.82-5.74 (m, 1H), 5.70 (d, J = 5.8 Hz, 0.4H), 5.51 (d, J = 9.8 Hz, 0.6H), 5.42 (d, J = 7.6 Hz, 0.4H), 5.13 (m, 
1H), 5.06-4.90 (m, 2.6H), 4.81 (d, J = 13.0 Hz, 0.4H), 3.77 (s, 1.8H), 3.74 (s, 1.2H), 3.17-2.92 (m, 1.6H), 2.97 (s, 1.8H), 
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2.87 (s, 1.2H), 2.78 (dd, J = 13.9 and 8.1 Hz, 0.4H), 1.49 (d, J = 7.2 Hz, 1.2H), J = 7.5 Hz, 1.8H); 13C NMR (100 MHz, 
CDCl3) δ 170.7, 169.3, 163.3, 157.5 and 157.0 (1C), 138.0 and 137.8 (1C), 137.3 and 137.1 (1C), 134.5 and 134.3 
(1C), 132.0 and 131.7 (1C), 129.4-127.1 (14C), 113.4-111.1 (2C), 67.9 and 67.5 (1C), 59.3 and 58.4 (1C), 57.4 and 
54.1 (1C), 53.2 and 52.9 (1C), 51.3 and 51.0 (1C), 36.2 and 35.6 (1C), 29.9 and 29.8 (1C), 15.5 and 15.0 (1C); HRMS 
(ESI) calcd for C32H33N3NaO6
+  [MNa]+  578.2262, found 578.2268. 
(S)-methyl 2-((R)-4-benzoyl-3-((S)-1-(((benzyloxy)carbonyl)(methyl)amino)-2-phenylethyl)-2-oxo-3,4-dihydropyrazin-1(2H)-yl)-3-
phenylpropanoate, 26a and (S)-methyl 2-((S)-4-benzoyl-3-((S)-1-(((benzyloxy)carbonyl)(methyl)amino)-2-phenylethyl)-2-oxo-3,4-
dihydropyrazin-1(2H)-yl)-3-phenylpropanoate (26b) 
Prepared according to the above general procedure from aldehyde 4 and isocyanide 6; FC: ethyl acetate:n-hexane, 3:7; 
yield: 26a (56 mg, 9%), 26b (284 mg, 45%). 26a: colorless oil; Rf  0.22 (7:3 n-hexane/ EtOAc); [α]30D - 11.1 (c 0.5, 
CHCl3); 
1H NMR (300 MHz, CDCl3, complex mixture of conformers) δ 7.68-6.81 (m, 20H), 6.38 (d, J = 5.8 Hz, 0.1H), 
5.94-5.80 (m, 0.7H), 5.79-5.72 (m. 0.2H), 5.72-5.54 (m, 1H), 5.51-5.37 (m, 0.5H), 5.31-4.65 (m, 4.5H), 3.74 (s, 0.3H), 
3.70 (s, 2H), 3.67 (s, 0.7H),  3.49-3.18 (m, 1H), 3.16-2.87 (m, 3H), 2.83 (s, 0.7H), 2.80 (s, 2H), 2.72 (s, 0.3H); 13C NMR 
(75 MHz, CDCl3) δ 170.2-169.6 (1C), 168.9-168.4 (1C), 163.6 and 163.1 (1C), 157.0 and 156.8 (1C), 137.3-135.7 (4C), 
131.8-130.9 (1C), 129.3-126.5 (19C), 112.5-106.7 (2C), 68.1-66.8 (1C), 58.0 and 57.7 (1C), 57.3-57.0 (1C), 55.8-55.3 
(1C), 54.1-52.2 (2C), 38.0-37.6 (1C), 35.3-34.7 (1C), 29.4 and 29.0 (1C); HRMS (ESI) calcd for C38H37N3NaO6
+ [MNa]+  
654.2575, found 654.2561. 26b: foam; Rf  0.30 (7:3 n-hexane/ EtOAc); [α]20D - 139.8 (c 1.0, CHCl3); 1H NMR (400 
MHz, CD3CN, mixture of two conformers 1.5:1) δ 7.64-7.01 (m, 20H), 6.01 (m, 0.8H), 5.96 (d, J = 5.9 Hz, 0.6H), 5.79 
(d, J = 5.4 Hz, 0.6H), 5.63 (dd, J = 11.1 and 5.4 Hz, 0.4H), 5.53 (dd, J = 10.8 and 5.4 Hz, 0.6H), 5.15-4.87 (m, 3.6H), 
4.69 (d, J = 12.9 Hz, 0.4H), 3.71 (s, 3H), 3.43 (dd, J = 14.7 and 5.4 Hz, 0.4H), 3.37 (dd, J = 14.7 and 5.4 Hz, 0.6H), 3.08 
(dd, J = 14.7 and 11.1 Hz, 0.4H), 3.07 (dd, J = 14.7 and 0.81 Hz, 0.6H), 3.04-2.87 (m, 2H), 2.83 (s, 3H); 13C NMR (100 
MHz, CD3CN) δ 170.1 and 169.9 (1C), 168.5 and 168.4 (1C), 163.6 and 163.3 (1C), 156.6 and 155.8 (1C), 138.0 and 
137.4 (1C), 136.5 and 136.4 (2C), 134.2 and 133.8 (1C), 131.1 and 130.9 (1C), 129.1-126.4 (19C), 112.0-111.5 (2C), 
66.5 and 66.3 (1C), 57.2 and 57.1 (1C), 56.0, 55.1-54.8 (2C), 52.2 and 52.1 (1C), 36.1 and 35.9 (1C), 34.9 and 34.6 
(1C), 29.0 and 28.8 (1C); HRMS (ESI) calcd for C38H37N3NaO6
+ [MNa]+  654.2575, found 654.2558. 
COMPUTATIONAL STUDIES 
Conformational analysis on compound 11. 
MMFF and DFT calculations were run with Spartan’10 (Wavefunction, Inc., Irvine CA, 2010), with standard 
parameters and convergence criteria. TDDFT calculations were run with Gaussian’09,27 with default grids and 
convergence criteria. Conformational searches were run with the Monte Carlo algorithm implemented in Spartan’10 
using Merck molecular force field (MMFF) in vacuo. All structures thus obtained were optimized with DFT method 
using B3LYP functional and 6-31G(d) basis set in vacuo. TDDFT calculations were run using CAM-B3LYP functional 
and SVP basis set,  including 36 excited states (roots). On some representative structures, we verified the consistency 
with the results obtained with the larger TZVP basis set. CD spectra were generated using the program SpecDis29 by 
applying a Gaussian band shape with 0.3 eV exponential half-width, from dipole-length rotational strengths. The 
difference with dipole-velocity values was checked to be minimal for all relevant transitions. 
Computational studies on models a, b and c. 
The starting geometries of compounds a, b and c (Figure 14), created by GaussView,27 were energy minimized by 
the conjugate gradient algorithm implemented in Gaussion09.27 Thus, The optimized geometries were subjected to 
heating, equilibration, and molecular dynamics simulation by sander module of AMBER 12.25 GAFF force field were 
used for the parametrization of  the molecules, modeled as neutral compounds in an implicit GB solvent model and a 
dielectric continuum of 80 (simulating water).26 With a time step 2 fs, each peptidomimetic was heated to 300 K, 700 
K and then to 1000 K over 20 ps. After an equilibration phase of 2 ns, each model were frozen to 700 K and then to 
300 K, over 20 ps. The production run of the MD simulations were performed for a total time of 20 ns with 
trajectories saved every 10 ps. The resulting structures in the trajectories were visually analyzed by VMD.30 In this 
stage, the fluctuation of the diverse torsion angles were analyzed and the different families of conformers were 
identified. They were then minimized by Gasussian09 at DFT/B3LYP/6-31g(d) level of theory and the lowest energy 
conformation and the Boltzmann equation was applied to calculate the conformers percentage distribution (Figure 
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14). Cβ-Cβ distances were measured by GaussView. 
BIOLOGICAL EVALUATION 
Cytotoxicities of compounds 11-14, 19-22 and 23-26. 
Cytotoxic activities were investigated using the NCI-SRB method on epithelial-like (Huh7) and PTEN deficient 
mesenchymal like Mahlavu cells.31 Cytotoxic effects of the compounds were observed after 72 hours (see Supporting 
Information). Human liver cancer cells (Huh7 and Mahlavu,) were grown in Dulbecco's Modified Eagle Medium 
(DMEM), with 10% fetal bovine serum, 1% non-essential amino acids and 1% penicillin/streptomycin (GIBCO, 
Invitrogen) at 37 °C under 5% CO2. 
NCI-60 Sulforhodamine B (SRB) assay. 
Huh7 and Mahlavu liver cancer cells were grown in 96-well plates (2000-cells/well in 150 µl). After 24hr one plate for 
each cell line was fixed with 100μl 10% ice-cold trichloroacetic acid (TCA). This plate represents the behavior of the 
cells just prior to drug treatment and is accepted as the time-zero plate (Tz). Then they were treated with serial 
dilution concentrations of the compounds (40, 20, 10, 5, 2.5 µM) dissolved in Dimethyl sulfoxide (DMSO). 
Corresponding DMSO vehicle were also applied to Huh7 and Mahlavu cells as negative controls. DMSO 
concentrations were always below 0.01%. After 72h, cells were washed with 1xPBS (CaCl2-, MgCl2-free) (Gibco, 
Invitrogen), and then fixed with cold 10% (v/v) trichloroacetic acid (MERCK). Microplates were left for 1h at 4°C, then 
washed with water and left to dry. The plates were then stained with 100μl of 0.4% sulphorhodamine B (SRB) (Sigma 
Aldrich) in 1% acetic acid solution for 10min. The unbound SRB was washed with 1% acetic acid. SRB was then 
solubilized in 200μl of 10mM Tris-base solution. The absorbance was read at 515 nm. The experiment was performed 
in duplicate and the absorbance values were normalized to DMSO controls and Tz values. Standard deviations were 
less than 10%. 
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2.2 Diamine-based peptidomimetics 
 
Figure 15. Examples of diamine-based peptidomimetics able to disrupt PPIs.30,31 
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α
   
Scheme 23. Multicomponent approach for the synthesis of diamine-based peptidomimetics  
through N-split Ugi reaction. 
α
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Scheme 24. One-pot synthesis of piperazine-based peptidomimetics 30a-d  
via N-split Ugi reaction employing chiral components. 
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Scheme 25. N-split Ugi reaction involving bispidine 28b with the formation of the desired product 31a  
in combination with 1,3-diazaadamantane 32. Determination of the role of 1,3-diazaadamantane. 
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Scheme 26. One-pot synthesis of bispidine-containing N-split Ugi adducts 31a-b  
and bispidine-based peptidomimetics 31c-e. 
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GENERAL INFORMATION 
All commercial materials (Aldrich, Fluka) were used without further purification. All solvents were of reagent grade or 
HPLC grade. Compound 28b was synthesized through a slightly modified reported procedure35 and stored as a 
perchlorate salt. All reactions were carried out under a nitrogen atmosphere unless otherwise noted. All reactions 
were monitored by thin layer chromatography (TLC) on precoated silica gel 60 F254; spots were visualized with UV 
light or by treatment with a 1% aqueous KMnO4 solution. Products were purified by flash chromatography on silica 
gel 60 (230–400 mesh). 1H NMR spectra and 13C NMR spectra were recorded on 300 and 400 MHz spectrometers. 
Chemical shifts are reported in parts per million relative to the residual solvent. 13C NMR spectra have been recorded 
using the APT pulse sequence (for further details see Appendix A.1). Multiplicities in 1H NMR are reported as follows: 
s = singlet, d = doublet, t = triplet, m = multiplet, br s = broad singlet. High resolution MS spectra were recorded with 
an FT-ICR (Fourier Transform Ion Cyclotron Resonance) instrument, equipped with an ESI source. CD spectra were 
recorded with a JASCO J-715 spectropolarimeter. 
GENERAL PROCEDURE FOR PIPERAZINE-BASED COMPOUNDS 30a-d  
To a solution of piperazine 28a (0.8 mmol, 1 eq) in 2 ml of dry MeOH under nitrogen was added N-Boc-L-Alanine 
27a (0.87 mmol, 1.1 eq) and paraformaldehyde (0.95 mmol, 1.2 eq). The solution was heated to reflux and stirred for 
2 h. After cooling to r.t., isocyanide 29 or 5 (0.95 mmol, 1.2 eq) was added and stirring was allowed to continue for 
48 h. The solvent was evaporated in vacuo and the crude reaction mixture was purified by flash chromatography on 
silica gel (EtOAc) to afford the pure product 30. 
(S)-tert-butyl (1-(4-(2-(tert-butylamino)-2-oxoethyl)piperazin-1-yl)-1-oxopropan-2-yl)carbamate (30a)  
White solid, 0.136 g (51%); [α]20D +8.3 (c 0.1.0, CHCl3); 1H NMR (400 MHz, CDCl3): δ 6.87 (s, 1H), 5.49 (d, J = 7.8 
Hz, 1H), 4.65-4.60 (m, 1H), 3.70-3.45 (m, 4H), 2.95 (s, 2H), 2.64-2.49 (m, 4H), 1.46 (s, 9H), 1.39 (s, 9H), 1.32 (d, J=6,9 
Hz ,3H); 13C NMR (100 MHz, CDCl3): δ 171.3, 168.4, 155.1, 79.6, 62.1, 53.3, 53.0, 50.7, 46.0, 45.4, 42.0, 28.8 (3C), 
28.4 (3C), 19.38; HRMS (ESI): calcd for [C18H35N4O4]
+ 371.2653, found 371.2661 [MH+]. 
(S)-tert-butyl(1-oxo-1-(4-(2-oxo-2-((2,2,3,3-tetramethylbutyl)amino)ethyl)piperazin-1-yl)propan-2-yl)carbamate (30b)  
White solid, 0.243 g (72%); [α]20D +7.19 (c 0.9, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.02 (s, 1H), 5.49 (d, J = 7.5 Hz 
1H), 4.62 (m, 1H), 3.82-3.43 (m, 4H), 2.94 (s, 2H), 2.54 (m, 4H), 1.72 (s, 2H), 1.45 (s, 15H), 1.31 (d, J = 6.8 Hz, 3H), 
1.04 (s, 9H); 13C NMR (100 MHz, CDCl3): δ 171.9, 168.9, 155.7, 80.3, 63.1, 55.4, 54.1, 53.7, 53.4, 46.7, 46.0, 42.7 (2C), 
32.2 (3C), 29.5 (2C), 29.0 (3C), 20.1; HRMS (ESI): calcd for [C22H43N4O4]
+ 427.3279, found 427,3271[MH+]. 
(S)-methyl-2-(2-(4-(2-((tert-butoxycarbonyl)amino)propanoyl)piperazin-1-yl)acetamido)acetate (30c)  
Yellowish oil, 0.242 g (79%); [α]20D +5.2 (c 0.3, CHCl3);  1H NMR (400 MHz, CDCl3): δ 7.54 (br, 1H), 5.48 (d, J = 7.7 
Hz, 1H), 4.59 (m, 1H), 4.08 (d, J = 5.7 Hz, 2H), 3.75 (s, 3H), 3.74-3.43 (m, 4H), 3.09 (s, 2H), 2.58 (m, 4H), 1.42 (s, 9H), 
1.29 (d, J = 6.9 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 171.8, 170.6, 169.7, 155.5, 80.2, 60.8, 53.4, 53.2, 52.9, 46.4, 
45.0, 41.2, 40.8, 28.8 (3C), 19.6; HRMS (ESI): calcd for [C17H31N4NaO6]
+ 409.2058, found 409.2071 [MNa+]. 
(S)-methyl2-(2-(4-((S)-2-((tert-butoxycarbonyl)amino)propanoyl)piperazin-1-yl)acetamido)propanoate (30d)  
Yellowish oil, 0.210 g (66%); [α]20D +4.1 (c 0.6, CHCl3);  1H NMR (400 MHz, DMSO-d6, 80°C): δ 7.57 (br, 1H), 5.51 (d, 
J = 7.7 Hz, 1H), 4.63 (m, 2H), 3.77 (s, 3H), 3.76-3.49 (m, 4H), 3.13 (d, J = 16.2 Hz, 1H), 3.03 (d, J = 16.2 Hz, 1H), 2.78-
2.47 (m, 4H), 1.47-1.42 (m, 12H), 1.31 (d, J = 6.9 Hz, 3H); 13C NMR (100 MHz, DMSO-d6, 80°C): δ 174.0, 171.9, 
169.8, 155.7, 80.3, 61.9, 54.0, 53.6, 53.2, 48.1, 46.7, 46.0, 42.7, 29.0 (3C), 20.0, 19.1; HRMS (ESI): calcd for 
[C18H32N4NaO6]
+ 423.2214, found 423.2209 [MNa+]. 
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GENERAL PROCEDURE FOR BISPIDINE-BASED COMPOUNDS 31a-e  
To a solution of bispidine 28b (0.8 mmol, 1 eq) in 1.6 mL of MeOH was added benzoic acid 27b (or 27, 0.950 mmol, 
1.2 eq) and aqueous formaldehyde solution 37 wt % (1.6 mmol, 2 eq). After 2h, isocyanide 29 or 5 (0.950 mmol, 1.2 
eq) was added and stirring was allowed to continue for 48 h. The solvent was evaporated in vacuo and the crude 
reaction mixture was purified by flash chromatography on silica gel (EtOAc) to afford pure product 31. 
2-(7-benzoyl-3,7-diazabicyclo[3.3.1]nonan-3-yl)-N-(4-methoxybenzyl)acetamide (31a)  
Yellowish solid, 0.194 g (60%); 1H NMR (300 MHz, CDCl3, rotameric mixture): δ 8.70 (m, 0.5H), 8.33 (m, 0.5H), 7.67-
7.24 (m, 5H), 7.17 (d, J = 8.7 Hz, 2H), 6.87 – 6.71 (m, 2H), 4.94 (br, d, J = 13.7 Hz, 1H), 4.45 (br, t, J = 6.4 Hz, 1H), 
4.33 (br, d, J = 5.5 Hz 2H), 3.81-3.50 (m, 6H), 3.40 (m, 1H), 3.25 (br, d, J = 11.2 Hz, 1H), 3.15 (m, 1H),  2.99 (d, J = 
12.0 Hz, 1H), 2.65 (m, 1H), 2.48-1.57 (m, 4H); 13C NMR (75 MHz, CDCl3): δ 172.2, 169.6, 158.5, 136.6, 131.9, 129.8 
(2C), 129.5, 128.5 (2C), 126.8 (2C), 113.6 (2C), 63.3, 58.7 (2C), 55.2, 53.4, 46.0, 42.2, 32.2, 29.7, 28.8; HRMS (ESI): 
calcd for [C24H30N3O3]
+ 408.2282, found 408.2286 [MH+]. 
2-(7-acetyl-3,7-diazabicyclo[3.3.1]nonan-3-yl)-N-(4-methoxybenzyl)acetamide (31b)  
Yellowish solid, 0.164 g (62%); 1H NMR (400 MHz, CDCl3): δ 7.74 (br, m, 1H), 7.36 (d, J = 8.2 Hz, 2H), 6.86 (d, J = 8.2 
Hz, 2H), 4.75 (br, d, J = 12.9 Hz, 1H), 4.47 (br, dd, J = 14.0, 6.7 Hz, 1H), 4.29 (br, dd, J = 14.0, 5.2 Hz, 1H) 3.86 (br, d, 
J = 11.7 Hz, 1H), 3.80 (s, 3H), 3.40 (br, d, J = 12.6 Hz, 1H), 3.15-2.97 (br, m, 2H), 2.93 (br, d, J = 9.5 Hz, 1 H), 2.83 
(br, d, J = 13.1 Hz, 1H), 2.70 (br, d, J = 15.8 Hz, 1H), 2.55 (br, d, J = 8.5 Hz, 1H), 2.20 (br, d, J = 9.5 Hz, 1H), 2.05-1.85 
(br, m, 5H), 1.83-1.63 (br, m, 2H); 13C NMR (100 MHz, CDCl3): δ 172.0, 169.5, 158.6, 131.6, 129.5 (2C), 113.7 (2C), 
61.6, 59.2, 58.7, 51.3, 45.8 (2C), 42.2, 29.7, 28.8 (2C), 22.1; HRMS (ESI): calcd for [C19H27N3NaO3]
+ 368.1945, found 
368.1954 [MNa+]. 
methyl (2-(7-((tert-butoxycarbonyl)-L-alanyl)-3,7-diazabicyclo[3.3.1]nonan-3-yl)acetyl)-L-alaninate (31c)  
White solid, 0.136 g (39%); [α]20D -17.6 (c 0.95, CHCl3);  1H NMR (400 MHz, CDCl3, rotameric mixture): δ 7.7 (m, 
0.5H), 7.6 (br, d, J = 9.5, 1H), 6.3 (m, 0.5H), 5.11-4.73 (m, 2H), 4.7-4.5 (m, 1H), 4.4 (br, d, J = 10.3, 0.75H), 4.20-4.07 
(m, 0.25), 3.8-3.7 (m, 3H), 3.5-3.3 (m, 1H), 3.2-3.0 (m, 1H), 3.0-2.8 (m, 1H), 2.7-2.5 (m, 1H), 2.5-2.35 (m, 1H), 2.2-2.1 
(m, 1H), 2.0-1.9 (m, 2H), 1.9-1.7 (m, 2H), 1.6-1.3 (m, 15H); 13C NMR (100 MHz, CDCl3): δ 174.5-173.2 (2C), 171.2, 
156.0, 80.1, 63.9-62.6, 59.0-58.3 (2C), 53.0-52.6, 51.0-50.7, 48.4-47.8, 47.2-46.6, 45.8, 34.5-32.0, 29.5-28.7 (5C), 19.2-
17.5 (2C); HRMS (ESI): calcd for [C21H36N4NaO6]
+ 463.2527, found 463.2516 [MNa+]. 
methyl (2-(7-(((benzyloxy)carbonyl)-L-alanyl)-3,7-diazabicyclo[3.3.1]nonan-3-yl)acetyl)-L-alaninate (31d)  
White solid, 0.143 g (38%); [α]20D -10.2 (c 0.8, CHCl3); 1H NMR (400 MHz, CDCl3, rotameric mixture): δ 7.61 (br, d, J 
= 9.0 Hz, 1H), 7.45-7.23 (m, 5H), 6.78 (br, d, J =  9.3 Hz, 1H), 5.20-4.98 (m, 2H), 4.91 (m, 1H), 4.87-4.75 (m, 2H), 
4.39-3.95 (m, 1H), 3.75 – 3.72 (m, 3H), 3.55 - 2.77 (m, 3H), 2.82 – 2.45 (m, 2H), 2.45 (d, J = 16.1Hz, 1H), 2.28-2.07 
(m, 2H), 2.07-1.60 (m, 4H), 1.58-1.44 (m, 3H), 1.36-1.29 (m, 3H); 13C NMR (100 MHz, CDCl3): δ 174.2-172.0 (2C), 
169.4, 155.9, 136.5, 128.5-128.1 (2C), 66.6, 62.7, 59.0-58.3 (2C), 52.4-52.1 (2C), 50.3, 47.2, 46.2-46 (2C), 45.8, 32.1, 
28.9 (2C), 18.7, 17.4; HRMS (ESI): calcd for [C24H35N4O6]
+ 475.2551, found 475.2562 [MH+].  
methyl (2-(7-((((9H-fluoren-9-yl)methoxy)carbonyl)-L-alanyl)-3,7-diazabicyclo[3.3.1]nonan-3-yl)acetyl)-L-alaninate (31e)  
White solid, 0.178 g (40%); [α]20D -6.8 (c 1, CHCl3); 1H NMR (400 MHz, CDCl3, rotameric mixture): δ 7.77 (br, 2d, J = 
6.9 Hz, 2H), 7.69 (br, d, J = 9.4 Hz, 1H), 7.65-7.58 (m, 2H), 7.41 (br, 2d, J = 7.3 Hz, 2H), 7.37-7.29 (m, 2H), 6.98 (br, d, 
J = 9.5, 1H), 4.97 (m, 1H), 4.92-4.78 (m, 1.5H), 4.71 (m, 0.5H), 4.54-4.30 (m, 2H), 4.30-4.13 (m, 1.5H), 4.13-3.93 (m, 
0.5), 3.84-3.69 (m, 3H), 3.58-3.35 (m, 1.5H), 3.20-3.03 (m, 1.5H), 3.01-2.93 (m, 1.5H), 2.92-2.82 (m, 1H), 2.66-2.42 (m, 
1.5H), 2.39 (br, d, J = 11.2 Hz, 1H), 2.10-1.92 (m, 2H), 1.90-1.65 (m, 2H), 1.62-1.44 (m, 3H), 1.44-1.34 (m, 3H); 13C 
NMR (100 MHz, CDCl3): δ 174.2-171.0 (2C), 169.4, 155.9, 143.9 (2C), 141.2 (2C), 127.7 (2C),  127.2-127.0 (2C), 
125.2 (2C), 119.9 (2C), 67.1, 62.6, 58.6-58.1 (2C), 52.3, 50.2, 47.4-47.0 (2C), 46.3, 46, 32.2, 29.0-28.5 (2C), 18.8, 17.5; 
HRMS (ESI): calcd for [C31H39N4O6]
+ 563.2864, found 563.2868 [MH+]. 
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2.3 Polyimidazole-based β-strand peptidomimetics 
β
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Figure 16. Hamilton’s β-strand non-peptidic scaffolds.42 
β
Scheme 27.  Polyimidazole-based β-strand peptidomimetic obtained through an iterative van Leusen three-
component reaction (vL-3CR). 
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Scheme 28. Screening of p-substituted benzaldehydes in the vL-3CR. 
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Scheme 29. Iterative synthesis of β-strand polyimidazole-based peptidomimetics, bearing two (34b), three (34c) and 
four (34d) side-chain residues. Reagents and conditions: (a) BuLI, THF, 2h, -78 °C; then DMF, -78 to rt, 24h. (b) 
MeNH2, DMF, 2h, rt; then K2CO3, TosMIC, 24h, 50 °C. (c) BuLI, TMEDA, THF, 2h, -78 °C; then DMF, -78 to rt, 24h. 
↔ ↔
↔ ↔ ↔
 
Figure 17. Solution-phase analysis of trimer 34c (a) and tetramer 34d (b). Selected regions of the NOESY NMR 
spectrum focusing on cross-peaks between N-Me and aromatic protons. Key observed (green) and absent (red) NOE 
correlations are indicated (CDCl3, 400 MHz, 298 K). 
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Figure 18. a) Torsion angle distributions derived from the MD simulations of 34d. b) Superimposition between 34d 
(yellow) and a hypothetical protein β-strand (cyan). 
β
β
Å
β
0
10
20
30
40
50
60
70
1
8
0
|1
5
0
1
5
0
|1
2
0
1
2
0
|9
0
9
0
|6
0
6
0
|3
0
3
0
|0
0
|-
3
0
-3
0
|-
6
0
-6
0
|-
9
0
-9
0
|-
1
2
0
-1
2
0
|-
1
5
0
-1
5
0
|-
1
8
0
t1
t1
t1
D
is
tr
ib
u
ti
o
n
 p
e
rc
e
n
ta
g
e
Torsion angles ranges (degrees)
t1
t3
t2
a) b)
2. Conformationally constrained peptidomimetics as inhibitors of PPIs 
 
69 
 
GENERAL INFORMATION 
All commercial materials (Aldrich, Fluka) were used without further purification. All solvents were of reagent grade or 
HPLC grade. All reactions were carried out under a nitrogen atmosphere unless otherwise noted. All reactions were 
monitored by thin layer chromatography (TLC) on precoated silica gel 60 F254; spots were visualized with UV light or 
by treatment with a 1% aqueous KMnO4 solution. Products were purified by flash chromatography on silica gel 60 
(230–400 mesh). 1H NMR spectra and 13C NMR spectra were recorded on 300 and 400 MHz spectrometers. 
Chemical shifts are reported in parts per million relative to the residual solvent. 13C NMR spectra have been recorded 
using the APT pulse sequence (for further details see Appendix A.1). Multiplicities in 1H NMR are reported as follows: 
s = singlet, d = doublet, t = triplet, m = multiplet, br s = broad singlet. High-resolution MS spectra were recorded 
with an FT-ICR (Fourier Transform Ion Cyclotron Resonance) instrument, equipped with an ESI source. UV-Vis 
spectra were obtained with Jasco V-650 spectrophotometer. CD spectra were obtained with JASCO J-715 
spectropolarimeter. 
GENERAL PROCEDURE FOR THE SYNTHESIS OF COMPOUNDS 33 ,  34a-d ,  35 
AND 36  
Aldehyde (4-nitrobenzaldehyde, benzaldehyde, 4-methoxybenzaldehyde, 4-(dimethylamino)benzaldehyde or 37a-c) (1 
eq) was dissolved in DMF (Conc. as indicated below). Methylamine aqueous solution 40 wt. % (2 eq) was added and 
the resulting mixture was kept under stirring for 2h at room temperature. Potassium carbonate (1.5 eq) and 
tosylmethyl isocyanide (1.2 eq) were sequentially added and the reaction was stirred for additional 24h at 50 °C. The 
resulting mixture was then partitioned between ethyl acetate/water, and the organic phase was washed with brine 
(x5), dried over Na2SO4 and concentrated under reduced pressure, to give a residue that was purified by flash 
chromatography (FC) as indicated below. 
1-methyl-5-(4-nitrophenyl)-1H-imidazole (33) 
Prepared according to the above general procedure from 4-nitrobenzaldehyde (0.6 mmol, 91 mg); Conc: 1 M; FC: 
ethyl acetate; yellowish solid (11 mg); yield: 9%; spectroscopic data are in agreement with literature.45  
1-methyl-5-phenyl-1H-imidazole (34a) 
Prepared according to the above general procedure from benzaldehyde (9.8 mmol, 1040 mg); Conc: 1 M; FC: ethyl 
acetate; yellowish solid (1285 mg); yield: 83%; spectroscopic data in agreement with literature.46 
1,3'-dimethyl-5-phenyl-1H,3'H-2,4'-biimidazole (34b) 
Prepared according to the above general procedure from 37a (3.8 mmol, 700 mg); Conc: 1 M; FC: CH2Cl2:methanol 
98:2 to 90:10; yellowish solid (633 mg); yield: 70%; 1H NMR (400 MHz, CDCl3) δ 7.60 (s, 1H), 7.51 – 7.48 (m, 1H), 
7.48 – 7.45 (m, 4H), 7.32 (br, d, J = 1.0 Hz, 1H), 7.23 (s, 1H), 3.93 (s, 3H), 3.71 (s, 3H); 13C NMR (100 MHz, ) δ 139.8, 
139.6, 134.9, 130.0, 129.9, 128.8 (2C), 128.7 (2C), 128.1, 127.7, 122.9, 33.4, 33.2; HRMS (ESI) calcd for C14H15N4
+  
[MH]+ 239.1291, found 239.1279. 
1,3',3''-trimethyl-5-phenyl-1H,3'H,3''H-2,4':2',4''-terimidazole (34c) 
Prepared according to the above general procedure from 37b (1.1 mmol, 292 mg); Conc: 0.5 M; FC: ethyl 
acetate:methanol 96:4 to 90:10 + 1% Et3N; yellowish solid (217 mg); yield: 62%; 
1H NMR (400 MHz, CDCl3) δ 7.61 (s, 
1H), 7.54 – 7.43 (m, 5H), 7.42 (s, 1H), 7.36 (d, J = 0.8 Hz, 1H), 7.26 (s, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 3.74 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 140.4, 140.0, 139.5, 135.1, 130.7, 130.0, 129.8, 128.8 (2C), 128.7 (2C), 128.2, 128.0, 123.9, 
122.4, 33.5, 33.4, 33.2; HRMS (ESI) calcd for C18H19N6
+  [MH]+ 319.1666, found 319.1659.  
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1,3',3'',3'''-tetramethyl-5-phenyl-1H,3'H,3''H,3'''H-2,4':2',4'':2'',4'''-quaterimidazole (34d) 
Prepared according to the above general procedure from 37c (0.12 mmol, 42 mg); Conc: 0.25 M; FC: ethyl 
acetate:methanol 85:15 + 1 % Et3N; yellowish solid (20 mg); yield: 43%;
 1H NMR (400 MHz, CDCl3) δ 7.64 (s, 1H), 
7.54 – 7.49 (m, 1H), 7.48 (d, J = 2.2 Hz, 4H), 7.46 (s, 1H), 7.45 (s, 1H), 7.39 – 7.34 (br, m, 1H), 7.27 (s, 1H), 3.98 (s, 
3H), 3.93 (s, 3H), 3.92 (s, 3H), 3.76 (s, 3H); 13C NMR (101 MHz, ) δ 140.6, 140.3, 140.0, 139.4, 135.1, 130.5, 130.1, 
129.7, 128.9 (2C), 128.7 (2C), 128.3 (2C), 127.9, 124.1, 123.4, 122.3, 33.6, 33.5, 33.4, 33.3; HRMS (ESI) calcd for 
C22H23N8
+  [MH]+ 399.2040, found 399.2046.       
5-(4-methoxyphenyl)-1-methyl-1H-imidazole (35) 
Prepared according to the above general procedure from 4-methoxybenzaldehyde (0.6 mmol, 82 mg); Conc: 1 M; FC: 
ethyl acetate; yellowish solid (86 mg); yield: 76%; spectroscopic data are in agreement with literature.46 
N,N-dimethyl-4-(1-methyl-1H-imidazol-5-yl)aniline (36) 
Prepared according to the above general procedure from 4-(dimethylamino)benzaldehyde (0.6 mmol, 88 mg); Conc: 1 
M; FC: ethyl acetate; yellowish solid (56 mg); yield: 46%; 1H NMR (400 MHz, CDCl3) δ 7.48 (s, 1H), 7.25 (d, J = 8.4 
Hz, 2H), 7.00 (s, 1H), 6.77 (d, J = 8.4 Hz, 2H), 3.62 (s, 3H), 3.00 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 150.8, 138.8, 
134.5, 130.2 (2C), 127.5, 118.0, 112.9 (2C), 41.0 (2C), 33.0; HRMS (ESI) calcd for C12H16N3
+ [MH]+ 202.1339, found 
202.1330. 
GENERAL PROCEDURE FOR THE SYNTHESIS OF COMPOUNDS 37a-b  
To a solution of compound 34a (or 34b) (1 eq) in dry THF under nitrogen atmosphere (Conc. as indicated below) 
cooled to -78 °C, was added dropwise a solution of n-butyl lithium in hexane(1.5 eq), and the resulting mixture was 
kept under stirring for 2h at the same temperature. Freshly distilled DMF (2eq) was added and the reaction was 
stirred for additional 24h at room temperature. The resulting mixture was then quenched with ice-water and 
extracted with ethyl acetate (x2). The organic phase was washed with brine (x4), dried over Na2SO4 and concentrated 
under reduced pressure, to give a residue that was purified by flash chromatography (FC) as indicated below. 
1-methyl-5-phenyl-1H-imidazole-2-carbaldehyde (37a) 
Prepared according to the above general procedure from 34a (6.3 mmol, 997 mg); Conc: 0.5 M; FC: ethyl acetate:n-
hexane 4:6; yellowish solid (727 mg); yield: 62%; 1H NMR (400 MHz, CDCl3) δ 9.87 (s, 1H), 7.56 – 7.46 (m, 3H), 7.44 
(dd, J = 7.7, 1.7 Hz, 2H), 7.36 (s, 1H), 4.00 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 182.9, 145.2, 140.5, 131.7, 130.0, 
129.7 (2C), 129.7 (2C), 128.5, 33.8; HRMS (ESI) calcd for C11H11N2O
+ [MH]+ 187.0866, found 187.0874. 
1,3’-dimethyl-5-phenyl-1H,3’H-[2,4’-biimidazole]-2’-carbaldehyde (37b) 
Prepared according to the above general procedure from 34b (2.5 mmol, 595 mg); Conc: 0.25 M; FC: ethyl acetate:n-
hexane 6:4; yellowish solid (345 mg); yield: 52%; 1H NMR (300 MHz, CDCl3) δ 9.88 (s, 1H), 7.51 (s, 1H), 7.50 – 7.40 
(m, 5H), 7.28 (s, 1H), 4.23 (s, 3H), 3.70 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 182.2, 144.6, 137.6, 135.9, 132.0, 129.3 
(2C), 128.9 (2C), 128.8 (2C), 128.5, 33.7, 33.3 (1 quaternary carbon is missed); HRMS (ESI) calcd for C15H15N4O
+ 
[MH]+ 267.1240, found 267.1245. 
PROCEDURE FOR THE SYNTHESIS OF 1,3',3''-trimethyl-5-phenyl-1H,3'H,3''H-[2,4':2',4''-
terimidazole]-2''-carbaldehyde (37c) 
To a solution of compound 34c (0.37 mmol, 118 mg, 1 eq) and TMEDA (0.74 mmol, 86 mg, 2 eq)  in dry THF under 
nitrogen atmosphere (0.05 M) cooled to -78 °C, was added dropwise a solution of n-butyl lithium in hexane (0.55 
mmol, 1.5 eq), and the resulting mixture was kept under stirring for 2h at the same temperature. Freshly distilled DMF 
(0.74 mmol, 54 mg, 2eq) was added and the reaction was stirred for additional 24h at room temperature. The 
resulting mixture was then quenched with ice-water and extracted with ethyl acetate (x2). The organic phase was 
washed with brine (x4), dried over Na2SO4 and concentrated under reduced pressure, to give a residue that was 
purified by flash chromatography (ethyl acetate:methanol 97.5:2.5 to 95:5), affording the desired product 37c (52 mg, 
2. Conformationally constrained peptidomimetics as inhibitors of PPIs 
 
71 
 
yield: 41%) as a yellowish solid. 1H NMR (400 MHz, CDCl3) δ 9.89 (s, 1H), 7.53 (s, 1H), 7.51 – 7.32 (m, 6H), 7.24 (s, 
1H), 4.19 (s, 3H), 3.94 (s, 3H), 3.72 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 182.91, 145.47, 139.18, 135.77, 133.18, 
131.12, 130.30, 129.52 (2C), 129.42 (2C), 128.99, 128.88, 34.34, 34.15, 33.88 (3 quaternary carbons are missed); 
HRMS (ESI) calcd for C19H19N6O
+ [MH]+ 347.1615, found 347.1608. 
COMPUTATIONAL STUDIES 
Conformational studies on compound 34d 
The starting geometries of 34d, created by GaussView,27 were energy minimized by the conjugate gradient algorithm 
implemented in Gaussion09.27 Thus, The optimized geometries were subjected to heating, equilibration, and molecular 
dynamics simulation by sander module of AMBER 12.25 GAFF force field were used for the parametrization of  the 
molecules, modeled as neutral compounds in an implicit GB solvent model and a dielectric continuum of 80 
(simulating water).26 With a time step 2 fs, each peptidomimetic was heated to 300 K, 700 K and then to 1000 K over 
20 ps. After an equilibration phase of 2 ns, each model were frozen to 700 K and then to 300 K, over 20 ps. The 
production run of the MD simulations were performed for a total time of 20 ns with trajectories saved every 10 ps. 
The resulting structures in the trajectories were visually analyzed by VMD.30 In this stage, the fluctuation of the diverse 
torsion angles were analyzed and the different families of conformers were identified. They were then minimized by 
Gasussian09 at DFT/B3LYP/6-31g(d) level of theory and the lowest energy conformation and the Boltzmann equation 
was applied to calculate the conformers percentage distribution. Cβ-Cβ distances were measured by GaussView. 
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3. PIPERAZINE-BASED DOPAMINE RECEPTORS LIGANDS 
 
Figure 19. Recently developed D3/D2 selective 1,4-DAP ligands.
4 
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Figure 20. Results of SAR (Structure-Activity Relationship) studies  
on 1,4-DAP dopaminergic drugs (fig. from ref. 3, pg. 152). 
 
 
Scheme 30. Synthesis of a library of novel D2/D3 receptors agonists,  
employing the N-split Ugi reaction as the key diversity-generation step. 
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Scheme 31. General scheme for the synthesis of compounds 38-62. 
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Scheme 32. General scheme for the synthesis of compounds 63-72. 
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Graphic 1. Selected radioligand binding data for the most promising 2-indolyl methyl derivatives 
46, 49, 50, 52 and the 3-indolyl ethyl ones 68, 70 employing the Human D2L and D3 receptors.
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Figure 21. Left: docking poses for 68 (cyan) and 70 (orange) on the D3 receptor model. 
Right: docking poses for 68 (cyan) and 70 (orange) on the D2 receptor model. 
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GENERAL INFORMATION 
All solvents were distilled and properly dried, when necessary, prior to use. All chemicals were purchased from 
commercial sources and used directly, unless indicated otherwise. All reactions were run under N2, unless otherwise 
indicated. All reactions were monitored by thin layer chromatography (TLC) on precoated silica gel 60 F254; spots 
were visualized with UV light or by treatment with 1% aqueous KMnO4 solution. Products were purified by flash 
chromatography on silica gel 60 (230 - 400 mesh). 
NMR spectra were recorded with 300 or 400 MHz spectrometers. Chemical shifts (δ) are expressed in ppm relative 
to TMS at δ = 0 ppm for 1H NMR and relative to CDCl3 at δ = 77.16 ppm for 13C NMR. 13C NMR spectra have been 
recorded using the APT pulse sequence; the signals of CH and CH3 are positive while CH2 and quarternary carbons 
are negative (for further details see Appendix A.1). High-resolution MS spectra were recorded with a Waters 
Micromass Q-ToF micro TM mass spectrometer, equipped with an ESI source. Formamides,13 isocyanides14 and N-
MOM protected indoles15 were prepared according to the literature. 
GENERAL PROCEDURE FOR THE SYNTHESIS OF COMPOUNDS 38-44 , 63-66 
To a solution of piperazine (3 mmol, 1.0 eq.) in 3 mL of methanol, paraformaldehyde (4.5 mmol, 1.5 eq.), carboxylic 
acid (3 mmol, 1.0 eq.) and isocyanide (3 mmol, 1.0 eq.) were added. The mixture was refluxed for 15 minutes, then 
cooled to room temperature and stirred for 1 hour. The resulting mixture was then concentrated under reduced 
pressure, to give a residue which was purified as indicated below. 
2-(4-(1H-indole-2-carbonyl)piperazin-1-yl)-N-(4-methoxyphenyl)acetamide (38) 
2-carboxy indole and 1-isocyano-4-methoxybenzene were used. The product was collected by filtration (70% yield). 
1H NMR (300 MHz, CDCl3): δ 9.37 (br, m, 1H), 8.86 (br, m, 1H), 7.64 (br, d, J = 7.8 Hz, 1H), 7.48 (d, J = 8.9 Hz, 2H), 
7.42 (br, d, J = 7.8 Hz, 1H), 7.28 (br, t, J = 7.5 Hz, 1H), 7.13 (br, t, J = 7.5 Hz, 1H), 6.89 (d, J = 8.9 Hz, 2H), 6.77 (s, 
1H), 4.01 (br, m, 4H), 3.80 (s, 3H), 3.20 (s, 2H), 2.72 (br, t, J = 4.9 Hz, 4H). 13C NMR (75 MHz, CDCl3): δ 167.4, 
162.6, 156.4, 135.7, 130.5, 128.8, 127.4, 124.5, 121.9, 121.3 (2C), 120.7, 114.2 (2C), 111.8, 105.3, 61.9, 55.4, 53.5 (2C), 
43.6 (2C). HRMS (ESI): calcd for [C22H25N4O3]
+ 393.1921, found 393.1933 [MH+]. 
2-(4-(1H-indole-2-carbonyl)piperazin-1-yl)-N-(4-bromophenyl)acetamide (39) 
2-carboxy indole and 1-bromo-4-isocyanobenzene were used. The product was collected by filtration (73% yield). 1H 
NMR (300 MHz, CDCl3): δ 9.31 (br, m, 1H), 9.02 (br, m, 1H), 7.64 (br, d J = 7.7 Hz, 1H), 7.55 – 7.38 (m, 5H), 7.29 
(br, t, J = 7.6 Hz, 1H), 7.14 (br, t, J = 7.5 Hz, 1H), 6.77 (s, 1H), 4.02 (br, m, 4H), 3.22 (s, 2H), (br, m, 4H).13C NMR (75 
MHz, DMF-d7): δ 169.3, 162.9, 138.6, 136.7, 131.9 (2C), 130.7, 127.6, 123.5, 121.9 (3C), 120.2, 115.4, 112.3, 104.6, 
62.1, 53.4 (2C), 45.8 (2C). HRMS (ESI): calcd for [C21H21BrN4NaO2]
+ 463.0740, found 463.0734 [MNa+]. 
2-(4-(1-(methoxymethyl)-1H-indole-2-carbonyl)piperazin-1-yl)-N-(4-methoxyphenyl)acetamide (40) 
1-(methoxymethyl)-indole-2-carboxylic acid and 1-isocyano-4-methoxybenzene were used. The solvent was 
evaporated under reduced pressure and the residue was purified by flash chromatography (EtOAc/Hex 8/2) (70% 
yield). 1H NMR (300 MHz, CDCl3): δ 8.90 (br, m, 1H), 7.62 (br, d, J = 7.7 Hz, 1H), 7.51 (br, d, J = 7.8 Hz, 1H), 7.47 (d, 
J = 8.9 Hz, 2H), 7.32 (br, t, J = 7.6 Hz, 1H), 7.18 (br, t, J = 7.5 Hz, 1H), 6.87 (d, J = 8.9 Hz, 2H), 6.65 (s, 1H), 5.65 (s, 
2H), 3.87 (br, m, 4H), 3.79 (s, 3H), 3.24 (s, 3H), 3.22 (s, 2H), 2.70 (br, m, 4H). 13C NMR (75 MHz, CDCl3): δ 163.0 
(2C), 156.6, 137.9, 130.4 (2C), 126.5, 124.1, 121.5, 121.0 (3C), 114.0 (2C), 110.3, 105.5, 74.7, 61.5, 56.0, 55.5, 53.4 
(2C), 49.0, 43.6. HRMS (ESI): calcd for [C24H28N4NaO4]
+ 459.2003, found 459.2014 [MNa+]. 
N-(4-bromophenyl)-2-(4-(1-(methoxymethyl)-1H-indole-2-carbonyl)piperazin-1-yl)acetamide (41) 
1-(methoxymethyl)-indole-2-carboxylic acid and 1-bromo-4-isocyanobenzene were used. The solvent was evaporated 
under reduced pressure and the residue was purified by flash chromatography (EtOAc/Hex 8/2) (75% yield). 1H NMR 
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(400 MHz, CDCl3): δ 9.06 (br, m, 1H), 7.66 (br, d, J = 7.7 Hz, 1H), 7.55 (br, d, J = 7.8 Hz, 1H), 7.51 (d, J = 8.9 Hz, 2H), 
7.47 (d, J = 8.9 Hz, 2H), 7.35 (t, J = 7.7 Hz, 1H), 7.22 (t, J = 7.5 Hz, 1H), 6.68 (s, 1H), 5.68 (s, 2H), 3.91 (br, m, 4H), 
3.25 (br, s, 2H), 3.27 (s, 3H), 2.74 (br, m, 4H). 13C NMR (100 MHz, CDCl3):
 δ 167.6, 163.8, 137.3, 135.2, 132.7 (2C), 
127.5, 124.7, 122.2, 121.8 (3C), 117.7, 111.1, 107.0, 106.0, 75.7, 62.6, 56.6, 54.2 (2C), 45.5 (2C). HRMS (ESI): calcd for 
[C23H25BrN4NaO3]
+ 507.1002, found 506.9987 [MNa+]. 
2-(4-(1H-indole-2-carbonyl)piperazin-1-yl)-N-(4-methoxybenzyl)acetamide (42) 
2-carboxy indole and 1-(isocyanomethyl)-4-methoxybenzene were used. The solvent was evaporated under reduced 
pressure and the residue was purified by flash chromatography (CH2Cl2/CH3OH/Et3N 98/1/1) (78% yield). 
1H NMR 
(300 MHz, CDCl3): δ 9.51 (br, m, 1H), 7.63 (br, d, J = 7.7 Hz, 1H), 7.41 (br, d, J = 7.8 Hz, 1H), 7.35 (br, m, 1H), 7.27 
(br, t, J = 7.6 Hz, 1H), 7.22 (d, J = 8.6 Hz, 2H), 7.12 (br, t, J = 7.6 Hz, 1H), 6.88 (d, J = 8.6 Hz, 2H), 6.73 (s, 1H), 4.43 
(d, J = 5.9 Hz, 2H), 3.92 (br, m, 4H), 3.79 (s, 3H), 3.14 (s, 2H), 2.63 (br, m, 4H). 13C NMR (75 MHz, CDCl3): δ 162.5 
(2C), 159.0, 135.8, 130.3, 129.1 (2C), 128.7, 127.1, 124.4, 121.9, 120.7, 114.0 (2C), 111.7, 105.4, 61.3, 55.2, 53.3 (2C), 
46.8, 42.6, 43.1. HRMS (ESI): calcd for [C23H26N4NaO3]
+ 429.1897, found 429.1891 [MNa+]. 
2-(4-(1H-indole-2-carbonyl)piperazin-1-yl)-N-(4-bromobenzyl)acetamide (43) 
2-carboxy indole and 1-bromo-4-(isocyanomethyl)benzene were used. The solvent was evaporated under reduced 
pressure and the residue was purified by flash chromatography (CH2Cl2/CH3OH/Et3N 98/1/1) (85% yield). 
1H NMR 
(300 MHz, CDCl3): δ 9.50 (br, m, 1H), 7.63 (br, d, J = 7.8 Hz, 1H), 7.54 – 7.34 (m, 4H), 7.27 (br, t, J = 7.6 Hz, 1H), 
7.18 – 7.03 (m, 3H), 6.74 (s, 1H), 4.45 (d, J = 6.1 Hz, 2H), 3.92 (br, m, 4H), 3.13 (s, 2H), 2.61 (br, m, 4H). 13C NMR 
(75 MHz, CDCl3): δ 167.6, 162.5, 137.4, 135.6, 131.8, 129.5 (2C), 129.0, 127.4, 124.5 (2C), 122.0, 121.8, 120.7, 111.7, 
105.3, 61.4, 53.5 (2C), 46.1, 42.5, 43.3. HRMS (ESI): calcd for [C22H23N4NaO2]
+ 477.0897, found 477.0884 [MNa+]. 
N-(4-methoxybenzyl)-2-(4-(1-(methoxymethyl)-1H-indole-2-carbonyl)piperazin-1-yl)acetamide (44) 
1-(methoxymethyl)-indole-2-carboxylic acid and 1-(isocyanomethyl)-4-methoxybenzene were used. The solvent was 
evaporated under reduced pressure and the residue was purified by flash chromatography (EtOAc/Et3N 99/1) (79% 
yield). 1H NMR (300 MHz, CDCl3): δ 7.61 (br, d, J = 7.9 Hz, 1H), 7.50 (br, d, J = 7.8 Hz, 1H), 7.31 (br, t, J = 7.7 Hz, 
1H), 7.20 (d, J = 8.6 Hz, 2H), 7.17 (br, t, J = 7.7 Hz, 1H), 6.86 (d, J = 8.6 Hz, 2H), 6.60 (s, 1H), 5.62 (s, 2H), 4.41 (d, J = 
5.9 Hz, 2H), 3.79 (s, 3H), 3.77 (br, m, 4H), 3.21 (s, 3H), 3.13 ( br, s, 2H), 2.59 (br, m, 4H). 13C NMR (75 MHz, CDCl3): 
δ 163.1 (2C), 159.1, 137.8, 130.8, 130.2, 129.1 (2C), 126.7, 124.2, 121.6, 121.2, 114.3 (2C), 110.4, 105.5, 75.0, 61.3, 
56.1, 55.3, 53.3 (2C), 46.9, 42.6, 41.8. HRMS (ESI): calcd for [C25H30N4NaO4]
+ 473.2159, found 473.2152 [MNa+]. 
2-(4-(2-(1H-indol-3-yl)acetyl)piperazin-1-yl)-N-(4-methoxyphenyl)acetamide (63) 
2-(1H-indol-3-yl)acetic acid and 1-isocyano-4-methoxybenzene were used. The solvent was evaporated under reduced 
pressure and the residue was purified by flash chromatography (CH2Cl2/CH3OH/Et3N 98/1/1) (82% yield). 
1H NMR 
(300 MHz, CDCl3): δ 8.77 (br, m, 1H), 8.35 (br, m, 1H), 7.61 (br, d, J = 7.8 Hz, 1H), 7.42 (d, J = 8.9 Hz, 2H), 7.36 (br, 
d, J = 7.8 Hz, 1H), 7.20 (br, t, J = 7.6 Hz, 1H), 7.12 (br, t, J = 7.6 Hz, 1H), 7.08 (s, 1H), 6.84 (d, J = 8.9 Hz, 2H), 3.85 (s, 
2H), 3.77 (s, 3H), 3.70 (br, m, 2H), 3.53 (br, m, 2H), 3.05 (s, 2H), 2.55 (br, m, 2H), 2.36 (br, m, 2H). 13C NMR (75 
MHz, CDCl3): δ 170.3, 167.4, 156.1, 136.1, 130.6, 126.7, 122.5, 122.2, 121.3 (2C), 119.6, 118.6, 114.1 (2C), 111.5, 
108.7, 61.8, 55.5, 53.3, 53.2, 46.1, 41.8, 31.5. HRMS (ESI): calcd for [C23H27N4O3]
+ 407.2078, found 407.2076 [MH+]. 
2-(4-(2-(1H-indol-3-yl)acetyl)piperazin-1-yl)-N-(4-bromophenyl)acetamide (64) 
2-(1H-indol-3-yl)acetic acid and 1-bromo-4-isocyanobenzene were used. The solvent was evaporated under reduced 
pressure and the residue was purified by flash chromatography (CH2Cl2/CH3OH/Et3N 98/1/1) (82% yield). 
1H NMR 
(300 MHz, CDCl3): δ 8.92 (br, m, 1H), 8.30 (br, m, 1H), 7.61 (br, d, J = 7.7 Hz, 1H), 7.41 (br, m, 4H), 7.36 (br, d, J = 
7.8 Hz, 1H), 7.21 (br, t, J = 7.6 Hz, 1H), 7.12 (br, t, J = 7.6 Hz, 1H), 7.09 (br, s, 1H), 3.85 (s, 2H), 3.72 (br, m, 2H), 3.53 
(br, m, 2H), 3.06 (s, 2H), 2.55 (br, m, 2H), 2.37 (br, m, 2H). 13C NMR (75 MHz, CDCl3): δ 170.5 (2C), 136.8, 136.5, 
132.4 (2C), 127.3, 122.8, 121.5 (2C), 120.1 (2C), 119.0, 117.4, 111.8, 109.2, 61.9, 53.6, 53.5, 46.1, 41.9, 31.7. HRMS 
(ESI): calcd for [C22H23BrN4NaO2]
+ 478.3368, found 478.3364 [MNa+]. 
2-(4-(2-(1-(methoxymethyl)-1H-indol-3-yl)acetyl)piperazin-1-yl)-N-(4-methoxyphenyl)acetamide (65) 
2-(1-(methoxymethyl)-indol-3-yl)acetic acid and 1-isocyano-4-methoxybenzene were used. The solvent was 
evaporated under reduced pressure and the residue was purified by flash chromatography (CH2Cl2/CH3OH/Et3N 
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98/1/1) (87% yield). 1H NMR (300 MHz, CDCl3): δ 8.78 (br, m, 1H), 7.60 (br, d, J = 7.9 Hz, 1H), 7.46 (br, d, J = 7.8 Hz, 
1H), 7.42 (d, J = 9.0 Hz, 2H), 7.26 (br, t, J = 7.6 Hz, 1H), 7.16 (br, t, J = 7.5 Hz, 1H), 7.10 (s, 1H), 6.85 (d, J = 9.0 Hz, 
2H), 5.41 (s, 2H), 3.84 (s, 2H), 3.78 (s, 3H), 3.73 (br, m, 2H), 3.56 (br, m, 2H), 3.23 (s, 3H), 3.08 (s, 2H), 2.56 (br, m, 
2H), 2.39 (br, m, 2H). 13C NMR (75 MHz, CDCl3): δ 169.7, 167.2, 156.4, 136.5, 130.5, 128.0, 126.1, 122.8, 121.2 (2C), 
120.3, 118.8, 114.3 (2C), 110.0, 109.2, 77.2, 61.8, 56.0, 55.4, 53.4, 53.2, 46.1, 41.7, 31.1. HRMS (ESI): calcd for 
[C25H30N4NaO4]
+ 473.2159, found 473.2126 [MNa+]. 
N-(4-bromophenyl)-2-(4-(2-(1-(methoxymethyl)-1H-indol-3-yl)acetyl)piperazin-1-yl)acetamide (66) 
2-(1-(methoxymethyl)-indol-3-yl)acetic acid and 1-bromo-4-isocyanobenzene were used. The solvent was evaporated 
under reduced pressure and the residue was purified by flash chromatography (CH2Cl2/CH3OH/Et3N 98/1/1) (72% 
yield). 1H NMR (300 MHz, CDCl3): δ 9.01 (br, m, 1H), 7.59 (br, d, J = 7.8 Hz, 1H), 7.52 – 7.37 (m, 5H), 7.26 (br, t, J = 
7.4 Hz, 1H), 7.16 (br, t, J = 7.4 Hz, 1H), 7.09 (s, 1H), 5.40 (s, 2H), 3.84 (s, 2H), 3.74 (br, m, 2H), 3.60 (br, m, 2H), 3.22 
(s, 3H), 3.19 (br, s, 2H), 2.67 (br, m, 2H), 2.49 (br, m, 2H). 13C NMR (75 MHz, CDCl3): δ 170.2 (2C), 137.0, 136.6, 
132.3 (2C), 128.4, 126.5, 123.1, 121.4 (2C), 120.7, 119.2, 117.3, 110.4, 109.3, 76.9, 62.2 and 61.8 (1C), 56.3, 53.7 (2C), 
46.4 and 46.1 (1C), 42.0 and 41.8 (1C), 31.5. HRMS (ESI): calcd for [C24H27BrN4NaO3]
+ 521.1159, found 521.1141 
[MNa+]. 
GENERAL PROCEDURE FOR THE SYNTHESIS OF COMPOUNDS 45-48 , 67-68 
LiAlH4 (1M in THF, 1.95 mmol) was dissolved in anhydrous THF (2 mL) at 40 °C under N2 atmosphere and a solution 
of compound 38 (or 39-43, 63-64 ) (0.65 mmol) in anhydrous THF (10 mL) was slowly added. After 15 minutes, the 
solution was refluxed until full conversion (monitored by TLC). Then the reaction was cooled to room temperature, 
quenched with H2O, NaOH 15% and H2O (n. g of LiAlH4 require n. mL of H2O, n. mL of NaOH 15%, and 3n. mL of 
H2O added in succession) and stirred vigorously overnight. The precipitate was removed by filtration over celite and 
the solvent was evaporated under reduced pressure. The resulting residue was purified by flash chromatography (FC) 
as indicated below. 
N-(2-(4-((1H-indol-2-yl)methyl)piperazin-1-yl)ethyl)-4-methoxyaniline (45) 
FC: CH2Cl2/CH3OH 98/2 (87% yield). 
1H NMR (300 MHz, CDCl3): δ 8.65 (br, m, 1H), 7.55 (br, d, J = 7.7 Hz, 1H), 7.33 
(br, d, d, J = 7.8 Hz, 1H), 7.14 (br, t, J = 7.5 Hz, 1H), 7.07 (br, t, J = 7.6 Hz, 1H), 6.79 (d, J = 8.8 Hz, 2H), 6.61 (d, J = 
8.8 Hz, 2H), 6.36 (s, 1H), 3.74 (s, 3H), 3.68 (s, 2H), 3.11 (t, J = 5.9 Hz, 2H), 2.62 (t, J = 5.9 Hz, 2H), 2.52 (br, m, 9H). 
13C NMR (75 MHz, CDCl3): δ 148.1, 138.7, 132.1, 131.2, 124.3, 117.6, 116.2, 115.7, 111.0 (2C), 110.3 (2C), 106.8, 
97.7, 52.93, 52.1, 51.7, 49.1 (2C), 48.6 (2C), 37.3. HRMS (ESI): calcd for [C22H29N4O]
+ 365.2336, found 365.2322 
[MH+]. 
N-(2-(4-((1H-indol-2-yl)methyl)piperazin-1-yl)ethyl)-4-bromoaniline (46) 
FC: CH2Cl2/CH3OH 98/2 (90% yield). 
1H NMR (300 MHz, CDCl3): δ 8.60 (br, m, 1H), 7.55 (br, d, J = 7.7 Hz, 1H), 7.33 
(br, d, J = 7.8 Hz, 1H), 7.24 (d, J = 8.8 Hz, 2H), 7.15 (br, t, J = 7.4 Hz, 1H ), 7.07 (br, t, J = 7.4 Hz, 1H), 6.49 (d, J = 8.8 
Hz, 2H), 6.36 (s, 1H), 4.31 (br, m, 1H), 3.70 (s, 2H), 3.10 (br, q, J = 5.5 Hz, 2H), 2.62 (t, J = 5.7 Hz, 2H), 2.53 (br, m, 
8H). 13C NMR (75 MHz, CDCl3): δ 147.3, 136.0, 135.0, 132.0 (2C), 128.3, 121.7, 120.2, 119.6, 114.5 (2C), 110.8, 
108.8, 101.9, 56.3, 55.7, 52.9 (2C), 52.5 (2C), 40.2. HRMS (ESI): calcd for [C21H26BrN4]
+ 413.1335, found 413.1342 
[MH+]. 
2-(4-((1H-indol-2-yl)methyl)piperazin-1-yl)-N-(4-methoxybenzyl)ethan-1-amine (47) 
FC: EtOAc/CH3OH/Et3N 90/9/1 (90% yield). 
1H NMR (300 MHz, CDCl3): δ 8.80 (br, m, 1H), 7.53 (br, d, J = 7.6 Hz, 
1H), 7.32 (br, d, J = 7.8 Hz, 1H), 7.26 (d, J = 8.6 Hz, 2H), 7.13 (br, t, J = 7.6 Hz, 1H), 7.06 (br, t, J = 7.6 Hz, 1H), 6.85 
(d, J = 8.6 Hz, 2H), 6.34 (s, 1H), 3.75 (s, 3H), 3.66 (s, 2H), 3.46 (s, 2H), 2.78 (br, m, 4H), 2.72 (t, J = 6.8 Hz, 2H), 2.64 
(t, J = 6.8 Hz, 2H), 2.49 (br, m, 5H). 13C NMR (75 MHz, CDCl3): δ 159.2, 136.2, 135.2, 130.4, 129.9 (2C), 128.2, 121.6, 
120.2, 119.6, 114.1 (2C), 110.8, 101.9, 56.7, 55.7, 55.3, 53.1 (2C), 52.9 (2C), 52.7, 44.7. HRMS (ESI): calcd for 
[C23H31N4O]
+ 379.2492, found 379.2481  [MH+]. 
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2-(4-((1H-indol-2-yl)methyl)piperazin-1-yl)-N-(4-bromobenzyl)ethan-1-amine (48) 
FC: EtOAc/CH3OH/Et3N 90/9/1 (93% yield). 1H NMR (300 MHz, CDCl3): δ 8.69 (br, m, 1H), 7.54 (br, d, J = 7.6 Hz, 
1H), 7.44 – 7.19 (m, 5H), 7.14 (br, t, J = 7.4 Hz, 1H), 7.06 (br, t, J = 7.4 Hz, 1H), 6.35 (s, 1H), 3.86 (s, 2H), 3.69 (s, 2H), 
3.64 (br, m, 1H),  2.74 (t, J = 6.0 Hz, 2H), 2.66 - 2.39 (m, 10H). 13C NMR (75 MHz, CDCl3): δ 139.4, 136.1, 135.3  
(2C), 128.4, 128.2, 127.1, 121.4  (2C), 120.0, 119.5, 111.3, 110.7, 101.7, 57.2, 55.7, 53.6, 53.1  (2C), 53.0  (2C), 45.2. 
HRMS (ESI): calcd for [C22H28BrN4]+ 427.1492, found 427.1481 [MH+]. 
N-(2-(4-(2-(1H-indol-3-yl)ethyl)piperazin-1-yl)ethyl)-4-methoxyaniline (67) 
FC: CH2Cl2/CH3OH/Et3N 97/2/1 (87% yield). 
1H NMR (300 MHz, CDCl3): δ 8.09 (br, m, 1H), 7.61 (br, d, J = 7.7 Hz, 
1H), 7.35 (br, d, J = 7.8 Hz, 1H), 7.18 (br, t, J = 7.4 Hz, 1H), 7.11 (br, t, J = 7.5 Hz, 1H), 7.04 (br, s, 1H), 6.79 (d, J = 8.9 
Hz, 2H), 6.61 (d, J = 8.9 Hz, 2H), 3.74 (s, 3H), 3.14 (t, J = 5.9 Hz, 2H), 3.02 (m, 2H), 2.78 (m, 2H), 2.67 (t, J = 5.9 Hz, 
2H), 2.63 (br, m, 9H). 13C NMR (75 MHz, CDCl3): δ 152.4, 143.1, 136.5, 127.9, 122.4, 122.1, 119.7, 119.2, 115.4 (2C), 
114.7 (2C), 114.3, 111.6, 59.6, 57.2, 56.3, 53.6 (2C), 53.1 (2C), 41.7, 23.2. HRMS (ESI): calcd for [C23H31N4O]
+ 
379.2492, found 379.2483 [MH+]. 
N-(2-(4-(2-(1H-indol-3-yl)ethyl)piperazin-1-yl)ethyl)-4-bromoaniline (68) 
FC: CH2Cl2/CH3OH/Et3N 97/2/1 (88% yield). 
1H NMR (300 MHz, CDCl3): δ 8.15 (br, m, 1H), 7.61 (br, d,  J = 7.7 Hz, 
1H), 7.35 (br, d, J = 7.8 Hz, 1H), 7.25 (d, J = 8.8 Hz, 2H), 7.18 (br, t, J = 7.5 Hz, 1H), 7.10 (br, t, J = 7.5 Hz, 1H), 7.01 
(s, 1H), 6.50 (d, J = 8.8 Hz, 2H), 4.36 (br, m, 1H), 3.12 (m, 2H), 3.04 – 2.89 (m, 2H), 2.74 (m, 2H),  2.70 – 2.44 (m, 
10H). 13C NMR (75 MHz, CDCl3): δ 147.3, 136.1, 132.0 (2C), 127.4, 122.0, 121.7, 119.2, 118.7, 114.5 (2C), 113.8, 
111.2, 108.8, 59.0, 56.3, 52.9 (2C), 52.4 (2C), 40.2, 22.6. HRMS (ESI): calcd for [C22H28BrN4]
+ 427.1492, found 
427.1478 [MH+]. 
GENERAL PROCEDURE FOR THE SYNTHESIS OF COMPOUNDS 49-52 , 69-70 
To a solution of compound 45 (or 46-48, 67-68) (0.26 mmol) in CH2Cl2 (1.5 mL) sodium triacetoxyboronhydride 
(0.31 mmol, 1.2 eq.) and propionaldehyde (0.29 mmol, 1.1 eq.) were added. The resulting mixture was stirred at room 
temperature until full conversion (monitored by TLC). The reaction was quenched with saturated aq. NaHCO3 (5 mL) 
and the organic layer was separated. The aqueous phase was then extracted with CH2Cl2 (3 x 5 mL), the combined 
organic layer was dried over anhydrous Na2SO4 and the solvent was evaporated under reduced pressure to give the 
desired product with no need for further purification. 
N-(2-(4-((1H-indol-2-yl)methyl)piperazin-1-yl)ethyl)-4-methoxy-N-propylaniline (49) 
95% yield. 1H NMR (300 MHz, CDCl3): δ 8.61 (br, m, 1H), 7.54 (br, d, J = 7.7 Hz, 1H), 7.33 (br, d, J = 7.8 Hz, 1H), 
7.15 (br, t, J = 7.5 Hz, 1H), 7.07 (br, t, J = 7.4 Hz, 1H), 6.80 (d, J = 8.9 Hz, 2H), 6.65 (d, J = 8.9 Hz, 2H), 6.36 (s, 1H), 
3.74 (s, 3H), 3.68 (s, 2H), 3.40 (t, J = 7.5 Hz, 2H), 3.14 (t, J = 7.5 Hz, 2H), 2.66 – 2.40 (m, 10H), 1.55 (br, sext, J = 7.4 
Hz, 2H), 0.89 (t, J = 7.4 Hz, 3H). 13C NMR (75 MHZ, CDCl3): δ 151.3, 143.1, 136.4, 135.5, 128.5, 121.8, 120.3, 119.6, 
115.1 (2C), 114.5 (2C), 110.9, 101.9, 56.0, 55.9, 55.7, 54.2, 53.7 (2C), 53.3 (2C), 49.7, 20.6, 11.7. HRMS (ESI): calcd for 
[C25H35N4O]
+ 407.2805, found 407.2788 [MH+]. 
N-(2-(4-((1H-indol-2-yl)methyl)piperazin-1-yl)ethyl)-4-bromo-N-propylaniline (50) 
92% yield. 1H NMR (400 MHz, CDCl3): δ 8.73 (br, m, 1H), 7.60 (br, d, J = 7.8 Hz, 1H), 7.37 (br, d, J = 7.8 Hz, 1H), 
7.29 (d, J = 9.0 Hz, 2H), 7.19 (br, t, J = 7.5 Hz, 1H), 7.12 (br, t,  J = 7.4 Hz, 1H), 6.56 (d, J = 9.0 Hz, 2H), 6.41 (s, 1H), 
3.72 (s, 2H), 3.45 (t, J = 7.5 Hz, 2H), 3.24 (t, J = 7.5 Hz, 2H), 2.68 – 2.42 (m, 10H), 1.63 (br, sext, J = 7.4 Hz, 2H), 0.96 
(t, J = 7.4 Hz, 3H). 13C NMR (100 MHZ, CDCl3):
 δ 147.0, 136.3, 135.3, 131.9 (2C), 128.3, 121.7, 120.2, 119.7, 113.4 
(2C), 110.8, 107.3, 101.9, 55.8, 55.0, 53.5 (2C), 53.1 (3C), 48.9, 20.3, 11.4. HRMS (ESI): calcd for [C24H32BrN4]
+ 
455.1805, found 455.1806 [MH+]. 
N-(2-(4-((1H-indol-2-yl)methyl)piperazin-1-yl)ethyl)-N-(4-methoxybenzyl)propan-1-amine (51) 
90% yield. 1H NMR (400 MHz, CDCl3):
 δ 8.63 (br, m, 1H), 7.57 (br, d, J = 7.7 Hz, 1H), 7.35 (br, d, J = 7.8 Hz, 1H), 7.25 
(d, J = 8.5 Hz, 2H), 7.17 (br, t, J = 7.6 Hz, 1H), 7.10 (br, t, J = 7.6 Hz, 1H), 6.86 (d, J = 8.5 Hz, 2H), 6.38 (s, 1H), 3.82 
(s, 3H), 3.68 (s, 2H), 3.56 (s, 2H), 2.71 – 2.36 (m, 14H), 1.51 (br, sext, J = 7.4 Hz, 2H), 0.88 (t, J = 7.4 Hz, 3H). 13C 
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NMR (100 MHZ, CDCl3):
 δ 159.5, 137.0, 136.5, 133.0, 130.4 (2C), 129.3, 122.2, 120.8, 120.3, 114.4 (2C), 111.2, 102.2, 
59.3, 57.3, 57.2, 56.4, 55.9, 54.1 (2C), 53.9 (2C), 52.1, 21.1, 12.2. HRMS (ESI): calcd for [C26H37N4O]
+ 421.2962, found 
421.2977 [MH+]. 
N-(2-(4-((1H-indol-2-yl)methyl)piperazin-1-yl)ethyl)-N-(4-bromobenzyl)propan-1-amine (52) 
92% yield. 1H NMR (400 MHz, CDCl3):
 δ 8.93 (br, m, 1H), 7.62 (br, d, J = 7.8 Hz, 1H), 7.42 – 7.25 (m, 5H), 7.20 (br, 
td, J = 7.6 and 1.2 Hz, 1H), 7.14 (br, td, J = 7.7 and 1.2 Hz, 1H), 6.41 (br, s, 1H), 3.67 (s, 2H), 3.65 (s, 2H), 2.70 – 2.45 
(m, 14H), 1.55 (br, sext, J = 7.4 Hz, 2H), 0.93 (t, J = 7.5 Hz, 3H). 13C NMR (100 MHZ, CDCl3): δ 140.1, 136.4, 135.6, 
128.9 (2C), 128.5 (2C), 128.2 (2C), 121.6, 120.3, 119.7, 110.9, 101.9, 59.2, 56.7, 56.5, 55.9, 53.6 (2C), 53.3 (2C), 51.3, 
20.4, 12.0. HRMS (ESI): calcd for [C25H34BrN4]
+ 469.1961, found 469.1945 [MH+]. 
N-(2-(4-(2-(1H-indol-3-yl)ethyl)piperazin-1-yl)ethyl)-4-methoxy-N-propylaniline (69) 
90% yield. 1H NMR (400 MHz, CDCl3):
 δ 8.45 (br, m, 1H), 7.67 (br, d, J = 7.8 Hz, 1H), 7.36 (br, d, J = 7.7 Hz, 1H), 7.23 
(br, t,  J = 7.5 Hz, 1H), 7.17 (br, t,  J = 7.5 Hz, 1H), 7.03 (s, 1H), 6.88 (d, J = 8.9 Hz, 2H), 6.73 (d, J = 8.9 Hz, 2H), 3.81 
(s, 3H), 3.48 (t, J = 7.5 Hz, 2H), 3.24 (t, J = 7.5 Hz, 2H), 3.01 (m, 2H), 2.79 (m, 2H), 2.69(br, m, 8H), 2.61 (m, 2H), 1.63 
(br, sext, J = 7.4 Hz, 2H), 0.97 (t, J = 7.4 Hz, 3H). 13C NMR (100 MHZ, CDCl3): δ 151.3, 143.1, 136.3, 127.5, 121.9, 
121.7, 119.2, 118.8, 115.0 (2C), 114.4 (2C), 114.2, 111.2, 59.3, 55.9, 55.6, 54.1, 53.7 (2C), 53.2 (2C), 49.5, 22.9, 20.6, 
11.6. HRMS (ESI): calcd for [C26H37N4O]
+ 421.2962, found 421.2950 [MH+]. 
N-(2-(4-(2-(1H-indol-3-yl)ethyl)piperazin-1-yl)ethyl)-4-bromo-N-propylaniline (70) 
91% yield. 1H NMR (300 MHz, CDCl3): δ 8.06 (br, m, 1H), 7.61 (br, d, J = 7.7 Hz, 1H), 7.35 (br, d,  J = 7.7 Hz, 1H), 
7.25 (d, J = 8.9 Hz, 2H), 7.18 (br, t, J = 7.4 Hz, 1H), 7.11 (br, t, J = 7.5 Hz, 1H), 7.04 (s, 1H), 6.52 (d, J = 8.9 Hz, 2H), 
3.43 (t, J = 8.0 Hz, 2H), 3.19 (t, J = 7.9 Hz, 2H), 3.03 (m, 2H), 2.88 – 2.47 (m, 12H), 1.58 (br, sext, J = 7.7 Hz, 2H), 0.91 
(t, J = 7.7 Hz, 3H). 13C NMR (75 MHZ, CDCl3): δ 147.3, 136.3, 132.0 (2C), 127.6, 122.1 and 121.8 (1C), 119.4, 119.0, 
114.3, 113.6 (2C), 112.0, 111.4, 107.5, 59.4, 55.3, 53.8 (2C), 53.3 (3C), 49.0, 23.0, 20.5, 11.6. HRMS (ESI) : calcd for 
[C25H34BrN4]
+ 469.961, found 469.1982 [MH+]. 
GENERAL PROCEDURE FOR THE SYNTHESIS OF COMPOUNDS 53-57 , 71-72 
To a suspension of NaH (80% in mineral oil, 5.5 mmol, 1.1 eq.) in anhydrous DMF (3 mL), cooled  to 0 °C under N2 
atmosphere, a solution of compound 40 (or 41, 44, 65-66) (5 mmol) in anhydrous DMF (7 mL) was added and the 
mixture was stirred for 15 minutes. After dropwise addition of the alkylating agent (6 mmol, 1.2 eq.), the solution was 
warmed to room temperature and stirred until full conversion (monitored by TLC). The reaction was quenched with 
H2O (10 mL), and the aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic phases were 
washed with saturated aq. NaCl (5 x 10 mL) and dried over anhydrous Na2SO4. The resulting mixture was then 
concentrated under reduced pressure, to give a residue which was purified by flash chromatography (FC) as indicated 
below. 
2-(4-(1-(methoxymethyl)-1H-indole-2-carbonyl)piperazin-1-yl)-N-(4-methoxyphenyl)-N-propylacetamide (53) 
FC: EtOAc (89% yield). 1H NMR (400 MHz, CDCl3):
  δ 7.63 (d, J = 7.7 Hz, 1H), 7.53 (br, d, J = 7.8 Hz, 1H), 7.32 (br, t, 
J = 7.7 Hz, 1H), 7.19 (br, t, J = 7.5 Hz, 1H), 7.09 (d, J = 8.8 Hz, 2H), 6.95 (d, J = 8.8 Hz, 2H), 6.63 (s, 1H), 5.65 (s, 2H), 
3.86 (s, 3H), 3.83 (br, m, 4H), 3.63 (m, 2H), 3.24 (s, 3H), 2.99 (br, s, 2H), 2.62 (br, m, 4H), 1.56 (br, sext, J = 7.6 Hz, 
2H), 0.91 (t, J = 7.6 Hz, 3H). 13C NMR (100  MHz, CDCl3):
 δ 168.5, 162.9, 159.3, 137.8, 134.2, 131.3, 129.3 (2C), 
127.0, 123.9, 121.6, 121.1, 114.9 (2C), 110.6, 105.2, 74.9, 59.1, 56.0, 55.5, 53.1 (2C), 51.1, 47.5, 41.8, 20.9, 11.2. HRMS 
(ESI): calcd for [C27H34N4NaO4]
+ 501.2472, found 501.2488 [MNa+]. 
2-(4-(1-(methoxymethyl)-1H-indole-2-carbonyl)piperazin-1-yl)-N-(4-methoxyphenyl)-N-(3-methylbut-2-en-1-yl)acetamide (54) 
FC: EtOAc (76% yield). 1H NMR (400 MHz, CDCl3):
 δ 7.63 (d, J = 7.8 Hz, 1H), 7.53 (d, J = 7.8 Hz, 1H), 7.32 (br, t, J = 
7.7 Hz, 1H), 7.19 (t, J = 7.6 Hz, 1H), 7.06 (d, J = 8.8 Hz, 2H), 6.92 (d, J = 8.8 Hz, 2H), 6.62 (s, 1H), 5.64 (s, 2H), 5.23 
(br, t,  J = 7.3 Hz, 1H), 4.26 (d, J = 7.3 Hz, 2H), 3.85 (s, 3H), 3.82 (br, m, 4H), 3.23 (s, 3H), 2.98 (s, 2H), 2.59 (br, m, 
4H), 1.69 (s, 3H), 1.46 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 168.4, 162.9, 159.2, 138.1, 136.6, 134.2, 131.4, 129.4 
(2C), 126.6, 123.9, 121.6, 121.1, 119.0, 114.7 (2C), 110.6, 105.2, 75.2, 59.1, 55.9, 55.5, 53.2 (2C), 47.5, 47.2, 42.0, 25.7, 
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17.7. HRMS (ESI): calcd for [C29H36N4NaO4]
+ 527.2629, found 527.2637 [MNa+]. 
N-(4-bromophenyl)-2-(4-(1-(methoxymethyl)-1H-indole-2-carbonyl)piperazin-1-yl)-N-propylacetamide (55) 
FC: EtOAc (80% yield). 1H NMR (300 MHz, CDCl3): δ 7.60 (br, d, J = 7.8 Hz, 1H), 7.55 (d, J = 8.6 Hz, 2H), 7.49 (br, d, 
J = 7.8 Hz, 1H),   7.29 (br, t, J = 7.5 Hz, 1H), 7.16 (br, t, J = 7.7 Hz, 1H), 7.05 (d, J = 8.6 Hz, 2H), 6.59 (s, 1H), 5.61 (s, 
2H), 3.79 (br, m, 4H), 3.60 (m, 2H), 3.20 (s, 3H), 2.95 (br, s, 2H), 2.56 (br, m, 4H), 1.50 (br, sext, J = 7.4 Hz, 2H), 0.87 
(t, J = 7.4 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ 163.3 (2C), 138.0, 136.4, 132.1 (2C), 126.7, 124.2, 121.7, 121.3, 
121.1 (2C), 117.1, 111.4, 110.4, 105.6, 74.8, 61.7, 56.1, 53.4 (2C), 47.3, 41.0, 29.7, 20.1, 11.0. HRMS (ESI): calcd for 
[C26H31BrN4NaO3]
+ 549.1472, found 549.1479 [MNa+]. 
N-(4-bromophenyl)-2-(4-(1-(methoxymethyl)-1H-indole-2-carbonyl)piperazin-1-yl)-N-(3-methylbut-2-en-1-yl)acetamide (56) 
FC: EtOAc (75% yield). 1H NMR (300 MHz, CDCl3): δ 7.59 (br, d, J = 7.8 Hz, 1H), 7.53 – 7.42 (m, 3H), 7.28 (br, t, J = 
7.6 Hz, 1H), 7.15 (t, J = 7.6 Hz, 1H), 7.02 (d, J = 8.4 Hz, 2H), 6.59 (s, 1H), 5.61 (s, 2H), 5.17 (br, t,  J = 7.8 Hz, 1H), 
4.24 (br, d, J = 7.8 Hz, 2H), 3.76 (br, m, 4H), 3.19 (s, 3H), 2.91 (s, 2H), 2.51 (br, m, 4H), 1.65 (s, 3H), 1.42 (s, 3H). 13C 
NMR (75 MHz, CDCl3): δ 167.9, 162.7, 140.6, 138.0, 137.1, 132.9 (2C), 131.5, 130.1 (2C), 126.7, 123.9, 121.8, 121.6, 
121.1, 118.7, 110.7, 105.3, 75.0, 59.5, 55.9, 53.3 (2C), 47.2, 44.2, 40.6, 25.8, 17.8. HRMS (ESI): calcd for 
[C28H33BrN4NaO3]
+ 575.1628, found 575.1636 [MNa+]. 
N-(4-methoxybenzyl)-2-(4-(1-(methoxymethyl)-1H-indole-2-carbonyl)piperazin-1-yl)-N-propylacetamide (57) 
FC: EtOAc/Hex 9/1 (87% yield). 1H NMR (300 MHz, CDCl3, mixture of 2 conformers in ratio 1:1): δ 7.62 (br, d, J = 
7.8 Hz, 1H), 7.51  (br, d, J = 7.8 Hz, 1H), 7.30  (br, t, J = 7.7 Hz, 1H), 7.25 – 7.13 (m, 2H), 7.08 (d, J = 8.6 Hz, 1H), 6.88 
(d, J = 8.6 Hz, 1H), 6.83 (d, J = 8.6 Hz, 1H), 6.64 (s, 0,5H), 6.62 (s, 0.5H), 5.64 (s, 1H), 5.62 (s, 1H), 4.54 (s, 1H), 4.52 
(s, 1H), 3.97 – 3.72 (br, m, 4H), 3.80 (s, 1.5H), 3.78 (s, 1.5H), 3.42 – 3.11 (m, 7H), 2.85 – 2.61 (br, m, 4H), 1.56 (m, 
2H), 0.98 – 0.81 (m, 3H). 13C NMR (75 MHz, CDCl3): δ 168.8 and 168.5 (1C), 162.9, 159.1 and 159.0 (1C), 137.8, 
131.2, 129.5, 128.8, 127.5, 126.8, 124.0, 121.6, 121.2, 114.3, 113.7, 110.5, 105.3, 74.9, 60.3 and 59.8 (1C), 56.0, 55.2, 
53.5 (2C), 50.2 and 48.0 (1C), 47.7 and 47.5 (1C), 47.1, 42.6, 21.7 and 20.7 (1C), 11.3. HRMS (ESI): calcd for 
[C28H36N4NaO4]
+ 515.2629, found 515.2610 [MNa+]. 
2-(4-(2-(1-(methoxymethyl)-1H-indol-3-yl)acetyl)piperazin-1-yl)-N-(4-methoxyphenyl)-N-propylacetamide (71) 
FC: CH2Cl2/CH3OH/Et3N 98/1/1 (72% yield). 
1H NMR (400 MHz, CDCl3):
 δ 7.60 (br, d, J = 7.8 Hz, 1H), 7.47 (br, d, J = 
7.8 Hz, 1H), 7.26 (br, t, J = 7.5 Hz, 1H), 7.17 (br, t, J = 7.8 Hz, 1H), 7.10 (s, 1H), 7.05 (d, J = 8.5 Hz, 2H), 6.92 (d, J = 
8.5 Hz, 2H), 5.42 (s, 2H), 3.84 (s, 3H), 3.81 (s, 2H), 3.73 (br, m, 2H), 3.60 (m, 2H), 3.55 (br, m, 2H), 3.22 (s, 3H), 2.91 
(br, s, 2H), 2.53 (br, m, 2H), 2.44 (br, m, 2H), 1.52 (br, sext, J = 7.6 Hz, 2H), 0.89 (t, J = 7.6 Hz, 3H). 13C NMR (100 
MHz, CDCl3):
 δ 169.4, 167.9, 158.9, 136.3, 133.8, 129.0 (2C), 127.7, 126.0, 122.3, 119.9, 118.6, 114.6 (2C), 109.7, 
109.0, 77.1, 58.6, 55.6, 55.2, 52.6, 52.4, 50.8, 45.5, 41.0, 30.7, 20.5, 10.9. HRMS (ESI): calcd for [C28H37N4O4]
+ 
493.2809, found 493.3707 [MH+]. 
N-(4-bromophenyl)-2-(4-(2-(1-(methoxymethyl)-1H-indol-3-yl)acetyl)piperazin-1-yl)-N-propylacetamide (72) 
FC: CH2Cl2/CH3OH/Et3N 98/1/1 (78% yield). 
1H NMR (400 MHz, CDCl3):
 δ 7.60 (br, d, J = 7.8 Hz, 1H), 7.55 (d, J = 8.5 
Hz, 2H), 7.46 (br, d, J = 7.7 Hz, 1H), 7.26 (br, t, J = 7.5 Hz, 1H), 7.17 (br, t, J = 7.5 Hz, 1H), 7.09 (s, 1H), 7.04 (d, J = 
8.5 Hz, 2H), 5.42 (s, 2H), 3.81 (s, 2H), 3.69 (br, m, 2H), 3.61 (br, t, J = 7.6 Hz, 2H), 3.51 (br, m, 2H), 3.22 (s, 3H), 2.87 
(s, 2H), 2.46 (br, m, 2H), 2.35 (br, m, 2H), 1.50 (sext, J = 7.6 Hz, 2H), 0.88 (t, J = 7.6 Hz, 3H). 13C NMR (100 MHz, 
CDCl3): δ 170.4, 168.6, 141.4, 137.3, 133.6 (2C), 130.6 (2C), 128.9, 126.9, 123.2, 122.7, 120.9, 119.6, 110.7, 109.7, 
78.0, 60.0, 56.6, 53.6, 53.4, 51.7, 46.5, 42.1, 31.6, 21.5, 11.8. HRMS (ESI): calcd for [C27H33BrN4NaO3]
+ 563.1628, 
found 563.1624 [MNa+]. 
GENERAL PROCEDURE FOR THE SYNTHESIS OF COMPOUNDS 58-62 
To a solution of 53 (or 54-57) (0.26 mmol) in THF (2 mL) HCl 3N (10 mL) was added and the solution was stirred at 
room temperature until full conversion (monitored by TLC). The solution was made basic (pH>12) with KOH 20% 
and then the aqueous phase was extracted with CH2Cl2 (3 x 10 mL). The reunited organic phases were washed with 
brine (10 mL) and dried over anhydrous Na2SO4. The resulting mixture was then concentrated under reduced 
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pressure, to give a residue which was purified by flash chromatography (FC) as indicated below. 
2-(4-(1H-indole-2-carbonyl)piperazin-1-yl)-N-(4-methoxyphenyl)-N-propylacetamide (58) 
FC: CH2Cl2/CH3OH 98.5/1.5 (95% yield). 
1H NMR (300 MHz, CDCl3): δ 9.43 (br, m, 1H), 7.61 (br, d, J = 7.8 Hz, 1H), 
7.36 (br, d, J = 7.8 Hz, 1H), 7.25 (br, t, J = 7.8 Hz, 1H),  7.11 (br, t, J = 7.8 Hz, 1H), 7.07 (br, d, J = 8.7 Hz, 2H),  6.91 
(br, d, J = 8.7 Hz, 2H),  6.71 (s, 1H), 4.04 (br, m, 4H), 3.82 (s, 3H), 3.61 (dd, J = 7.8 and 5.8 Hz, 2H), 2.95 (s, 2H), 2.60 
(br, m, 4H), 1.53 (m, 2H), 0.92 (t, 7.4 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ 168.5, 162.1, 159.1, 135.6, 134.2, 129.4 
(2C), 127.4, 124.4, 121.9, 120.4, 114.6 (2C), 111.9, 111.4, 104.9, 59.2, 55.5, 53.1 (2C), 51.1, 41.8, 39.9, 20.8, 11.2. 
HRMS (ESI): calcd for [C25H31N403]
+ 435.2391, found 435.2409 [MH+]. 
2-(4-(1H-indole-2-carbonyl)piperazin-1-yl)-N-(4-methoxyphenyl)-N-(3-methylbut-2-en-1-yl)acetamide (59) 
FC: CH2Cl2/CH3OH/Et3N 98/1/1 (85% yield). 
1H NMR (300 MHz, CDCl3): δ 9.76 (br, m, 1H), 7.60 (br, d, J = 7.8 Hz, 
1H), 7.40 (br, d, J = 7.8 Hz, 1H), 7.23 (br, t, J = 7.5 Hz, 1H), 7.08 (br, t, J = 7.5 Hz, 1H), 7.02 (d, J = 8.7 Hz, 2H), 6.87 
(d, J = 8.7 Hz, 2H), 6.70 (br, s, 1H), 5.21 (br, t, J = 7.7 Hz, 1H), 4.22 (d, J = 7.7 Hz, 2H), 3.93 (br, m, 4H), 3.80 (s, 3H), 
2.93 (s, 2H), 2.57 (br, m, 4H), 1.65 (s, 3H), 1.42 (s, 3H). 13C NMR (75 MHz, CDCl3): δ 168.6, 162.2, 159.1, 136.4, 
135.7, 134.0, 129.5 (2C), 127.3, 124.2, 121.8, 120.3, 118.8, 114.7 (2C), 111.9, 111.5, 105.1, 59.3, 55.3, 53.2 (2C), 47.1, 
42.9 (2C), 25.6, 17.7. HRMS (ESI): calcd for [C27H32N4NaO3]
+ 483.2367, found 483.2343 [MNa+]. 
2-(4-(1H-indole-2-carbonyl)piperazin-1-yl)-N-(4-bromophenyl)-N-propylacetamide (60) 
FC: CH2Cl2/CH3OH/Et3N 98/1/1 (78% yield). 
1H NMR (300 MHz, CDCl3): δ 9.41 (br, m, 1H), 7.61 (br, d, J = 7.8 Hz, 
1H), 7.55 (d, J = 8.5 Hz, 2H), 7.40 (br, d, J = 7.8 Hz, 1H), 7.25 (br, t, J = 7.8 Hz, 1H), 7.11 (br, t, J = 7.6 Hz, 1H), 7.06 
(d, J = 8.5 Hz, 2H), 6.72 (br, s, 1H), 3.92 (br, m, 4H), 3.62 (br, t, J = 7.8 Hz, 2H), 2.94 (s, 2H), 2.56 (br, m, 4H), 1.52 
(sext, J = 7.8 Hz, 2H), 0.88 (t, J = 7.8 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ 168.1, 162.5, 140.8, 135.5, 132.9, 129.9 
(2C), 129.0, 127.3, 124.4, 122.1, 121.9 (2C), 120.6, 111.9, 105.3, 59.6, 52.7 (2C), 51.4, 42.8, 40.0, 20.7, 10.9. HRMS 
(ESI): calcd for  [C24H28BrN4O2]
+ 483.1390, found 483.1377 [MH+]. 
2-(4-(1H-indole-2-carbonyl)piperazin-1-yl)-N-(4-bromophenyl)-N-(3-methylbut-2-en-1-yl)acetamide (61) 
FC: EtOAc/CH3OH/Et3N 98/1/1 (85% yield). 
1H NMR (300 MHz, CDCl3): δ 9.69 (br, m, 1H), 7.61 (br, d, J = 7.8 Hz, 
1H), 7.51 (d, J = 8.4 Hz, 2H), 7.40 (br, d, J = 7.8 Hz, 1H), 7.24 (br, t, J = 7.8 Hz, 1H), 7.10 (br,t, J = 7.5 Hz, 1H), 7.02 
(d, J = 8.4 Hz, 2H), 6.72 (br, s, 1H), 5.19 (br, t, J = 7.8 Hz, 1H), 4.25 (br, d, J = 7.8 Hz, 2H), 3.93 (br, m, 4H), 2.94 (s, 
2H), 2.58 (br, m, 4H), 1.66 (s, 3H), 1.43 (br, s, 3H). 13C NMR (75 MHz, CDCl3): δ 167.4, 162.4, 140.4, 137.2, 135.7, 
132.9 (2C), 130.0, 129.0, 127.3, 124.4, 122.2, 121.8 (2C), 120.5, 118.5, 111.8, 105.3, 59.0, 52.9 (2C), 47.1, 45.8, 40.0, 
25.7, 17.7. HRMS (ESI): calcd for [C26H29BrN4NaO2]
+ 531.1366, found 531.1341 [MNa+]. 
2-(4-(1H-indole-2-carbonyl)piperazin-1-yl)-N-(4-methoxybenzyl)-N-propylacetamide (62) 
FC: CH2Cl2/CH3OH/Et3N 98/1/1 (90% yield). 
1H NMR (400 MHz, CDCl3, mixture of 2 conformers in ratio 1:1):
 δ 9.88 
(br, m, 0.5H), 9.86 (br, m, 0.5H), 7.65 (dd, J = 8.2 and 2.4 Hz, 1H), 7.45  (dd, J = 8.2 and 2.6 Hz, 1H), 7.27  (br, t, J = 
7.7 Hz, 1H), 7.23 – 7.08 (m, 3H),  6.95 – 6.83 (m, 2H), 6.78 (br, s, 0.5H), 6.76 (br, s, 0.5H), 4.58 (s, 1H), 4.56 (s, 1H), 
4.02 (br, m, 2H), 3.97 (br, m, 2H), 3.82 (br, s, 3H), 3.40 – 3.29 (m, 3H), 3.20 (br, t, J = 7.6 Hz, 1H), 2.76 (br, m, 2H), 
2.69 (br, m, 2H), 1.59 (m, 2H), 0.90 (m, 3H). 13C NMR (100 MHz, CDCl3): δ 167.5, 163.1, 159.1, 136.6, 131.2, 125.0 
(2C), 124.6, 122.4, 121.7, 121.2, 120.0, 116.1 (2C), 112.4 and 110.7 (1C), 106.9 and 105.8 (1C), 60.8 and 60.4 (1C), 
55.9, 53.8 (2C), 48.9 and 48.6 (1C), 48.1*, 43.0*, 45.5, 21.6, 11.8. HRMS (ESI): calcd for [C26H33N4O3]
+ 449.2547, found 
449.2535 [MH+]. 
COMPUTATIONAL STUDIES 
Docking studies 
The selected ligands were first submitted to a Monte Carlo conformational search with the MMFF94 force field in 
vacuo with Spartan ‘08.16  The obtained conformers were used for docking studies. Docking was performed using 
AutoDock9  using the default docking parameters supplied with AutoDock in the 'examples' subdirectory, and point 
charges initially assigned according to the AMBER03 force field,17  and then damped to mimic the less polar Gasteiger 
charges used to optimize the AutoDock scoring function. The setup was done with the YASARA molecular modeling 
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program10 (Krieger E et al, 2002). For each ligands 50 Autodock LGA runs were executed. Results, were sorted by 
binding energy (more positive energies indicate stronger binding, and negative energies mean no binding). After 
clustering the 50 runs, the resulting complex conformations were originated (they all differ by at least 5.0 A heavy 
atom RMSD). 
Molecular dynamics studies 
The highest binding energy complex of each ligand was then submitted to molecular dynamics studies. Simulations 
were run at 298K and 1 bar in a protein membrane of phosphatidyl-ethanolamine (PEA) with the AMBER03 
ForceField. The protein was scanned for secondary structure elements with hydrophobic surface residues and 
oriented accordingly and embedded in the membrane. Water was then added as 0.9% NaCl physiological solution. A 
250 ps restrained equilibration simulation was run, which ensures that the membrane can adapt to the newly 
embedded protein. Then a simulation was run for 15 ns (5 fs timestep, simulation snapshots saved every 250000 fs). 
For each compound, the lowest energy complex from MD simulations was further minimized with the same force 
field. 
BIOLOGICAL EVALUATION 
Receptor Binding Studies  
Dopamine receptor binding was determined by competition binding experiments with membranes from CHO cells 
stably expressing the human D2L, D2S, D3 and D4 receptor displacing the radioligand [
3H]spiperone. Affinities for the D1 
and D5 receptor were performed using transiently transfected HEK cells expressing the appropriate receptor and the 
radioligand [3H]SCH23390. 
Receptor binding studies were carried out as described previously.18 In brief, competition binding experiments with 
the human D2L,
19 D2S,
19 D3
20 and D4
21 receptor were done with preparations of membranes from CHO cells stably 
expressing the corresponding receptor and the radioligand [3H]spiperone (specific activity = 81 Ci/mmol, PerkinElmer, 
Rodgau, Germany) at a final concentration of 0.10 nM, 0.15 nM, 0.20-0.50 nM and 0.30 nM for D2L, D2S, D3 and D4 
binding, respectively. The assays were carried out at a protein concentration of 1-6 µg/assay tube, KD values of 0.058 
nM, 0.032 nM, 0.20-0.50 nM and 0.25 nM and corresponding Bmax values of 910 fmol/mg, 8500 fmol/mg, 4200-5000 
fmol/mg and 1300 fmol/mg for D2L, D2S, D3 and D4, respectively. Human D1 and D5 binding was achieved using 
homogenates of membranes from HEK 293 cells, which were transiently transfected with the pcDNA3.1 vector 
containing the appropriate human gene (from Missouri S&T cDNA Resource Center (UMR), Rolla, MO) by the 
calcium phosphate method22 and worked up as described.18 Binding assays were performed using the radioligand 
[3H]SCH23390 (specific activity 80 Ci/mmol; Biotrend, Cologne, Germany) at 0.40 nM and 0.50 nM with membranes 
expressing the receptors at a density of 4500 fmol/mg and 2300 fmol/mg, a protein content of 3 µg/well and 6 µg/well 
and KD values of 0.34 nM and 0.43 nM for D1 and D5, respectively. Unspecific binding was determined for all receptors 
in the presence of haloperidol (10 µM). Protein concentration was established by the method of Lowry using bovine 
serum albumin as standard.23 The resulting competition curves of the receptor binding experiments were analyzed by 
nonlinear regression using the algorithms in PRISM 5.0 (GraphPad Software, San Diego, CA). The data were initially fit 
using a sigmoid model to provide an IC50 value, representing the concentration corresponding to 50% of maximal 
inhibition. IC50 values were transformed to Ki values according to the equation of Cheng and Prusoff.
24 
cAMP BRET Assay  
HEK293T cells were transiently co-transfected with pcDNA3L-His-CAMYEL (purchased from ATCC via LGC 
Standards, Wesel, Germany) and D2S, respectively. Twenty-four hours after transfection cells were split into white 
half-area 96-well plates at 20 x 104 cells/well and grown overnight. On the following day phenol red free medium was 
removed and replaced by phosphate buffered saline (PBS) and cells were serum starved for 1 hour before treatment. 
The assay was started by adding 10 µl coelenterazine-h (Promega, Mannheim, Germany) to each well at a final 
concentration of 5 µM. After 5 minutes incubation time compounds were added containing 50µM forskolin (final 
concentration 10µM). Determination of BRET signals started 15 minutes after agonist addition using a CLARIOstar 
plate reader (BMG LabTech, Ortenberg, Germany). Emission signals from Renilla Luciferase and YFP were measured 
simultaneously using a BRET filter set (475-30nm/535-30nm).25 
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4. ENANTIOENRICHED SPIRO[INDOLINE-
PYRIMIDINE]-DIONES DERIVATIVES 
 
Figure 22. Selected examples of small bioactive molecules based on 3,3’-disubstituted  
or spiro-fused 2-oxindole motifs. 
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Scheme 33. Synthesis of a library of enantioenriched spiro[indoline-pyrimidine]-diones derivatives  
by means of a BINOL-derived monophosphoric acids catalyzed Biginelli-like reaction. 
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Table 2. Asymmetric Biginelli-like condensation of N-benzyl isatin 73a, urea and ethyl acetoacetate, catalyzed by chiral 
phosphoric acids (R)-74.  
entry catalyst solvent 
conc. 
[mol/L] 
temp. [°C], 
time [h] 
yielda 
[%] 
eeb 
[%] 
1 74a CH2Cl2 0.2 rt, 96 trace / 
2 74a Tol 0.2 rt, 96 trace / 
3 74a CH2Cl2 0.2 50, 48 32 75 
4 74a Tol 0.2 50, 48 51 80 
5 74b Tol 0.2 50, 48 trace / 
6 74c Tol 0.2 50, 48 30 79 
7 74d Tol 0.2 50, 48 31 81 
8 74e Tol 0.2 50, 48 trace / 
9 74f Tol 0.2 50, 48 trace / 
10 74g Tol 0.2 50, 48 26 79 
11 74a Tol 0.2 50, 96 60 80 
12 74a Tol 0.2 50, 240 66 77 
13 74a Tol 0.2 70, 96 65 48 
14 74a Tol 0.4 50, 96 62 66 
β
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Scheme 34. Substrate scope of the Biginelli-like reaction catalyzed by (R)-74a. 
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Scheme 35. Synthetic transformations on compounds 75a and 75j. 
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Figure 23. Experimental 1H NMR spectra and calculated chemical shifts  
for selected protons of diastereoisomers 79a and 79b. 
Diastereoisomeric
mixture
79a 
(3S,1’S)
79b
(3R,1’S)
Calculated
1H chemical shift
Proton CH3 DHMP CH3 Bn
(3S,1’S) 1.91 1.07
(3R,1’S) 2.10 1.32
1.912.01 1.041.32
CH3 DHMP CH3 Bn
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Scheme 36. Possible stereoisomers formed in the initial step of the acid-catalyzed Biginelli-like reaction.  
 
20
 
Figure 24. a) Proposed transition states of the BINOL-derived phosphoric acid catalyzed Biginelli-like reaction.  
b) Gibbs free energy profiles for both the two possible transition states. 
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Figure 25. 3D structures of the two possible transition states TS-A and TS-B. 
 
TS-A TS-B
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GENERAL INFORMATION 
All commercial materials (Aldrich, Fluka) were used without further purification. All solvents were of reagent grade or 
HPLC grade. All reactions were carried out under a nitrogen atmosphere unless otherwise noted. All reactions were 
monitored by thin layer chromatography (TLC) on precoated silica gel 60 F254; spots were visualized with UV light or 
by treatment with a 1% aqueous KMnO4 solution. Products were purified by flash chromatography on silica gel 60 (230–
400 mesh). 1H NMR spectra and 13C NMR spectra were recorded on 300 and 400 MHz spectrometers. Chemical shifts 
are reported in parts per million relative to the residual solvent. 13C NMR spectra have been recorded using the APT 
pulse sequence (for further details see Appendix A.1). Multiplicities in 1H NMR are reported as follows: s = singlet, d = 
doublet, t = triplet, m = multiplet, br s = broad singlet. High-resolution MS spectra were recorded with a Waters 
Micromass Q-ToF micro TM mass spectrometer, equipped with an ESI source. HPLC analysis was performed on Jasco 
PU-2080 (UV Detector and binary HPLC pump) at 254 nm. Chiralcel OD column were purchased from Daicel Chemical 
Industries®. Optical rotator power [α]TD was measured with a Jasco P-1030 polarimeter, endowed with a cell of 1 dm 
pathlength and 1 mL capacity. The light used has a wavelength of 589 nm (Sodium D line). N-substituted isatins21 and 
BINOL-phosphoric acids22 were synthetized according to reported literature. 
GENERAL PROCEDURE FOR THE SYNTHESIS OF COMPOUNDS 75a-j 
Substituted isatin 73 (0.16 mmol, 1 eq), urea (0.19 mmol, 1.2 eq), alkyl acetoacetate (0.48 mmol, 3 eq) and (R)-74a 
catalyst (0.03 mmol, 0.2 eq) were dissolved in toluene (0.800 mL, 0.2 M). The reaction was stirrer at 50 °C for 96h. The 
resulting mixture was then concentrated under reduced pressure, to give a residue which was purified by flash 
chromatography (FC) as indicated below. 
(S)-ethyl 1-benzyl-6'-methyl-2,2'-dioxo-2',3'-dihydro-1'H-spiro[indoline-3,4'-pyrimidine]-5'-carboxylate (75a) 
Prepared according to general procedure starting from N-benzyl isatin and ethyl acetoacetate; FC: 
dichlorometane:methanol, 97.5:2.5; yield: 60%; white solid; [α]20D – 45.5 (c 0.2, CHCl3); 1H NMR (400 MHz, CDCl3) δ 
8.50 (br, m, 1H), 7.42 (d, J = 7.4 Hz, 2H), 7.38 – 7.24 (m, 4H), 7.21 (t, J = 7.5 Hz, 1H), 7.03 (t, J = 7.5 Hz, 1H), 6.76 (d, 
J = 7.8 Hz, 1H), 5.69 (br, m, 1H), 4.99 (d, J = 15.5 Hz, 1H), 4.80 (d, J = 15.5 Hz, 1H), 3.99 – 3.86 (m, 1H), 3.70 – 3.55 
(m, 1H), 2.38 (s, 3H), 0.71 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 176.5, 165.2, 151.9, 149.9, 143.2, 136.3, 
132.9, 130.5, 129.5 (2C), 128.5 (3C), 124.6, 124.0, 109.9, 99.4, 64.2, 60.6, 45.0, 20.1, 14.1; HRMS (ESI) calcd for 
C22H21N3NaO4+ [MNa]+ 414.1434, found 414.1442; enantiomeric excess: 80%, determined by chiral HPLC (n-
hexane:isopropanol = 80:20, flow rate 1.0 mL/min): tR = 14.98 min (major), tR = 33.78 min (minor). 
(S)-ethyl 1-(4-methoxybenzyl)-6'-methyl-2,2'-dioxo-2',3'-dihydro-1'H-spiro[indoline-3,4'-pyrimidine]-5'-carboxylate (75b) 
Prepared according to general procedure starting from N-(4-methoxybenzyl) isatin and ethyl acetoacetate; FC: 
dichlorometane:methanol, 97.5:2.5; yield: 63%; white solid; [α]20D  4.5 (c 0.35, CHCl3); 1H NMR (300 MHz, CDCl3, 
mixture of conformers 6:1) δ 8.87 (br, m, 0.15H), 8.74 (br, m, 0.85H), 7.33 (d, J = 8.7 Hz, 2H), 7.26 (d, J = 8.2 Hz, 1H), 
7.17 (t, J = 7.7 Hz, 1H), 6.98 (t, J = 7.3 Hz, 1H), 6.88 – 6.70 (m, 3H), 6.01 (br, m, 0.86H), 5.81 (br, m, 0.14H), 4.85 (d, J 
= 15.3 Hz, 1H), 4.71 (d, J = 15.3 Hz, 1H), 3.96 – 3.78 (m, 1H), 3.74 (s, 0.43H), 3.71 (s, 2.57H), 3.64 – 3.43 (m, 1H), 2.33 
(s, 0.44H), 2.27 (s, 2.56H), 0.64 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3, mixture of conformers 6:1) δ 175.9, 
164.6, 159.1, 152.1, 149.5, 142.6, 132.5, 129.7, 129.2 (2C), 127.8, 123.9, 123.2, 114.1 (2C), 109.2, 98.5, 63.4, 59.8, 55.2, 
43.7, 19.1, 13.5; HRMS (ESI) calcd for C23H23N3NaO5
+ [MNa]+ 444.1530, found 444.1519; enantiomeric excess: 75%, 
determined by chiral HPLC (n-hexane:isopropanol = 65:35, flow rate 1.0 mL/min): tR = 9.85 min (major), tR = 27.96 min 
(minor). 
(S)-ethyl 6'-methyl-1-(4-nitrobenzyl)-2,2'-dioxo-2',3'-dihydro-1'H-spiro[indoline-3,4'-pyrimidine]-5'-carboxylate (75c) 
Prepared according to general procedure starting from N-(4-nitrobenzyl) isatin and ethyl acetoacetate; FC: 
dichlorometane:methanol, 97.5:2.5; yield: 49%; white solid; [α]20D – 8.2 (c 0.3, CHCl3); 1H NMR (300 MHz, CDCl3, 
mixture of conformers 5:1) δ 8.48 (br, m, 0.17H), 8.40 (br, m, 0.83H), 8.21 – 8.08 (m, 2H), 7.65 – 7.54 (m, 2H), 7.30 (d, 
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J = 7.3 Hz, 1H), 7.19 (t, J = 7.3 Hz, 1H), 7.03 (t, J = 7.5 Hz, 1H), 6.62 (d, J = 7.6 Hz, 1H), 6.28 (br, m, 0.84H), 6.12 (br, 
m, 0.16H), 5.09 – 4.87 (m, 2H), 4.07 – 3.89 (m, 1H), 3.86 – 3.68 (m, 1H), 2.34 (s, 0.5H), 2.30 (s, 2.5H), 0.88 (m, 3H). 13C 
NMR (75 MHz, CDCl3, mixture of conformers 5:1) δ 176.0, 164.6, 151.8, 149.0, 147.5, 143.0, 141.9, 132.2, 130.0, 128.4 
(2C), 124.1, 124.0 (2C), 123.8, 109.0, 98.9, 63.51, 60.3, 43.7, 19.5, 13.8; HRMS (ESI) calcd for C22H20N4NaO6
+ [MNa]+ 
459.1275, found 459.1268. enantiomeric excess: 70%, determined by chiral HPLC (n-hexane:isopropanol = 50:50, flow 
rate 1.0 mL/min): tR = 10.05 min (major), tR = 45.50 min (minor). 
(S)-ethyl 1,6'-dimethyl-2,2'-dioxo-2',3'-dihydro-1'H-spiro[indoline-3,4'-pyrimidine]-5'-carboxylate (75d) 
Prepared according to general procedure starting from N-methyl isatin and ethyl acetoacetate; FC: 
dichlorometane:methanol, 95:5; yield: 93%; white solid; [α]20D – 1.6 (c 0.35, CHCl3); 1H NMR (400 MHz, DMSO-d6) δ 
9.45 (br, m, 1H), 7.75 (br, m, 1H), 7.30 (t, J = 7.7 Hz, 1H), 7.18 (d, J = 7.3 Hz, 1H), 7.01 (t, J = 7.4 Hz, 1H), 6.97 (d, J = 
7.8 Hz, 1H), 3.68 (q, J = 7.1 Hz, 2H), 3.10 (s, 3H), 2.26 (s, 3H), 0.75 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz, DMSO-d6) 
δ 176.2, 164.8, 150.9 (2C), 144.0, 134.0, 129.6, 123.4, 122.8, 108.7, 97.1, 63.1, 59.5, 26.6, 18.7, 13.8; HRMS (ESI) calcd 
for C16H17N3NaO4
+ [MNa]+ 338.1111, found 338.1123. enantiomeric excess: 50%, determined by chiral HPLC (n-
hexane:isopropanol = 65:35, flow rate 1.0 mL/min): tR = 7.25 min (major), tR = 38.20 min (minor). 
(S)-ethyl 1-benzyl-5-fluoro-6'-methyl-2,2'-dioxo-2',3'-dihydro-1'H-spiro[indoline-3,4'-pyrimidine]-5'-carboxylate  (75e) 
Prepared according to general procedure starting from 5-fluoro-N-benzyl isatin and ethyl acetoacetate; FC: 
dichlorometane:methanol, 97.5:2.5; yield: 51%; white solid; [α]20D 3.8 (c 0.3, CHCl3); 1H NMR (300 MHz, CDCl3, mixture 
of conformers 5:1) δ 8.76 – 8.49 (br, m, 1H), 7.38 (d, J = 7.2 Hz, 2H), 7.34 – 7.16 (m, 3H), 7.03 (dd, J = 7.3, 2.5 Hz, 1H), 
6.88 (td, J = 8.8, 2.4 Hz, 1H), 6.67 (dd, J = 8.5, 3.8 Hz, 1H), 6.13 – 5.88 (br, m, 1H), 4.92 (d, J = 15.5 Hz, 1H), 4.76 (d, J 
= 15.5 Hz, 1H), 4.04 – 3.83 (m, 1H), 3.74 – 3.52 (m, 1H), 2.35 (s, 0.5H), 2.30 (s, 2.5H), 0.83 – 0.68 (m, 3H). 13C NMR 
(75 MHz, CDCl3, mixture of conformers 5:1) δ 175.7, 164.4, 161.1, 157.9, 151.80, 149.75, 138.42, 135.34, 128.77 (2C), 
127.81, 127.74 (2C), 116.17 and 115.86 (1C), 112.19 and 111.9 (1C), 110.0 and 109.9 (1C), 98.2, 63.6, 60.1, 44.4, 19.3, 
13.6; HRMS (ESI) calcd for C22H20FN3NaO4
+ [MNa]+ 432.1330, found 432.1326. enantiomeric excess: 75%, determined 
by chiral HPLC (n-hexane:isopropanol = 70:30, flow rate 1.0 mL/min): tR = 8.15 min (major), tR = 16.35 min (minor). 
(S)-ethyl 1-benzyl-5-chloro-6'-methyl-2,2'-dioxo-2',3'-dihydro-1'H-spiro[indoline-3,4'-pyrimidine]-5'-carboxylate (75f) 
Prepared according to general procedure starting from 5-chloro-N-benzyl isatin and ethyl acetoacetate; FC: 
dichlorometane:methanol, 97.5:2.5; yield: 66%; white solid; [α]20D 33.6 (c 0.2, CHCl3); 1H NMR (300 MHz, CDCl3, 
mixture of conformers 5:1) δ 8.76 (br, m, 0.16H), 8.69 (br, m, 0.84H), 7.37 (d, J = 7.1 Hz, 2H), 7.33 – 7.18 (m, 4H), 7.14 
(d, J = 8.3, 1H), 6.67 (d, J = 8.3 Hz, 1H), 6.24 (br, m, 0.83H), 6.18 (br, m, 0.17H), 4.90 (d, J = 15.6 Hz, 1H), 4.77 (d, J = 
15.7 Hz, 1H), 4.01 – 3.84 (m, 1H), 3.75 – 3.56 (m, 1H), 2.34 (s, 0.5H), 2.29 (s, 2.5H), 0.83 – 0.68 (m, 3H). 13C NMR (75 
MHz, CDCl3) δ 175.5, 164.4, 151.9, 149.8, 141.1, 135.2, 134.0, 129.7, 128.8 (2C), 128.5, 127.8, 127.7 (2C), 124.3, 110.3, 
98.1, 63.4, 60.1, 44.4, 19.3, 13.6; HRMS (ESI) calcd for C22H20ClN3NaO4
+ [MNa]+ 448.1035, found 448.1049. 
enantiomeric excess: 74%, determined by chiral HPLC (n-hexane:isopropanol = 70:30, flow rate 1.0 mL/min): tR = 9.05 
min (major), tR = 16.45 min (minor). 
(S)-ethyl 1-benzyl-6-chloro-6'-methyl-2,2'-dioxo-2',3'-dihydro-1'H-spiro[indoline-3,4'-pyrimidine]-5'-carboxylate (75g) 
Prepared according to general procedure starting from 6-chloro-N-benzyl isatin and ethyl acetoacetate; FC: 
dichlorometane:methanol, 97.5:2.5; yield: 62%; white solid; [α]20D – 1.0 (c 0.3, CHCl3); 1H NMR (300 MHz, CDCl3) δ 
8.44 (br, m, 1H), 7.39 (d, J = 7.0 Hz, 2H), 7.35 – 7.22 (m, 3H), 7.19 (d, J = 7.7 Hz, 1H), 6.98 (d, J = 7.6 Hz, 1H), 6.79 (s, 
1H), 6.14 (br, m, 1H), 4.90 (d, J = 15.5 Hz, 1H), 4.75 (d, J = 15.5 Hz, 1H), 3.90 (m, 1H), 3.60 (m, 1H), 2.29 (s, 3H), 0.74 
(t, J = 6.8 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 175.8, 164.4, 151.9, 149.4, 143.9, 135.6, 135.1, 130.7, 128.8 (2C), 127.9, 
127.8 (2C), 124.8, 123.1, 109.9, 98.4, 63.0, 60.1, 44.4, 19.2, 13.6; HRMS (ESI) calcd for C22H20ClN3NaO4
+ [MNa]+ 
448.1035, found 448.1039; enantiomeric excess: 77%, determined by chiral HPLC (n-hexane:isopropanol = 65:35, flow 
rate 1.0 mL/min): tR = 8.65 min (major), tR = 15.35 min (minor). 
(S)-ethyl 1-benzyl-6-bromo-6'-methyl-2,2'-dioxo-2',3'-dihydro-1'H-spiro[indoline-3,4'-pyrimidine]-5'-carboxylate (75h) 
Prepared according to general procedure starting from 6-bromo-N-benzyl isatin and ethyl acetoacetate; FC: 
dichlorometane:methanol, 97.5:2.5; yield: 63%; white solid; [α]20D 7.6 (c 0.55, CHCl3); 1H NMR (300 MHz, CDCl3) δ 8.52 
(br, m, 1H), 7.39 (d, J = 7.3 Hz, 2H), 7.26 (m, 3H), 7.18 – 7.06 (m, 2H), 6.95 (s, 1H), 6.22 (m, 1H), 4.87 (d, J = 15.6 Hz, 
1H), 4.75 (d, J = 15.6 Hz, 1H), 4.00 – 3.77 (m, 1H), 3.70 – 3.49 (m, 1H), 2.27 (s, 3H), 0.72 (t, J = 7.1 Hz, 3H). 13C NMR 
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(75 MHz, CDCl3) δ 175.7, 164.4, 152.0, 149.5, 144.0, 135.1, 131.3, 128.8 (2C), 127.9, 127.8 (2C), 126.1, 125.2, 123.4, 
112.6, 98.3, 63.1, 60.1, 44.1, 19.2, 13.6; HRMS (ESI) calcd for C22H20BrN3NaO4
+ [MNa]+ 492.0529, found 492.0518; 
enantiomeric excess: 75%, determined by chiral HPLC (n-hexane:isopropanol = 70:30, flow rate 1.0 mL/min): tR = 9.35 
min (major), tR = 16.50 min (minor). 
(S)-methyl 1-benzyl-6'-methyl-2,2'-dioxo-2',3'-dihydro-1'H-spiro[indoline-3,4'-pyrimidine]-5'-carboxylate (75i) 
Prepared according to general procedure starting from N-benzyl isatin and methyl acetoacetate; FC: 
dichlorometane:methanol, 97.5:2.5; yield: 65%; white solid; [α]20D – 6.8 (c 0.35, CHCl3); 1H NMR (300 MHz, CDCl3) δ 
7.77 (br, m, 1H), 7.40 (d, J = 7.7 Hz, 2H), 7.36 – 7.23 (m, 4H), 7.20 (td, J = 7.8, 1.2 Hz, 1H), 7.01 (t, J = 7.5 Hz, 1H), 6.75 
(d, J = 7.7 Hz, 1H), 5.29 (br, m, 1H), 4.94 (d, J = 15.5 Hz, 1H), 4.83 (d, J = 15.4 Hz, 1H), 3.20 (s, 3H), 2.37 (s, 3H). 13C 
NMR (75 MHz, CDCl3) δ 175.8, 165.0, 151.3, 149.2, 142.3, 135.6, 132.1, 129.9, 128.8 (2C), 127.9 (2C), 127.8, 123.8, 
123.3, 109.2, 98.7, 63.5, 51.0, 44.3, 19.4; HRMS (ESI) calcd for C21H19N3NaO4
+ [MNa]+ 400.1268, found 400.1257; 
enantiomeric excess: 61%, determined by chiral HPLC (n-hexane:isopropanol = 70:30, flow rate 1.0 mL/min): tR = 9.15 
min (major), tR = 18.30 min (minor). 
(S)-benzyl 1-benzyl-6'-methyl-2,2'-dioxo-2',3'-dihydro-1'H-spiro[indoline-3,4'-pyrimidine]-5'-carboxylate (75j) 
Prepared according to general procedure starting from N-benzyl isatin and benzyl acetoacetate; FC: 
dichlorometane:methanol, 97.5:2.5; yield: 55%; white solid; [α]20D 17.2 (c 0.5, dioxane); 1H NMR (300 MHz, CDCl3) δ 
8.15 (m, 1H), 7.41 – 7.17 (m, 10H), 7.18 – 7.09 (m, 1H), 6.98 (t, J = 7.5 Hz, 1H), 6.85 (d, J = 6.5 Hz, 1H), 6.44 (d, J = 7.8 
Hz, 1H), 5.39 (br, m, 1H), 4.85 – 4.70 (m, 2H), 4.63 (d, J = 12.0 Hz, 1H), 3.81 (d, J = 15.6 Hz, 1H), 2.39 (s, 3H). 13C NMR 
(75 MHz, ) δ 175.8, 164.4, 162.2, 150.2, 142.3, 135.8, 132.2, 129.9, 128.9 (4C), 128.6 (2C), 128.3, 127.8, 127.7 (2C), 
124.0, 123.4, 109.8, 66.5, 43.8, 19.6 (3 quaternary carbons are missed); HRMS (ESI) calcd for C27H23N3NaO4
+ [MNa]+ 
476.1581, found 476.1589. enantiomeric excess: 74%, determined by chiral HPLC (n-hexane:isopropanol = 80:20, flow 
rate 1.0 mL/min): tR = 13.50 min (major), tR = 28.20 min (minor). 
PROCEDURE FOR THE SYNTHESIS OF ethyl (S)-1,1'-dibenzyl-6'-methyl-2,2'-dioxo-2',3'-
dihydro-1'H-spiro[indoline-3,4'-pyrimidine]-5'-carboxylate (76) 
To a solution of compound 75a (0.25 mmol, 1 eq) in anhydrous dimethylformamide (0.830 mL, 0.3 M), CsCO3 (0.33 
mmol, 1.3 eq) was added, then the mixture was stirred for 1 hour at room temperature. Benzyl bromide (0.38 mmol, 
1.5 eq) was slowly added and the mixture was stirred overnight. After the completion of reaction (monitored by TLC), 
saturated aq. NaCl (1 mL) was added. The reaction mixture was extracted with ethyl acetate (3 x 2 mL). The combined 
organic layer was washed with water (2 x 6 mL), followed by brine (2 x 6 mL). the organic phase was dried over 
anhydrous Na2SO4 and concentrated in vacuo to afford the crude product, which was purified by FC (n-hexane:ethyl 
acetate, 7:3), affording the desired product 76 (115 mg, 96%) as a white solid. [α]20D – 32.4 (c 0.5, CHCl3); 1H NMR (300 
MHz, CDCl3) δ 7.51 – 7.24 (m, 11H), 7.21 (d, J = 7.7 Hz, 1H), 7.02 (t, J = 7.4 Hz, 1H), 6.75 (d, J = 7.8 Hz, 1H), 5.32 (d, 
J = 17.0 Hz, 1H), 5.16 (br, m, 1H), 4.93 (d, J = 15.2 Hz, 2H), 4.83 (d, J = 15.4 Hz, 1H), 3.91 – 3.73 (m, 1H), 3.57 – 3.42 
(m, 1H), 2.40 (s, 3H), 0.52 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 175.9, 165.1, 152.2, 150.7, 142.9, 137.7, 
135.6, 131.7, 129.8, 128.9 (2C), 128.7 (2C), 127.8 (3C), 127.1, 126.0 (2C), 123.9, 123.2, 109.1, 101.9, 62.3, 60.0, 46.0, 
44.2, 16.8, 13.2; HRMS (ESI) calcd for C29H27N3NaO4
+ [MNa]+ 504.1894, found 504.1898. 
PROCEDURE FOR THE SYNTHESIS OF (S)-1-benzyl-6'-methyl-2,2'-dioxo-2',3'-dihydro-
1'H-spiro[indoline-3,4'-pyrimidine]-5'-carboxylic acid (77) 
Palladium (10 wt.% on carbon, 0.025 mmol, 0.05 eq) was added to a solution of Biginelli-adduct 75j (0.50 mmol, 1 eq) 
and Et3N (0.50 mmol, 1 eq) in 7.5 mL of dioxane/methanol (2:1). The reaction mixture was degassed in vacuo, placed 
under an atmosphere of H2 (g), and stirred in the dark at rt for 3h. The mixture was filtered through a pad of Celite 
eluting with methanol (10 mL), and the combined organic layers were concentrated in vacuo to give the crude carboxylic 
acid derivative 77 (173 mg, 95%) as a white solid, sufficiently pure to be directly used in the next step. [α]20D – 19.2 (c 
0.25, CHCl3);  
1H NMR (300 MHz, DMSO-d6) δ 11.97 (br, s, 1H), 9.39 (br, m, 1H), 7.89 (br, m, 1H), 7.47 (d, J = 6.7 Hz, 
2H), 7.39 – 7.25 (m, 3H), 7.23 (d, J = 7.2 Hz, 1H), 7.16 (t, J = 7.7 Hz, 1H), 6.98 (t, J = 7.4 Hz, 1H), 6.62 (d, J = 7.7 Hz, 
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1H), 4.96 (d, J = 16.3 Hz, 1H), 4.70 (d, J = 16.3 Hz, 1H), 2.29 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 176.1, 166.4, 
150.7, 149.4, 142.7, 136.3, 133.9, 128.8, 128.3 (2C), 127.1 (2C), 127.0, 123.0, 122.3, 108.9, 97.8, 63.0, 43.4, 18.5; HRMS 
(ESI) calcd for C20H17N3NaO4
+ [MNa]+ 386.1111, found 386.1121. 
PROCEDURE FOR THE SYNTHESIS OF (R)-1-benzyl-6'-methyl-1'H-spiro[indoline-3,4'-
pyrimidine]-2,2'(3'H)-dione (78) 
To a solution of the carboxylic acid derivative 77 (0.1 mmol, 1 eq) in 1 mL of dioxane/methanol (1:1), hydrochloric acid 
in dioxane (4 M, 0.4 mmol, 4 eq) was added, and the reaction was stirred at 90 °C for 0.5h. The solvent was removed 
under reduced pressure to afford compound 78 (31 mg, 98%) in high purity as a white solid, with no need for further 
purifications. [α]20D – 25.6 (c 0.5, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.82 (br, m, 1H), 7.40 (d, J = 7.3 Hz, 1H), 7.37 
– 7.23 (m, 5H), 7.18 (t, J = 7.7 Hz, 1H), 7.06 (t, J = 7.5 Hz, 1H), 6.71 (d, J = 7.8 Hz, 1H), 5.72 (br, m, 1H), 4.93 (d, J = 
15.6 Hz, 1H), 4.79 (d, J = 15.6 Hz, 1H), 4.24 (s, 1H), 1.86 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 177.2, 154.4, 142.0, 
136.4, 136.1, 132.6, 130.5, 129.5 (2C), 128.4, 128.0 (2C), 125.7, 124.2, 110.2, 95.4, 64.3, 44.7, 19.4; HRMS (ESI) calcd 
for C19H17N3NaO2
+ [MNa]+ 342.1213, found 342.1206. 
PROCEDURE FOR THE SYNTHESIS OF DIASTEREOISOMERS (S)-1-benzyl-6'-methyl-
2,2'-dioxo-N-((S)-1-phenylethyl)-2',3'-dihydro-1'H-spiro[indoline-3,4'-pyrimidine]-5'-
carboxamide (79a) AND (R)-1-benzyl-6'-methyl-2,2'-dioxo-N-((S)-1-phenylethyl)-2',3'-
dihydro-1'H-spiro[indoline-3,4'-pyrimidine]-5'-carboxamide (79b) 
To a solution of carboxylic acid derivative 78 (0.9 mmol, 1 eq) and DIPEA (1.8 mmol, 2 eq) in 9.4 mL of anhydrous 
dimethylformamide, HATU (1.4 mmol, 1.5 eq) was added. After 5 min, (S)-(−)-α-methylbenzylamine (0.9 mmol, 1 eq) 
and DIPEA (1.8 mmol, 2 eq) were added, and the reaction was stirred at room temperature for 24 hours. The resulting 
mixture was partitioned between ethyl acetate (20 mL) and water (20 mL). The organic phase was washed with brine 
(6 x 10 mL), dried over Na2SO4 and concentrated in vacuo to afford the crude diastereoisomeric mixture 79, which was 
purified by flash chromatography (ethyl acetate:n-hexane, 95:5), obtaining the two isolated stereoisomers 79a (358 mg, 
86%) and 79b (54 mg, 12%). 
79a: white solid; [α]20D   16.5 (c 0.9, CHCl3); 1H NMR (400 MHz, DMSO-d6) δ 8.79 (br, m, 1H), 8.18 (d, J = 8.4 Hz, 1H), 
7.62 (br, m, 1H), 7.46 (d, J = 7.3 Hz, 2H), 7.33 (d, J = 7.4 Hz, 1H), 7.32 – 7.22 (m, 7H), 7.18 (q, J = 8.4, 7.8 Hz, 2H), 7.00 
(t, J = 7.5 Hz, 1H), 6.63 (d, J = 7.8 Hz, 1H), 4.78 (s, 2H), 4.71 – 4.59 (m, 1H), 1.91 (s, 3H), 1.04 (d, J = 7.0 Hz, 3H). 13C 
NMR (100 MHz, DMSO-d6) δ 177.4, 165.6, 153.2, 145.3, 144.4, 138.0, 137.3, 132.4, 130.2, 129.4 (2C), 129.3 (2C), 128.3 
(2C), 128.1, 127.6, 127.2 (2C), 125.3, 123.0, 109.9, 105.1, 64.3, 48.6, 44.2, 23.0, 18.3. HRMS (ESI) calcd for 
C28H26N4NaO3
+ [MNa]+ 489.1897, found 489.1905. 
79b: white solid; [α]20D – 89.5 (c 1, CHCl3); 1H NMR (400 MHz, DMSO-d6) δ 8.81 (br, m, 1H), 8.13 (d, J = 8.3 Hz, 1H), 
7.62 (br, m, 1H), 7.42 (d, J = 6.4 Hz, 2H), 7.31 (d, J = 7.2 Hz, 1H), 7.29 – 7.19 (m, 3H), 7.17 (t, J = 7.6 Hz, 1H), 7.11 (m, 
3H), 7.00 (t, J = 7.4 Hz, 1H), 6.83 (d, J = 7.4 Hz, 2H), 6.57 (d, J = 7.8 Hz, 1H), 4.88 – 4.67 (m, 3H), 2.01 (s, 3H), 1.32 (d, 
J = 7.0 Hz, 3H). 13C NMR (100 MHz, DMSO-d6) δ 177.4, 165.6, 153.0, 144.9, 144.32, 138.3, 137.3, 132.7, 130.1, 129.4 
(2C), 128.9 (2C), 128.2 (2C), 128.07, 127.1, 126.8 (2C), 125.3, 123.2, 110.0, 105.12, 64.4, 48.1, 44.2, 22.5, 18.4. HRMS 
(ESI) calcd for C28H26N4NaO3
+ [MNa]+ 489.1897, found 489.1909. 
COMPUTATIONAL STUDIES 
Determination of the stereochemistry of the C-3 quaternary stereocenter 
Mono- and bidimensional NMR analysis on both diastereoisomers 79a and 79b allowed to assign each proton and 
carbon to experimental chemical shifts, although NH protons chemical shifts were not futher considered. Monte Carlo 
conformational search was run with Spartan ‘0823 using MMFF forcefield on both possible stereoisomers with (3S,1’S) 
and (3R,1’S) absolute configurations, with standard parameters and convergence criteria. All structures with population 
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> 1% were further optimized with GAUSSIAN0924 at quantum-mechanics DFT/B3LYP/6-31g(d,p) in gas phase, followed 
by single-point ab initio calculations of energy (DFT/B3LYP/6-31g(d,p)) and GIAO shielding constants at the DFT/6-
311+G(2d,p)/SCRF-dmso level. Boltzmann averaging over the conformers, followed by linear regression employing 
reported25 1H and 13C NMR scaling factors afforded theoretical NMR chemical shift for the two possible (3S,1’S) and 
(3R,1’S) absolute configurations. Comparison parameters 3 (CP3) were computed for protons, carbons and all data. 
Application of the Bayes’ theorem afforded the percentage probability for each assignment.26 
Transition-state calculation 
All the structures were first submitted to a Monte Carlo conformational search with MM (MMFF94 force field) 
minimization. The global minima were then submitted to a geometry optimization with DFT at the B3LYP/6-31G(d,p) 
level. All the minima were confirmed by frequency calculation. Transition state (TS) search was first attempted with 
HF/3-21G on a simplified model and then refined with DFT B3LYP/6-31G. Single point calculation at the B3LYP/6-
31G(d,p) level was then performed on the complete TS structures. TS were confirmed by analysis of the imaginary 
frequencies. 
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A.1 NMR SPECTRA 
Chapter 2.1 
Compound 7a: 1H NMR (300 MHz, CD3CN) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 7a: 13C NMR (75 MHz, CD3CN) 
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Compound 7b: 1H NMR (300 MHz, CD3CN) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 7b: 13C NMR (100 MHz, CDCl3) 
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Compound 8: 1H NMR (300 MHz, CD3CN) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 9: 1H NMR (300 MHz, CD3CN) 
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Compound 10: 1H NMR (400 MHz, CDCl3) 
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Compound 11a: 1H NMR (300 MHz, CD3CN) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 11a: 13C NMR (100 MHz, CD3CN) 
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Compound 11b: 1H NMR (400 MHz, CD3CN) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 11b: 13C NMR (100 MHz, CD3CN) 
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Compound 12: 1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 12: 13C NMR (100 MHz, CDCl3) 
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Compound 13: 1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 13: 13C NMR (100 MHz, CDCl3) 
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Compound 14: 1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 14: 13C NMR (100 MHz, CDCl3) 
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Compound 15a: 1H NMR (300 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 15a: 13C NMR (75 MHz, CDCl3) 
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Compound 15b: 1H NMR (300 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 15b: 13C NMR (75 MHz, CDCl3) 
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Compound 16: 1H NMR (300 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 17: 1H NMR (300 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
A.1 NMR spectra 
125 
 
Compound 18: 1H NMR (300 MHz, CDCl3) 
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Compound 19a: 1H NMR (300 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 19a: 13C NMR (100 MHz, CDCl3) 
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Compound 19b: 1H NMR (400 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 19b: 13C NMR (100 MHz, CDCl3) 
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Compound 20: 1H NMR (400 MHz, CD3CN) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 20: 13C NMR (100 MHz, CD3CN) 
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Compound 21: 1H NMR (400 MHz, CD3CN) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 21: 13C NMR (100 MHz, CD3CN) 
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Compound 22: 1H NMR (400 MHz, CD3CN) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 22: 13C NMR (100 MHz, CD3CN) 
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Compound 23a: 1H NMR (300 MHz, CDCl3) 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Compound 23a: 13C NMR (75 MHz, CDCl3) 
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Compound 23b: 1H NMR (400 MHz, CDCl3) 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Compound 23b: 13C NMR (100 MHz, CDCl3) 
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Compound 24a: 1H NMR (300 MHz, CDCl3) 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
Compound 24a: 13C NMR (75 MHz, CDCl3) 
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Compound 24b: 1H NMR (400 MHz, CDCl3) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Compound 24b: 13C NMR (100 MHz, CDCl3) 
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Compound 25a: 1H NMR (300 MHz, CDCl3) 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
Compound 25a: 13C NMR (75 MHz, CDCl3) 
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Compound 25b: 1H NMR (400 MHz, CDCl3) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Compound 25b: 13C NMR (100 MHz, CDCl3) 
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Compound 26a: 1H NMR (300 MHz, CDCl3) 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
Compound 26a: 13C NMR (75 MHz, CDCl3) 
 
 
 
 
 
 
 
 
 
 
 
 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
Multicomponent approaches to the synthesis of small bioactive molecules 
138 
 
Compound 26b: 1H NMR (400 MHz, CD3CN) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Compound 26b: 13C NMR (100 MHz, CD3CN) 
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Chapter 2.2 
Compound 30a: 1H NMR (400 MHz, CDCl3) 
Compound 30a: 13C NMR (100 MHz, CDCl3)
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Compound 30b: 1H NMR (400 MHz, CDCl3)  
Compound 30b: 13C NMR (100 MHz, CDCl3)
 
A.1 NMR spectra 
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Compound 30c: 1H NMR (400 MHz, CDCl3)  
Compound 30c: 13C NMR (100 MHz, CDCl3)
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Compound 30d: 1H NMR (400 MHz, DMSO-d6, 80 °C)  
Compound 30d: 13C NMR (100 MHz, DMSO-d6, 80 °C)
 
A.1 NMR spectra 
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Compound 31a: 1H NMR (300 MHz, CDCl3)  
Compound 31a: 13C NMR (75 MHz, CDCl3)
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Compound 31b: 1H NMR (400 MHz, CDCl3)  
Compound 31b: 13C NMR (100 MHz, CDCl3)
 
A.1 NMR spectra 
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Compound 31c: 1H NMR (400 MHz, CDCl3)  
Compound 31c: 13C NMR (100 MHz, CDCl3)
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Compound 31d: 1H NMR (400 MHz, CDCl3)   
Compound 31d: 13C NMR (100 MHz, CDCl3)
  
A.1 NMR spectra 
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Compound 31e: 1H NMR (400 MHz, CDCl3)  
Compound 31e: 13C NMR (100 MHz, CDCl3)
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Chapter 2.3 
Compound 34b: 1H NMR (400 MHz, CDCl3)  
 
Compound 34b: 13C NMR (100 MHz, CDCl3)
 
A.1 NMR spectra 
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Compound 34c: 1H NMR (400 MHz, CDCl3)  
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Chapter 4 
Compound 75a: 1H NMR (400 MHz, CDCl3)  
 
Compound 75a: 13C NMR (100 MHz, CDCl3) 
 
A.1 NMR spectra 
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Compound 75b: 1H NMR (300 MHz, CDCl3)  
 
 
Compound 75b: 13C NMR (75 MHz, CDCl3) 
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Compound 75c: 1H NMR (300 MHz, CDCl3)  
 
 
Compound 75c: 13C NMR (75 MHz, CDCl3) 
 
A.1 NMR spectra 
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Compound 75d: 1H NMR (400 MHz, DMSO-d6)  
 
 
Compound 75d: 13C NMR (100 MHz, DMSO-d6) 
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Compound 75e: 1H NMR (300 MHz, CDCl3)  
 
 
Compound 75e: 13C NMR (75 MHz, CDCl3) 
 
A.1 NMR spectra 
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Compound 75f: 1H NMR (300 MHz, CDCl3)  
 
 
Compound 75f: 13C NMR (75 MHz, CDCl3) 
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Compound 75g: 1H NMR (300 MHz, CDCl3)  
 
 
Compound 75g: 13C NMR (75 MHz, CDCl3) 
 
A.1 NMR spectra 
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Compound 75h: 1H NMR (300 MHz, CDCl3)  
 
 
Compound 75h: 13C NMR (75 MHz, CDCl3) 
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Compound 75i: 1H NMR (300 MHz, CDCl3)  
 
 
Compound 75i: 13C NMR (75 MHz, CDCl3) 
 
A.1 NMR spectra 
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Compound 75j: 1H NMR (300 MHz, CDCl3)  
 
 
Compound 75j: 13C NMR (75 MHz, CDCl3) 
 
Multicomponent approaches to the synthesis of small bioactive molecules 
202 
 
Compound 76: 1H NMR (300 MHz, CDCl3)  
 
  
Compound 76: 13C NMR (75 MHz, CDCl3) 
 
A.1 NMR spectra 
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Compound 77: 1H NMR (300 MHz, DMSO-d6)  
 
 
Compound 77: 13C NMR (75 MHz, DMSO-d6) 
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Compound 78: 1H NMR (400 MHz, CDCl3)  
 
 
Compound 78: 13C NMR (100 MHz, CDCl3) 
 
A.1 NMR spectra 
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Compound 79a: 1H NMR (400 MHz, DMSO-d6)  
 
 
Compound 79a: 13C NMR (100 MHz, DMSO-d6) 
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Compound 79b: 1H NMR (400 MHz, DMSO-d6)  
 
 
Compound 79b: 13C NMR (100 MHz, DMSO-d6) 
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A.2 COMPUTATIONAL DATA 
Chapter 2.1 
CONFORMATIONAL STUDIES FOR C-2(S) AND C-2(R) ISOMERS OF COMPOUND 11: 
 
Superposition of the first 8 low-energy structures of isomer C-2(R) of compound 11, calculated at B3LYP/6-31G(d) 
level. 
 
Superposition of the first 9 low-energy structures of isomer C-2(S) of compound 11, calculated at B3LYP/6-31G(d) 
level (a, more favored; b, less favored) 
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EXPERIMENTAL AND THEORETICAL CD STUDIES FOR COMPOUND 11: 
  
Experimental UV (top) and CD (bottom) spectra of the major diastereoisomer 11b, measured in acetonitrile solution 
(2.0 mM). Cell length 0.01 cm and 0.05 cm (expansion). 
 
Calculated CD spectra for C-2(S) and C-2(R) isomers of 11 with CAM-B3LYP/SVP//B3LYP/6-31G(d) method. Boltzmann 
averages at 300K; Gaussian bandshape with 0.3 eV width; red-shift 30 nm. 
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Chapter 3 
DOCKING STUDIES: 
D2 receptor 
Compound 68. Three clusters were originated: 
Clu |      Bind.energy      |Dissoc. constant            | Contacting receptor residues 
----+-----------------------+----------------------------+----------------------------- 
001 |         000011.2300 | 00000000005910.0000 | VAL A 91 LEU A 94 GLU A 95 PHE A 110 VAL A 111 ASP A 114 
VAL A 115 CYS A 118 CYS A 182 ILE A 183 ILE A 184 VAL A 190 SER A 193 SER A 194 SER A 197 TRP A 386 PHE 
A 389 PHE A 390 HIS A 393 TYR A 408 THR A 412 TYR A 416 
002 |         000011.0800 | 00000000007530.0000 | LEU A 41 TRP A 90 VAL A 91 LEU A 94 GLU A 95 PHE A 110 
VAL A 111 ASP A 114 VAL A 115 CYS A 182 ILE A 183 ILE A 184 VAL A 190 SER A 193 SER A 194 TRP A 386 PHE 
A 389 PHE A 390 HIS A 393 ILE A 394 TYR A 408 SER A 409 THR A 412 TYR A 416 
003 |         000009.1700 | 00000000188850.0000 | LEU A 41 VAL A 91 LEU A 94 GLU A 95 VAL A 97 GLY A 98 PHE 
A 110 VAL A 111 ASP A 114 VAL A 115 CYS A 182 ILE A 183 ILE A 184 PHE A 389 HIS A 393 TYR A 408 SER A 
409 THR A 412 TRP A 413 
 
Compound 70. Five clusters were originated: 
Clu |      Bind.energy      |Dissoc. constant            | Contacting receptor residues 
----+-----------------------+----------------------------+----------------------------- 
001 |         000011.5900 | 00000000003170.0000 | LEU A 41 VAL A 91 LEU A 94 GLU A 95 PHE A 110 VAL A 111 
ASP A 114 VAL A 115 CYS A 118 GLU A 181 CYS A 182 ILE A 183 ILE A 184 VAL A 190 SER A 193 SER A 194 SER 
A 197 TRP A 386 PHE A 389 PHE A 390 HIS A 393 TYR A 408 SER A 409 THR A 412 TRP A 413 
002 |         000011.5200 | 00000000003600.0000 | VAL A 91 LEU A 94 VAL A 97 GLY A 98 PHE A 110 VAL A 111 
ASP A 114 VAL A 115 CYS A 118 THR A 119 ILE A 122 GLU A 181 CYS A 182 ILE A 183 ILE A 184 VAL A 190 SER 
A 193 SER A 194 SER A 197 TRP A 386 PHE A 389 PHE A 390 HIS A 393 ILE A 394 TYR A 408 THR A 412 TYR A 
416 
003 |         000010.0900 | 00000000040030.0000 | LEU A 41 VAL A 87 VAL A 91 LEU A 94 GLU A 95 PHE A 110 
VAL A 111 ASP A 114 VAL A 115 CYS A 182 ILE A 183 ILE A 184 VAL A 190 PHE A 389 HIS A 393 TYR A 408 SER 
A 409 THR A 412 TRP A 413 TYR A 416 
004 |         000009.5400 | 00000000102030.0000 | TYR A 34 LEU A 41 VAL A 91 LEU A 94 GLU A 95 VAL A 97 GLY 
A 98 PHE A 110 VAL A 111 ASP A 114 VAL A 115 CYS A 182 ILE A 183 ILE A 184 PHE A 389 HIS A 393 TYR A 408 
SER A 409 THR A 412 TRP A 413 
005 |         000008.6100 | 00000000489850.0000 | VAL A 91 LEU A 94 GLU A 95 VAL A 97 GLY A 98 GLU A 99 
TRP A 100 PHE A 110 VAL A 111 ASP A 114 VAL A 115 ASN A 180 GLU A 181 CYS A 182 ILE A 183 ILE A 184 
TRP A 386 PHE A 389 TYR A 408 SER A 409 THR A 412 TYR A 416 
 
 
D3 receptor 
Compound 68. Five clusters were originated: 
Clu |      Bind.energy      |Dissoc. constant            | Contacting receptor residues 
----+-----------------------+----------------------------+----------------------------- 
001 |         000011.4600 | 00000000003990.0000 | ARG A 27 TYR A 36 VAL A 86 LEU A 89 GLU A 90 GLY A 94 
PHE A 106 VAL A 107 ASP A 110 VAL A 111 CYS A 114 THR A 115 SER A 182 ILE A 183 VAL A 189 SER A 192 
SER A 193 SER A 196 TRP A 342 PHE A 345 PHE A 346 HIS A 349 TYR A 365 SER A 366 THR A 369 TRP A 370 
TYR A 373 
002 |         000011.0500 | 00000000007980.0000 | ARG A 27 TYR A 36 VAL A 86 LEU A 89 GLU A 90 GLY A 94 
PHE A 106 VAL A 107 ASP A 110 VAL A 111 CYS A 114 THR A 115 CYS A 181 SER A 182 ILE A 183 VAL A 189 
SER A 192 SER A 196 TRP A 342 PHE A 345 PHE A 346 HIS A 349 TYR A 365 SER A 366 THR A 369 TRP A 370 
TYR A 373 
003 |         000008.8100 | 00000000345950.0000 | TYR A 36 VAL A 86 LEU A 89 GLU A 90 GLY A 94 PHE A 106 
VAL A 107 ASP A 110 CYS A 181 SER A 182 ILE A 183 PHE A 345 PRO A 362 TYR A 365 SER A 366 THR A 369 
TYR A 373 
004 |         000008.6400 | 00000000460910.0000 | ARG A 27 TYR A 32 TYR A 36 VAL A 86 LEU A 89 GLU A 90 
GLY A 93 GLY A 94 PHE A 106 VAL A 107 ASP A 110 VAL A 111 CYS A 181 SER A 182 ILE A 183 PHE A 345 HIS 
A 349 TYR A 365 SER A 366 THR A 369 TYR A 373 
005 |         000007.8400 | 00000001800000.0000 | ARG A 27 TYR A 36 VAL A 86 LEU A 89 GLU A 90 THR A 92 
GLY A 93 GLY A 94 VAL A 95 VAL A 180 CYS A 181 SER A 182 PRO A 362 TYR A 365 SER A 366 THR A 369 TYR 
A 373 
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Compound 70. Seven clusters were originated: 
Clu |      Bind.energy      |Dissoc. constant            | Contacting receptor residues 
----+-----------------------+----------------------------+----------------------------- 
001 |         000011.0600 | 00000000007840.0000 | ARG A 27 TYR A 36 VAL A 86 LEU A 89 GLU A 90 GLY A 94 
PHE A 106 VAL A 107 ASP A 110 VAL A 111 CYS A 114 THR A 115 CYS A 181 SER A 182 ILE A 183 VAL A 189 
SER A 192 SER A 196 TRP A 342 PHE A 345 PHE A 346 HIS A 349 PRO A 362 TYR A 365 SER A 366 THR A 369 
TYR A 373 
002 |         000010.5200 | 00000000019370.0000 | ARG A 27 TYR A 36 VAL A 86 LEU A 89 GLU A 90 PHE A 106 
VAL A 107 ASP A 110 VAL A 111 CYS A 114 CYS A 181 SER A 182 ILE A 183 VAL A 189 SER A 192 TRP A 342 
PHE A 345 PHE A 346 HIS A 349 PRO A 362 TYR A 365 SER A 366 THR A 369 GLY A 372 TYR A 373 
003 |         000009.8800 | 00000000057660.0000 | ARG A 27 TYR A 36 VAL A 82 VAL A 86 LEU A 89 GLU A 90 
GLY A 94 PHE A 106 VAL A 107 ASP A 110 CYS A 181 SER A 182 ILE A 183 PHE A 345 HIS A 349 PRO A 362 TYR 
A 365 SER A 366 THR A 369 TYR A 373 
004 |         000008.6600 | 00000000451390.0000 | ARG A 27 VAL A 86 LEU A 89 GLU A 90 GLY A 93 GLY A 94 
PHE A 106 VAL A 107 ASP A 110 CYS A 181 SER A 182 ILE A 183 PHE A 345 HIS A 349 ASN A 352 VAL A 360 SER 
A 361 PRO A 362 TYR A 365 SER A 366 THR A 369 TYR A 373 
005 |         000008.3000 | 00000000820720.0000 | ARG A 27 TYR A 36 VAL A 86 LEU A 89 GLU A 90 GLY A 94 
PHE A 106 VAL A 107 ASP A 110 CYS A 181 SER A 182 PRO A 362 TYR A 365 SER A 366 THR A 369 TRP A 370 
TYR A 373 
006 |         000008.1400 | 00000001080000.0000 | ARG A 27 TYR A 36 VAL A 86 LEU A 89 GLU A 90 GLY A 94 
VAL A 95 TRP A 96 PHE A 106 THR A 179 VAL A 180 CYS A 181 SER A 182 PRO A 362 TYR A 365 SER A 366 
THR A 369 TYR A 373 
007 |         000007.9100 | 00000001600000.0000 | ARG A 27 TYR A 36 VAL A 86 LEU A 89 GLU A 90 GLY A 93 
GLY A 94 PHE A 106 VAL A 107 ASP A 110 CYS A 181 SER A 182 PHE A 345 VAL A 360 SER A 361 PRO A 362 
GLU A 363 TYR A 365 SER A 366 THR A 369 TYR A 373 
 
 
MOLECULAR DYNAMICS STUDIES: 
Plots of the energy and the Cα RMSD profiles after MD simulations 
 D2 receptor, compound 68 
  
D2 receptor, compound 70 
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D3 receptor, compound 68 
 
D3 receptor, compound 70 
 
 
 
The D3 receptor embedded in the membrane 
 
For each compound, the lowest energy complex from MD simulations was further minimized with the same force 
field. The binding energy of the obtained complex was then recalculated with Autodock, giving the following results 
(binding energy are reported in kcal/mol):  
 D2 D3 
68 10.79 9.30 
70 10.66 11.97 
69 9.20 8.83 
67 9.66 8.50 
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Chapter 4 
COMPUTATIONAL DATA FOR THE TWO TRANSITION STATES TS-A AND TS-B 
TS-A 
Cartesian Coordinates (Angstroms) 
 
1 C -1.8892290 1.7792323 -1.5767275 
2 O -1.9099040 1.3892922 -2.7191745 
3 N -1.8670942 0.8156962 -0.4775048 
4 N -1.7997383 3.0374635 -1.1551571 
5 H -1.8329944 3.7591594 -1.8424761 
6 C -2.8887838 0.3864052 0.2242179 
7 H -1.8601058 3.2953184 -0.1879628 
8 C -3.7709850 2.9042266 1.6067527 
9 O -3.1609968 3.8602303 1.1563790 
10 C -3.2091039 1.6255850 2.0134133 
11 H -3.8742699 0.9906672 2.5626707 
12 C -1.8407773 1.5213665 2.3481786 
13 O -0.9227088 2.2404134 1.9121698 
14 H 0.4863183 1.7950655 2.0951394 
15 P 1.4975814 0.2367059 0.9733152 
16 O 1.3669767 1.2612068 2.0681876 
17 O 0.2479051 -0.4901086 0.6081588 
18 H -0.9758390 0.3497510 -0.2809162 
19 O 2.1653719 0.9088527 -0.3736185 
20 O 2.6414851 -0.8479806 1.4436987 
21 C 3.4793745 1.3088645 -0.3576033 
22 C 4.4738249 0.3086206 -0.2823161 
23 C 3.1983978 -1.6886087 0.5133777 
24 C 4.0725981 -1.1197153 -0.4370685 
25 C -4.2780130 0.5947345 -0.3961390 
26 C -3.0154971 -1.0312558 0.7574272 
27 C -4.2921838 -1.5182674 0.4423307 
28 N -5.0334024 -0.5492690 -0.2446699 
29 O -4.6133988 1.6393854 -0.9376629 
30 C -2.1673153 -1.7862926 1.5266990 
31 H -1.2207507 -1.3750714 1.8490764 
32 C -4.7100993 -2.7861951 0.8235505 
33 H -5.6879970 -3.1665981 0.5615406 
34 C -3.8307415 -3.5657177 1.5757999 
35 H -4.1205165 -4.5590134 1.9018997 
36 C -2.5742873 -3.0601655 1.9366622 
37 H -1.8956681 -3.6388924 2.5545045 
38 C 5.8342864 0.6978946 -0.0802179 
39 C 8.5129522 1.5604550 0.2967438 
40 C 6.8911152 -0.2143039 0.1667434 
41 C 6.1640407 2.0721529 -0.1116004 
42 C 7.4954572 2.4852979 0.0701582 
43 C 8.2099514 0.2079731 0.3489551 
44 H 6.6817561 -1.2798169 0.2398993 
45 H 7.7431242 3.5439276 0.0479613 
46 H 8.9877252 -0.5243496 0.5420936 
47 H 9.5330454 1.8993094 0.4457855 
48 C 4.5437699 -1.9320065 -1.5135754 
49 C 5.4680070 -3.6287121 -3.5944840 
50 C 5.3031687 -1.4400799 -2.6050714 
51 C 4.2340124 -3.3109904 -1.5143331 
52 C 4.7062501 -4.1417559 -2.5464417 
53 C 5.7631133 -2.2740067 -3.6269537 
54 H 5.5255190 -0.3769109 -2.6752246 
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55 H 4.4645000 -5.2019210 -2.5444193 
56 H 6.3381735 -1.8544694 -4.4469483 
57 H 5.8118327 -4.2829236 -4.3890750 
58 C 5.1588047 3.0237323 -0.3321751 
59 H 5.4179786 4.0802784 -0.3710943 
60 C 3.8051627 2.6697086 -0.4665060 
61 C 3.4540664 -3.8507178 -0.4800880 
62 H 3.2499474 -4.9194626 -0.4777129 
63 C 2.9099878 -3.0617260 0.5497967 
64 O -5.1412978 2.9330513 1.7698927 
65 C -5.7432007 4.1226198 1.2662198 
66 H -5.4055789 4.9856495 1.8509770 
67 H -5.4824488 4.2647568 0.2110771 
68 C -7.2477355 3.9792765 1.3956200 
69 H -7.5316728 3.8199695 2.4411385 
70 H -7.6010397 3.1084330 0.8332650 
71 H -7.7582750 4.8715805 1.0227852 
72 C -6.3766433 -0.6868792 -0.7254693 
73 H -6.7656873 0.2972868 -1.0136476 
74 H -6.9933618 -1.0380766 0.1109966 
75 C -6.5269602 -1.6097703 -1.9173111 
76 C -6.8707722 -3.2846897 -4.1475700 
77 C -7.6550348 -2.4386889 -2.0237025 
78 C -5.5859495 -1.6181359 -2.9581544 
79 C -5.7534122 -2.4569667 -4.0612412 
80 C -7.8235570 -3.2737747 -3.1306456 
81 H -8.4077628 -2.4395499 -1.2392114 
82 H -4.7037959 -0.9770918 -2.9132388 
83 H -5.0013630 -2.4588944 -4.8463577 
84 H -8.6970461 -3.9157459 -3.1982489 
85 H -6.9952060 -3.9362139 -5.0073081 
86 C 2.8220668 3.7321524 -0.7484350 
87 C 0.9717824 5.7944104 -1.3024426 
88 C 1.7749504 4.0195656 0.1306942 
89 C 2.9250739 4.5118245 -1.9166716 
90 C 2.0108093 5.5346751 -2.1918748 
91 C 0.8536133 5.0338770 -0.1432627 
92 H 1.6361609 3.4270533 1.0355368 
93 H 3.7133796 4.2998394 -2.6335296 
94 H 2.0968038 6.1062277 -3.1094513 
95 H 0.0254164 5.1770840 0.5488882 
96 H 0.2360398 6.5617198 -1.5162299 
97 C 2.1153528 -3.7103866 1.6189545 
98 C 0.6846913 -5.0485907 3.6602892 
99 C 1.1306233 -4.6683358 1.3159208 
100 C 2.3450200 -3.4301366 2.9761523 
101 C 1.6350548 -4.0860581 3.9866031 
102 C 0.4307720 -5.3397840 2.3233169 
103 H 0.8758818 -4.8681635 0.2774993 
104 H 3.0676500 -2.6656681 3.2563595 
105 H 1.8105637 -3.8136696 5.0228883 
106 H -0.3401559 -6.0546744 2.0549799 
107 H 0.1164804 -5.5370571 4.4446620 
108 C -1.5317760 0.6815223 3.6474475 
109 H -1.4319744 1.3617462 4.4996729 
110 H -0.6086860 0.1059486 3.5385628 
111 H -2.3522032 -0.0098574 3.8568810 
 
Translational Enthalpy: 0.889 kcal/mol 
Rotational Enthalpy: 0.889 kcal/mol 
Vibrational Enthalpy: 583.960 kcal/mol 
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gas constant (RT): 0.593 kcal/mol 
Translational Entropy: 46.298 cal/mol.K 
Rotational Entropy: 40.660 cal/mol.K 
Vibrational Entropy: 195.074 cal/mol.K 
Total Enthalpy: 586.330 kcal/mol 
Total Entropy: 282.033 cal/mol.K 
 
TS-B 
1 C -2.426682 -2.408128 0.707203 
2 O -3.554436 -2.830458 0.852490 
3 N -2.185059 -1.004436 0.593342 
4 N -1.288257 -3.099359 0.628425 
5 H -1.327048 -4.093185 0.674452 
6 C -3.153860 -0.135645 0.711594 
7 H -0.408886 -2.619520 0.535719 
8 C -4.165168 1.946489 2.195336 
9 O -3.821716 2.625795 1.235846 
10 C -3.401378 0.875460 2.794472 
11 H -3.918982 0.255830 3.500374 
12 C -2.012392 0.884222 2.876246 
13 O -1.212344 1.591040 2.204959 
14 H 0.126850 1.342882 2.228921 
15 P 1.546666 0.031600 0.982235 
16 O 0.496477 -0.902764 0.476545 
17 H -1.206230 -0.722114 0.483098 
18 O 1.126355 0.956156 2.132304 
19 O 2.706239 -0.816709 1.303235 
20 O 2.189006 1.047592 -0.308464 
21 C 3.595844 -1.466715 0.439669 
22 C 4.354521 -0.760966 -0.406247 
23 C 4.528990 0.671834 -0.319761 
24 C 3.504398 1.526216 -0.398939 
25 C 5.837748 1.249351 -0.113883 
26 C 8.401498 2.449992 0.236915 
27 C 7.001656 0.490350 0.179537 
28 C 6.013582 2.656493 -0.190085 
29 C 7.283583 3.235531 -0.027025 
30 C 8.259666 1.076059 0.347346 
31 H 6.942713 -0.590977 0.291515 
32 H 7.409665 4.314456 -0.093823 
33 H 9.122210 0.452142 0.566260 
34 H 9.375933 2.912276 0.366790 
35 C 3.557890 -2.883824 0.486613 
36 C 4.295254 -3.586254 -0.469132 
37 C 3.631238 2.929473 -0.504365 
38 C 4.909892 3.476290 -0.421681 
39 H 5.030562 4.556085 -0.486406 
40 C 5.002461 -1.496106 -1.473696 
41 C 4.984913 -2.912579 -1.473282 
42 H 4.299201 -4.674797 -0.448370 
43 C 5.644195 -3.647745 -2.474084 
44 C 6.309328 -3.006554 -3.514089 
45 C 6.317096 -1.622587 -3.566502 
46 H 6.819991 -1.107247 -4.380631 
47 C 5.672973 -0.885760 -2.568432 
48 H 5.695399 0.198536 -2.666319 
49 H 6.808269 -3.586876 -4.285012 
50 H 5.633518 -4.735832 -2.457085 
51 C 2.462864 3.808408 -0.686721 
52 C 0.192292 5.427274 -1.078931 
53 C 2.267741 4.496149 -1.895764 
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54 C 1.504259 3.964903 0.326685 
55 C 0.372538 4.759033 0.129361 
56 C 1.141996 5.301216 -2.090224 
57 H 2.988903 4.391708 -2.703551 
58 H 1.624319 3.452219 1.279315 
59 H -0.371820 4.841755 0.918157 
60 H 1.001673 5.819184 -3.034989 
61 H -0.692642 6.038967 -1.231701 
62 C 2.757054 -3.630792 1.482903 
63 C 1.239225 -5.070561 3.378605 
64 C 1.878223 -4.654968 1.085895 
65 C 2.858856 -3.354550 2.856871 
66 C 2.103031 -4.061919 3.795586 
67 C 1.129445 -5.371349 2.024132 
68 H 1.764966 -4.898763 0.031210 
69 H 3.536404 -2.578644 3.209570 
70 H 2.194679 -3.824237 4.852239 
71 H 0.460705 -6.162581 1.696043 
72 H 0.654687 -5.622361 4.109816 
73 C -4.608044 -0.599708 0.539093 
74 N -5.162966 -0.142531 -0.634260 
75 C -4.235505 0.644936 -1.295115 
76 C -2.037330 2.120095 -2.186888 
77 C -3.040757 0.714311 -0.560879 
78 C -4.327822 1.321254 -2.496849 
79 C -3.220895 2.058538 -2.942552 
80 C -1.937501 1.438165 -0.976049 
81 H -5.227356 1.287060 -3.099780 
82 H -3.279045 2.597228 -3.885825 
83 H -1.043714 1.504914 -0.368927 
84 H -1.195389 2.711772 -2.540478 
85 C -6.545504 -0.305145 -1.022866 
86 H -6.977515 0.671626 -1.275931 
87 H -7.142017 -0.682693 -0.181445 
88 C -6.710103 -1.274247 -2.174662 
89 C -7.068131 -3.084759 -4.291845 
90 C -7.433437 -0.902780 -3.318630 
91 C -6.182343 -2.573173 -2.102974 
92 C -6.357044 -3.470473 -3.157649 
93 C -7.607634 -1.802591 -4.372090 
94 H -7.866881 0.091476 -3.399409 
95 H -5.626142 -2.892673 -1.222553 
96 H -5.937132 -4.470703 -3.091143 
97 H -8.166178 -1.504110 -5.255571 
98 H -7.203527 -3.784787 -5.112022 
99 C -1.373461 -0.135542 3.779410 
100 H -0.948741 -0.942938 3.177619 
101 H -2.100332 -0.560725 4.476253 
102 H -0.576946 0.334877 4.362288 
103 O -5.388492 2.091435 2.791034 
104 C -6.213082 3.100195 2.200936 
105 H -6.387711 2.867468 1.144200 
106 H -5.724841 4.077097 2.289937 
107 C -7.536482 3.121191 2.940773 
108 H -8.028303 2.144785 2.878060 
109 H -8.204278 3.880468 2.524348 
110 H -7.380633 3.331673 4.004014 
111 O -5.267656 -1.086902 1.451423 
 
Translational Enthalpy: 0.889 kcal/mol 
Rotational Enthalpy: 0.889 kcal/mol 
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Vibrational Enthalpy: 583.225 kcal/mol 
gas constant (RT): 0.593 kcal/mol 
Translational Entropy: 46.298 cal/mol.K 
Rotational Entropy: 40.707 cal/mol.K 
Vibrational Entropy: 185.822 cal/mol.K 
Total Enthalpy: 585.595 kcal/mol 
Total Entropy: 272.827 cal/mol.K 
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A.3 BIOLOGICAL DATA 
Chapter 2.1 
Biological evaluation (cytotoxicities of compounds 11-14, 19-22 and 23-26). IC50 values in Huh7 and Mahlavu cell 
lines. Non growth inhibition for compounds 11-13, 19-22, 23, 24, 25a and 26. 
Compound Huh7 MV 
IC50(µM) R2 s.d IC50(µM) R2 s.d 
14 15,2 1,0 1,8 11,3 0,9 0,4 
25b 16,2 0,9 1,1 30,5 0,8 3,7 
Chapter 3 
Radioligand binding data for the compounds 38-72 employing the human D2L  and D3 receptors 
Ki ± (SD) [nM]
a 
compd 
[3H]spiperone  
compd 
[3H]spiperone 
hD2L hD3  hD2L hD3 
38 69000 ± 45000 75000 ± 4200  57 60000 ± 2000 82000 ± 18000 
39 24000 ± 7800 100000 ± 0  58 91000 ± 13000 100000 ± 0 
40 44000 ± 17000 72000 ± 29000  59 3400 ± 750 2600 ± 0 
41 44000 ± 17000 72000 ± 29000  60 28000 ± 8500 49000 ± 20000b 
42 100000 ± 0 87000 ± 8100  61 19000 ± 5500 35000 ± 19000 
43 11000 ± 0 6600 ± 2300  62 33000 ± 1000 48000 ± 3000 
44 100000 ± 0 100000 ± 0  63 36000 ± 22000 6500 ± 300 
45 7500 ± 990 18000 ± 0  64 2800 ± 800 4200 ± 150 
46 920 ± 49 2300 ± 730  65 60000 ± 40000 8000 ± 3100 
47 4000 ± 2500 4300 ± 1600  66 4200 ± 2500 2600 ± 450 
48 5200 ± 1800 1800 ± 640  67 430 ± 160 620 ± 65 
49 520 ± 150 1300 ± 0  68 53 ± 11 200 ± 18 
50 220 ± 32 600 ± 100  69 120 ± 15 280 ± 38 
51 4100 ± 990 4600 ± 570  70 58 ± 6.7 89 ± 3.8 
52 920 ± 680 930 ± 28  71   
53 68000 ± 8000 100000 ± 0  71 14000 ± 3000 5600 ± 1000 
54 14000 ± 4400 5600 ± 950  72 16000 ± 10000 4500 ± 500 
55 42000 ± 3000 100000 ± 0  haloperidol 0.96 ± 0.15 6.8 ± 1.3 
56 4500 ± 1800 3300 ± 300     
aKi values in nM  standard deviation (SD) derived from two individual experiments each performed in triplicate. 
b Ki 
values in nM  standard error of mean (SEM) derived from 3 individual experiments each performed in triplicate. 


